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Introduction 
Obesity is derived from the Latin obesitas, which means fat, or plump and morbid from morbidus 
which means disease. Therefore, morbid obesity indicates an extend of bodily fat deposition that 
leads to disease [1]. Obesity is a complex multifactorial chronic disease that develops from an 
interaction of genotype and the environment [2-4]. The Quetelet index, better known as body mass 
index (BMI) is used for the classification of overweight. It is named after Alphonse Quetelet (1795-
1844) [5], a Belgian astronomer turned statistician, who, in his attempts to define the average man 
(l’homme moyen) used data from the heights and weights of the French and Scottish armies to show 
that most cases fell within the range defined as a person’s weight in kilograms divided by the square 
of the person’s height in meters Weight (kg) / [Hight2 (meter)] (Table 1). 
BMI is as followed calculated:  
𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵 (𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘 𝑚𝑚𝑚𝑚2)⁄ =
𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑘𝑘𝑘𝑘ℎ𝑡𝑡𝑡𝑡 (𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘)
𝑙𝑙𝑙𝑙𝑤𝑤𝑤𝑤𝑙𝑙𝑙𝑙𝑘𝑘𝑘𝑘𝑡𝑡𝑡𝑡ℎ2 (𝑚𝑚𝑚𝑚)
 
Table 1: BMI and its relation with co-morbidity 
Category BMI  range (Kg/m2) Risk of co-morbidity 
Underweight  <18.5 Low  
Normal range 18.5 – 25 Average 
Overweight    
At risk  > 25 Increased 
Obese class I 30 - 35 Moderate 
Obese class II 35-40 Severe 
Obese class III ≥ 45 Severe 
 
According to the WHO, Worldwide obesity (BMI >30kg/m2) has more than doubled since 1980. 
• In 2014, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 600 
million were obese. 
• In 2014, 39% of adults aged 18 years and over (38% of men and 40% of women) were 
overweight. 
• More than 42 million children under the age of five were obese in 2013. 
• 65% of the world's population lives in countries where overweight and obesity kills more people 
than underweight.  
If the recent trends continue unabated, in 2030 the absolute numbers of overweight and obese will 
respectively increase to total of 2.16 billion and 1.12 billion individuals [6]. 
Obesity is associated with an elevated risk for obesity-related co-morbidities, such as diabetes 
mellitus type 2, hypertension, hypercholesterolemia, heart disease, osteoarthritis and obstructive 
sleep apnea [7-9]. Furthermore, obesity is a risk factor for developing breast, endometrium, ovarian, 
kidney cancer [10, 11] and certain types of gastrointestinal cancer [12]. There is also evidence which 
shows contribution of the obesity to the liver failure as well, which has been underestimated until 
now [13]. 
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Obesity from an evolutionary perspective 
In the evolutionary history of humankind, bodily fat seems to have served nature’s purpose by 
outfitting the species with a built-in mechanism for storing its food reserves. This ability to store 
surplus fat from the least possible amount of food intake may have made the difference between 
life and death, not only for the individual but also more importantly for the species. Those who 
could store fat easily had an evolutionary advantage in the harsh environment of early hunters and 
gatherers societies [14-17]. From a historical point of view obesity was the symbol of unlimited 
wealth and good health. In some parts of the world obesity still is a symbol of wealth. An obese 
person could afford to eat as much as he or she wanted.  Human obesity is depicted in numerous ice 
age artifacts. The discovery of the famous figurine ‘Venus of Willendorf’, in 1908 near the town of 
Willendorf in Austria by archeologist named Joseph Szombathy is a good example. This statue dated 
from 22.000-24.000 BC, is an important icon of prehistory [18]. Archeologists have suggested many 
different ways of understanding its significance. The first suggestion is that it was a "Venus figure" or 
"Goddess," used as a symbol of fertility. When one takes a closer look into the figurine, it becomes 
clear that this statuette emphasizes the importance of body fat and its relation to fertility, which is 
contradicted with the current knowledge of the risks of obesity to overall wellbeing and in particular 
to diminished fertility in women and in men.  
In many works of later artists, 
overweight women have been related 
to fertility as well. The painting of the 
famous Sir Peter Paul Rubens (1577–
1640) a born German who lived in 
today’s Antwerp, regularly emphasized 
full-bodied women in his painting. 
These women, however, still 
maintained the "hourglass" shape, 
which he related to healthy, fertile 
women. 
Anna Wake painted by Rubens (1627) 
Obviously, the pathogenesis of obesity 
is more complex than a simple 
paradigm of available food and the 
effort spent to obtain it. Factors 
beyond diet and exercise influence 
obesity and make the consequences of 
bad diet and limited exercise much 
worse than they would be otherwise 
[19,20] 
 
Management of obesity  
The Ancient Greek physician Hippocrates and one of the most prominent figures of the Arabic 
medical tradition Abu Ali Ibn Sina (Avicenna) were aware of the health hazards associated with 
obesity. They knew that obesity caused infrequent menses, infertility in women and the sweet taste 
of diabetic urine [20]. In the last few decades, obesity has increased to epidemic proportions and 
resulted in an increase in mortality and morbidity and a decrease in quality of life [21-26]. To face 
these consequences, doctors have tried to come up with many sorts of solutions and treatments in 
the past, some more successful than others. But one could ask the question, when is an approach for 
obesity treatment successful? We know that 10% of total body weight loss produces substantial 
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improvement to the risk factors like diabetes and heart diseases. One is researching the different 
ways to answer this question. 
1- Conservative management (diet and behavioral) 
Obesity is considered the result of the imbalance between energy intake and energy expenditure. 
Especially an excess of dietary fat is fundamental in the development of obesity. There are various 
approaches to weight loss like:  low-, very low-, and moderate-fat diets, high-protein diets, and low-
carbohydrate diets. Overweight and obese individuals are often in search of the next diet, which may 
be able to help them lose weight. Dietary treatment only is insufficient to achieve enough weight 
reduction for a healthy weight on the long term [27, 28].  
The low-fat diets consist of less calories and helps to lose weight. Lowering the proportion of energy 
intake from fat was associated with lower body weight (by 1.6 kg), body mass index, and waist 
circumference in adults [29]. The PREMIER trial [30] and Diabetes Prevention Program [31] showed 
the same effect when compared to the controls receiving standard lifestyle. Not only caloric intake 
should be restricted; a healthier diet is also very important. The diet should be rich in micronutrients 
like fruits, vegetables, low fat or nonfat dairy.  
There are hypotheses which emphasize the role of sugar in the development of the obesity. However 
maybe due to lack of information or influence of food industry, little has been done to tackle sugar as 
an independent factor [32, 33, 34]. 
Treatment of obesity in patients requires a multifactorial approach. Physical activity and behavioral 
assistance are important components in the treatment of the obesity. 
The maintenance of the achieved weight loss by dieting alone is, however, insufficient in the long 
term and these patients will eventually all regain weight [28]. 
2- Pharmacologic management of the obesity  
Numerous studies have been conducted with different types of medication to investigate the 
pharmacological management of obesity [35,36]. However, the weight loss with the help obesity 
medicine is modest; weight loss is often not maintained after the drug is discontinued and the use of 
medications is often accompanied by many side effects.  The effect of the following medication has 
been tested in the research trails: Sibutramine, Phenotermine, Orlistat, Metformin, Exenatide, 
Bupropion and Fluoxetine [37,38] 
3- Bariatric surgery  
Bariatric surgery is performed for over 50 years to treat morbid obesity and includes a large number 
of different surgical and laparoscopic procedures. Bariatric surgery has proven its effectiveness in 
achieving and maintaining weight loss and improving obesity-related co-morbidities, quality of life, 
and survival [39, 40]. The first bariatric surgical procedure, the jejunoileal (JI) bypass, was performed 
in 1953 by Dr. Richard Varco at the University of Minnesota. This procedure was a pure malabsorptive 
procedure, bypassing over 90% of the small intestine, so that many of the ingested calories were not 
absorbed [41, 42]. This procedure was associated with a high incidence of complications due to 
malnutrition and various deficiency states and was associated with a significant long-term mortality 
[42]. 
In 1966, Dr. Edward Mason at the University of Iowa developed the gastric bypass (Figure 1B) [43]. 
The gastric bypass is a combination of creating a small gastric pouch and rerouting the small intestine. 
This was initially considered a restrictive and malabsorptive procedure in one. Later on, in 1977 Dr. 
Ward Griffen from the University of Kentucky modified Dr. Mason’s gastric bypass to a Roux-en-Y 
gastric bypass (RYGB) in which the jejunum was transected about 30 cm below the ligament of Treitz 
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and a 75 cm Roux limb was connected to the proximal gastric pouch, creating a modest amount of 
malabsorption in addition to the gastric restriction. (Figure 1C) 
Bariatric procedures have gone through numerous modifications and additions since then. For 
example, the Gastric Sleeve (Figure 1D), Duodenal switch (Figure 1E) Scopinaro (Figure 1F), were 
added to the arsenal of bariatric surgery.  
The RYGB on the other hand has proven its effectiveness in achieving and maintaining weight loss and 
improving T2DM, quality of life, and survival [44-45]. Especially when it comes to type 2 diabetes, it 
has been recognized that RYGB surgery leads to reduction and even remission of T2DM in the 
majority of operated patients within days after surgery [46-47]. The latter suggests that weight loss 
independent mechanisms are responsible for the early remission. It has been proposed that the early 
improvement in glycemic control following RYGB depends on the changes in intestinal anatomy and 
resulting alternated levels of incretins, especially GLP-1 (glucagon-like peptide-and) and GIP (gastric 
inhibitory peptide) [48,49]. GIP and GLP-1 secreted, respectively, by K and L cells in the gut. Both GLP-
1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4)  
Incretins are assumed to be main effectors in the ‘foregut hypothesis’ that states that exclusion of the 
foregut from nutrient exposure is most responsible for the rapid improvement of hyperglycemia 
[50,51]. Incretins do so by causing an increase in the amount of insulin released from pancreatic beta 
cells of the islets of Langerhans after eating, before blood glucose levels become elevated. They also 
slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may 
directly reduce food intake. As expected, they also inhibit glucagon release from the alpha cells of the 
islets of Langerhans.  
GLP-1 Is the main candidate for the ‘hindgut theory’ that explains improved glycaemia by a faster 
delivery of nutrients to the hindgut after RYGB surgery. Both theories are currently still being debated 
[52-53]. Although RYGB surgery is an efficient bariatric intervention for remission of T2DM, it is 
associated with potential complications, and although rare, mortality [54].  Additionally, the RYGB is 
only offered when patients meet the criteria of the IFSO, of which in this perspective a minimal BMI 
of 35kg/m2 is required combined with a co-morbidity related to morbid obesity like T2DM. This 
means that all diabetic patients with a lower BMI, for now in most countries, cannot be offered a 
RYGB. This is by far the majority of T2DM patients worldwide who can only be treated with 
medication without a perspective of improving their T2DM. Therefore, less invasive and safer 
techniques that will offer treatment for a broader spectrum of patients are searched for [55-58]. 
 
Figure 1A. Normal anatomy of the stomach. 
 
Figure 1B. The first gastric bypass according to Mason. 
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4- New model (duodenal – jejunal bypass liner) 
In recent years, a number of endoscopic interventional techniques for the treatment of obesity have 
been introduced as possible minimally invasive alternatives to surgery or for patients with low BMI’s. 
These techniques are promising and might eventually provide additional approaches to treat obesity 
and T2DM [59-61]. Such interventions may offer economic benefits and minimally invasive outpatient 
options for the growing numbers of obese and diabetic patients. The development of endoluminal 
therapies may extend the current indications for intervention to those with multiple comorbidities, 
older age and those with overweight or obesity (BMI 28-35 kg/m2). 
Still recently, a novel non-surgical bariatric technique has been developed, the duodenal-jejunal 
bypass liner (DJBL, GI Dynamics, Lexington, MA). The DJBL consists of a 60 cm long fluoropolymer 
liner which is delivered into and retrieved from the duodenum endoscopically (Figure 2). 
Its principle is based on the effectiveness of surgical duodenal-jejunal exclusion in treating obesity 
and T2DM; once placed in the duodenum it mimics the intestinal bypass component of the Roux-en-Y 
gastric bypass and surgical duodenal-jejunal exclusion. To date, clinical experience has demonstrated 
the safety of the DJBL and its ability to rapidly improve blood glucose control and induce weight loss 
[61-63]. In addition, the DJBL has been shown to improve other metabolic parameters, including lipid 
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profile and blood pressure [64-67]. Although to some extend we know how the DJBL works, many 
questions remain unanswered. 
Is DJBL a safe and effective procedure to treat patients with?  
What is the possible working mechanism of DJBL?  
What are the complications and can they be prevented?  
Does the effect last after explantation and is it possible to re-implant DJBL? 
 
In this thesis, we will attempt to clarify many of these remaining questions.  We have chosen for two 
different types of studies, a randomized controlled trail and an observational study with human 
models as subject. With the randomized controlled trials, we will study whether treating patients with 
DJBL comparing to the diet group is significant. And the observational study will answer the 
remainder of the questions.  
Figure 2. (A, B) Schematic overview of RYGB 
surgery (A) and implantation of DJBL (B). The 
arrows designate the comparable duodenal-
jejunal part of the intestine that is ‘bypassed’ in 
both bariatric procedures. (C, D) Devices for 
implantation of DJBL. (C) Illustration of the DJBL 
(60cm long impermeable fluoropolymer sleeve 
and a nitinol anchor, (D) DJBL implantation 
system. 
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Aim and outline of the thesis  
As we earlier have discussed there are different modalities to manage the obesity. In this thesis, we 
will evaluate the outcomes of the duodenal jejunal bypass liner. The reason to choose for this 
endoscopic device is mainly based on its safety and reversibility compared to the bariatric surgery. 
The general aim of this thesis is to review the feasibility, safety, effectiveness and management of the 
complication of the DJBL, as a non-surgical endoscopic treatment for type 2 diabetes and obesity. This 
thesis will discuss the following hypotheses.  
Hypotheses:  
1- The duodenal jejunal bypass liner will improve type 2 diabetes and obesity comparing diet alone.  
2- The effect of duodenal jejunal bypass liner is based on the gut hormones. 
3- The effect of the duodenal jejunal bypass liner will maintain when it’s in place. 
4- Duodenal jejunal bypass liner is safe in use. 
5- It’s safe to implant the duodenal jejunal bypass liner under conscious sedation. 
6- The Re-implantation of the duodenal jejunal bypass liner is feasible.  
Because this device has already been researched in animal models and has proven its efficacy there, 
for this thesis this device is researched in the human model.  A randomized control trail will be the 
best type of study to answer the questions about the effectiveness of the duodenal jejunal bypass 
liner comparing to the diet. Chapter 2 describes the outcomes of a prospective randomized controlled 
trial towards the safety and efficacy of six months duodenal-jejunal bypass liner (DJBL) treatment in 
comparison to dietary intervention for obesity and type 2 diabetes mellitus (T2DM).  
Through an observational study, the hormonal effect of the DJBL has been researched when the DJBL 
was in placed. Chapter 3 evaluates the improvement of glycaemic control and weight loss in the 
course of the treatment (0-24 weeks after DJBL implantation) and analyzes accompanying gut 
hormone responses. In this chapter, we investigated the mechanism of action and the possible 
relation of the gut hormones and early T2DM improvement. In Chapter 4 the medium term follow up 
results of the DJBL are presented. The results show that the maximum effect of the DJBL is reached 
six months after the DJBL is in place. Explantation of the DJBL is associated with weight gain and 
worsening of glycemic control, although some beneficial effects remained detectable 12 months after 
explantation. A change in strategy is needed to preserve the beneficial effects of DJBL treatment. In 
Chapter 5 we share our experience with DJBL on managing complications that have occurred or might 
occur. The DJBL is a noninvasive device with manageable complications in experience hands. 
Nevertheless, it can potentially cause mild, but also some serious complications. Chapter 6 
demonstrates the safety, efficacy and feasibility of delivering the DJBL under conscious sedation. In 
the first cohort of patients, the DJBL was implanted under general anesthesia. This approach will have 
impact on hospital stay and on the cost as well. This will help to make the DJBL more affordable and 
more cost efficient. From December 2011, the DJBL has a CE mark to treat patients for twelve months 
and it should be explanted at the end of these twelfth months. After our first study, we observed 
weight regain and increasing HbA1c levels post-explant after a mean two years. Chapter 7 
demonstrates that re-implantation of the DJBL is feasible and safe. Although the study describes only 
a small group of patients we can conclude that in experienced hands the re-implantation of the DJBL 
is feasible and useful to further decrease HbA1c and weight.   
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Abstract 
 
Background. The DJBL is a bariatric procedure involving an impermeable sleeve which is delivered 
endoscopically in the proximal intestine. This procedure is less invasive than conventional surgical 
techniques, but also has beneficial effects on obesity and T2DM. 
 
Methods. A multicenter randomized controlled trial was performed. Seventy-seven patients with 
obesity and T2DM were included. Thirty-eight patients were randomized to six months DJBL 
treatment in combination with dietary intervention, (34 successfully implanted, 31 completed the 
study), 39 patients received only dietary intervention (controls, 35 completed the study). Total study 
duration for both groups was twelve months, including six months of post-DJBL-removal follow-up. 
 
Results. After six months, just prior to DJBL removal, the DJBL group had lost 32.0[22.0-46.7]% of 
their excess weight vs. 16.4[4.1-34.6]% in the control group (p<0.05). HbA1c improved to 7.0[6.4-
7.5]% in the DJBL group and to 7.9[6.6-8.3]% in the control group (p<0.05). Additionally, 85.3% of 
DJBL patients showed decreased postprandial glucose excursions vs. 48.7% of control patients 
(p<0.05). At twelve months, excess weight loss of the DJBL group was 19.8[10.6-45.0]% vs. 11.7[1.4-
25.4]% in the control group (p<0.05). HbA1c was 7.3[6.6-8.0]% vs. 8.0[6.8-8.8]%, DJBL vs. control 
respectively (p=ns). 
 
Conclusions. The DJBL is a safe and effective alternative to invasive bariatric procedures. Six months 
of DJBL treatment combined with a diet leads to superior weight loss and improvement of T2DM 
when compared to diet alone. 
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Introduction  
Obesity is a rapidly growing problem worldwide. Once considered only a problem in western society, 
obesity rates are now also rising dramatically in formerly developing countries [1]. Importantly, 
obesity is a major risk factor for several chronic diseases, including type 2 diabetes mellitus (T2DM) 
and cardiovascular diseases [2]. Furthermore, it is associated with impaired health-related quality of 
life [3]. Today, more than 500 million adults are overweight and millions of these people face the dual 
challenge of managing T2DM and obesity [1,4]. Lifestyle changes resulting in weight loss improve 
T2DM and are, next to medication, the most important treatment modality for T2DM. Although 
conservative therapy is usually successful in weight control in the short term, long term results are 
often disappointing [5]. Bariatric surgery, on the other hand, has proven its effectiveness in achieving 
and maintaining weight loss and improving T2DM, quality of life, and survival [5, 6]. While, surgery is 
increasingly performed and effective, it is associated with potentially important complications, and 
although rare, mortality [9]. Therefore, less invasive and safer techniques that will offer treatment for 
a broader spectrum of patients are searched for [10].  
Recently, a novel non-surgical bariatric technique has been developed, the duodenal-jejunal bypass 
liner (DJBL, GI Dynamics, Lexington, MA). The DJBL consists of a 60 cm long fluoropolymer liner which 
is delivered into and retrieved from the duodenum endoscopically. Its principle is based on the 
effectiveness of surgical duodenal-jejunal exclusion in treating obesity and T2DM; once placed in the 
duodenum it mimics the intestinal bypass component of the well-known Roux-en-Y gastric bypass and 
surgical duodenal-jejunal exclusion. Clinical experience to date has demonstrated the safety of the 
DJBL and its ability to rapidly improve blood glucose control and induce weight loss [11-16]. In 
addition, the DJBL has been shown to improve other metabolic parameters, including lipid profile and 
blood pressure [17-19]. In the current randomized controlled study, we aimed to investigate the 
safety of six months DJBL treatment and the effect on obesity, T2DM, and cardiovascular risk profile 
in obese patients with T2DM. After DJBL treatment patients were followed up for six months to 
evaluate post-removal effects.  
Methods 
Patients 
Patients were considered eligible if they were between 18 and 65 years old; had a BMI between 30 
and 50 kg/m2; and had T2DM for less than 10 years with an HbA1c level between 7.5 and 10.0 %. 
Patients could take metformin, sulfonylurea derivates (SU), and/or insulin with a maximum dose of 
150 IU per day. Exclusion criteria were: weight loss of >4.5 kg within 12 weeks prior to screening; 
pregnancy or intention to become pregnant; use of NSAIDS, anticoagulation therapy, corticosteroids, 
weight loss medication, or drugs known to affect gastrointestinal motility; substance abuse; active H. 
pylori infection; probable insulin production failure as indicated by a c-peptide level of <1.0 ng/mL; 
iron deficiency or iron deficiency anemia; GI tract abnormalities or previous surgery in the 
gastrointestinal tract that could affect the ability to place the device; symptomatic gallstones or 
kidney stones; known infection; bleeding disorders; gastroesophageal reflux disorder; connective 
tissue disorders; and severe liver or kidney failure as indicated by a creatinine level of >180 mmol/L.  
Study Protocol 
In a prospective, randomized, controlled, multicenter study, 77 patients were included in Rijnstate 
Hospital, Arnhem; Maastricht University Medical Center, Maastricht; and Atrium Medical Centrum 
Parkstad, Heerlen. As shown in Figure 1, 38 patients were randomized to the DJBL treatment group 
and 39 patients were randomized to the control group. Patients in the DJBL group were to be treated 
for six months with the DJBL and were followed up for an additional six months after removal of the 
device. Of the DJBL group, 34 patients were implanted (three failures, one withdrawal). Groups were 
comparable with respect to age, gender, BMI and comorbidities, see Table 1.  
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At the initiation of the study, data on patient demographics, physical examination (including weight, 
BMI, and blood pressure), and medical history were collected. An ECG, chest X-ray, and abdominal 
ultrasound were performed to rule out the presence of apparent pulmonary, cardiovascular, or 
gastrointestinal disease. Laboratory parameters were obtained prior to the start of the treatment 
(HbA1C, fasting glucose and insulin, total cholesterol, HDL, LDL, triglycerides, amylase, lipase, 
haemoglobin, haematocrit, iron, serum creatinine, vitamin D, calcium, and c-peptide) and a 4-hour 
standard meal tolerance test was performed, using a standard liquid meal (Ensure Plus vanilla flavor, 
Abbott Laboratories, IL; 333 mL, 500 kcal, 20.8 gr protein, 67.3 gr carbohydrates, and 16.4 gr fat). 
During the study, all patients were prescribed a diet with a maximum of 1,200 kcal for women and 
1,500 kcal for men which was liquid for the first week. In addition, patients were advised to increase 
their physical activities. Medical treatment for T2DM was managed by a diabetes nurse under 
supervision of an endocrinologist. To avoid hypoglycemic events, the dose of glucose lowering 
medication, except for metformin, was reduced by 50% at the time of implant or initiation of the diet. 
If hypoglycemic or hyperglycemic episodes were experienced, additional adaptations to the medical 
treatment were performed as regular. Additionally, DJBL patients were prophylactically prescribed a 
proton pump inhibitor for the duration of DJBL treatment to prevent peptic ulcer formation in the 
stomach and duodenum. 
Regular follow-up visits were performed at 1 week, 1 month, 2 months, 3 months, 4 months, 5 
months, 6 months, 7 months, 8 months, 9 months, and at 12 months. DJBL patients had an additional 
hospital visit 1 week after removal of the device. During these visits weight and blood pressure were 
measured, adverse events were assessed, nutritional and diabetes counselling was performed, and 
blood was withdrawn to determine the same laboratory parameters as determined at the start of the 
study. The percentage of excess weight loss was calculated as: (initial weight - current weight) / 
weight corresponding with BMI of 25 kg/m2. In addition, a standard 4-hour meal tolerance test was 
performed at 1 week and at 1, 3, and 6 months in both groups.  
 
Table 1. Subject characteristics 
Parameter Device Group Diet Group P-value 
 n=34 n=39  
Sex (male, No. of subjects) 21 (61.8) 25 (64.1)  
Age (yr) 49.8 ± 1.6 49.3 ± 1.2  
Weight (kg) 110.1 ± 3.3 113.5 ± 3.1 0.46 
BMI (kg/m²) 35.7 ± 0.9 37.2 ± 0.8 0.19 
Duration of T2DM (yr) 5.2 ± 0.5 5.0 ± 0.4  
HbA1c (%) 8.4 ± 0.1 8.4 ± 0.1 0.94 
Fasting glucose (mmol/L) 11.2 ± 0.4 11.2 ± 0.4 0.91 
Fasting insulin (mU/L) 22.3 ± 4.8 30.8 ± 6.5 0.29 
Systolic blood pressure (mmHg) 146.6 ± 2.4 149.8 ± 2.9 0.41 
Diastolic blood pressure (mmHg) 89.2 ± 1.6 88.9 ± 1.7 0.89 
Total cholesterol (mmol/L) 4.5 ± 0.1 4.5 ± 0.2 0.77 
Values are presented as No of subjects (%) or mean ± standard error of the mean. 
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device. Of the DJBL group, 34 patients were implanted (three failures, one withdrawal). Groups were 
comparable with respect to age, gender, BMI and comorbidities, see Table 1.  
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At the initiation of the study, data on patient demographics, physical examination (including weight, 
BMI, and blood pressure), and medical history were collected. An ECG, chest X-ray, and abdominal 
ultrasound were performed to rule out the presence of apparent pulmonary, cardiovascular, or 
gastrointestinal disease. Laboratory parameters were obtained prior to the start of the treatment 
(HbA1C, fasting glucose and insulin, total cholesterol, HDL, LDL, triglycerides, amylase, lipase, 
haemoglobin, haematocrit, iron, serum creatinine, vitamin D, calcium, and c-peptide) and a 4-hour 
standard meal tolerance test was performed, using a standard liquid meal (Ensure Plus vanilla flavor, 
Abbott Laboratories, IL; 333 mL, 500 kcal, 20.8 gr protein, 67.3 gr carbohydrates, and 16.4 gr fat). 
During the study, all patients were prescribed a diet with a maximum of 1,200 kcal for women and 
1,500 kcal for men which was liquid for the first week. In addition, patients were advised to increase 
their physical activities. Medical treatment for T2DM was managed by a diabetes nurse under 
supervision of an endocrinologist. To avoid hypoglycemic events, the dose of glucose lowering 
medication, except for metformin, was reduced by 50% at the time of implant or initiation of the diet. 
If hypoglycemic or hyperglycemic episodes were experienced, additional adaptations to the medical 
treatment were performed as regular. Additionally, DJBL patients were prophylactically prescribed a 
proton pump inhibitor for the duration of DJBL treatment to prevent peptic ulcer formation in the 
stomach and duodenum. 
Regular follow-up visits were performed at 1 week, 1 month, 2 months, 3 months, 4 months, 5 
months, 6 months, 7 months, 8 months, 9 months, and at 12 months. DJBL patients had an additional 
hospital visit 1 week after removal of the device. During these visits weight and blood pressure were 
measured, adverse events were assessed, nutritional and diabetes counselling was performed, and 
blood was withdrawn to determine the same laboratory parameters as determined at the start of the 
study. The percentage of excess weight loss was calculated as: (initial weight - current weight) / 
weight corresponding with BMI of 25 kg/m2. In addition, a standard 4-hour meal tolerance test was 
performed at 1 week and at 1, 3, and 6 months in both groups.  
 
Table 1. Subject characteristics 
Parameter Device Group Diet Group P-value 
 n=34 n=39  
Sex (male, No. of subjects) 21 (61.8) 25 (64.1)  
Age (yr) 49.8 ± 1.6 49.3 ± 1.2  
Weight (kg) 110.1 ± 3.3 113.5 ± 3.1 0.46 
BMI (kg/m²) 35.7 ± 0.9 37.2 ± 0.8 0.19 
Duration of T2DM (yr) 5.2 ± 0.5 5.0 ± 0.4  
HbA1c (%) 8.4 ± 0.1 8.4 ± 0.1 0.94 
Fasting glucose (mmol/L) 11.2 ± 0.4 11.2 ± 0.4 0.91 
Fasting insulin (mU/L) 22.3 ± 4.8 30.8 ± 6.5 0.29 
Systolic blood pressure (mmHg) 146.6 ± 2.4 149.8 ± 2.9 0.41 
Diastolic blood pressure (mmHg) 89.2 ± 1.6 88.9 ± 1.7 0.89 
Total cholesterol (mmol/L) 4.5 ± 0.1 4.5 ± 0.2 0.77 
Values are presented as No of subjects (%) or mean ± standard error of the mean. 
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The study was conducted in accordance with the Standard ISO 14155: 2003 on clinical investigations 
with medical devices and the recommendations guiding physicians in biomedical research involving 
human patients adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and later 
revisions. The study was approved by the medical ethical committee of all three participating 
hospitals. Prior to the start of the study, written informed consent was obtained from all patients.  
And the study was registered in the ClinicalTrials.gov with trial number NCT00985114. 
DJBL procedure 
The DJBL is a single use endoscopic device mimicking the intestinal bypass component of the Roux-en-
Y gastric bypass (Fig. 2A+B). The device consists of a 60 cm long impermeable fluoropolymer liner and 
a nitinol anchor, which is used to reversibly affix the device to the duodenum (Fig. 2C+D). The anchor 
is located in the duodenal bulb and the liner stretches out through the duodenum and the proximal 
part of the jejunum. To allow food passage, the DJBL is open at both the proximal and the distal end. 
As a result, chyme passes through the interior of the DJBL while pancreatic enzymes and bile pass on 
the outside of the liner. Digestion and absorption of nutrients therefore start at the end of the liner, 
creating a bypass of the proximal intestinal tract.  
Inclusion
N=77
DJBL group
N=38
Start3 implant 
failures
1 withdrawal
Start treatment
N=34
1 early removal
Month 6
N=33
2 lost to follow-
up
Month 12
N=31
Diet group
N=39
Start treatment
N=39
Month 6
N=37
Month 12
N=34
2 withdrew 
consent
1 lost to follow-
up
2 withdrew 
consent
Figure 1. Randomization chart 
26   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
A 
D C 
B 
 
FIGURE 2. Illustration of the DJBL and the delivery system. A, DJBL. The device is endoscopically placed in the duodenum to 
form a barrier between chyme and the intestinal wall, mimicking the intestinal bypass component of the Roux-en-Y gastric 
bypass (B). C, The device comprises a 60-cm long impermeable fluoropolymer sleeve and a nitinol anchor with barbs. The 
polypropylene drawstring is necessary for removal of the device. D, The implant device with a guide wire, deployment 
device, and the encapsulated sleeve. 
 
Implantation of the DJBL was performed under general anesthesia with endotracheal intubation. 
Initial access to the stomach and duodenum was achieved by a standard gastroduodenoscopy. Next, a 
guide wire was advanced into the duodenum and the encapsulated device was tracked over the guide 
wire into the duodenum. The capsule at the distal end holds the liner and anchor. The catheter has an 
atraumatic ball at the end which is advanced through the intestine deploying the liner behind it. After 
full extension of the liner, the anchor was deployed in the duodenal bulb, approximately 0.5 cm distal 
to the pylorus. Endoscopic and fluoroscopic guidance was used to verify the correct position of the 
DJBL. Mean procedure time was 32±4 minutes. After six months, the DJBL was removed as previously 
described [15]. Seventeen removals were performed under general anesthesia and 17 under 
conscious sedation. The mean procedure time of the removals was 11±2 minutes. 
Statistical analysis  
With a population of 35 subjects per group, a Fisher’s exact test employing a two-tailed alpha of 0.05 
will have 80% power to achieve statistical significance between subject proportions of 25% (control) 
and 60% (device) achieving a ≥ 0.5% reduction in HbA1C at month 6 or time of explant. In addition, 
with a sample size of 35 subjects per group, the probability of observing at least one occurrence of an 
adverse event will be 80% when the true probability of this event is 5.0%. Analyses were performed 
on all patients randomized into the study and successfully treated with DJBL or diet with at least one 
follow-up visit. A univariate analysis using the Shapiro-Wilk test for normality suggested that several 
variables in the efficacy and other metabolic data were not normally distributed. Therefore, the 
median and interquartile ranges are presented of all efficacy, laboratory, and physiological variables. 
Wilcoxon Rank Sum test were used to compare the difference between two groups for numeric 
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atraumatic ball at the end which is advanced through the intestine deploying the liner behind it. After 
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to the pylorus. Endoscopic and fluoroscopic guidance was used to verify the correct position of the 
DJBL. Mean procedure time was 32±4 minutes. After six months, the DJBL was removed as previously 
described [15]. Seventeen removals were performed under general anesthesia and 17 under 
conscious sedation. The mean procedure time of the removals was 11±2 minutes. 
Statistical analysis  
With a population of 35 subjects per group, a Fisher’s exact test employing a two-tailed alpha of 0.05 
will have 80% power to achieve statistical significance between subject proportions of 25% (control) 
and 60% (device) achieving a ≥ 0.5% reduction in HbA1C at month 6 or time of explant. In addition, 
with a sample size of 35 subjects per group, the probability of observing at least one occurrence of an 
adverse event will be 80% when the true probability of this event is 5.0%. Analyses were performed 
on all patients randomized into the study and successfully treated with DJBL or diet with at least one 
follow-up visit. A univariate analysis using the Shapiro-Wilk test for normality suggested that several 
variables in the efficacy and other metabolic data were not normally distributed. Therefore, the 
median and interquartile ranges are presented of all efficacy, laboratory, and physiological variables. 
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variables. Proportions between the two groups were compared using Fisher’s Exact test. Missing data 
were not imputed. A p-value <0.05 was considered statistically significant. 
Results 
DJBL vs. control: effect on weight 
Baseline characteristics of both groups are shown in table 1. At baseline, the mean body weight of the 
DJBL group was 105.4 [98.2-116.1] vs. 110.8 [99.7-129.0] kg in the control group (p=0.29). Mean BMI 
was 34.6 [32.4-38.1] kg/m2 in the DJBL group at baseline vs. 36.8 [32.6-42.0] kg/m2 in the control 
group (p=0.16). After six months, body weight had decreased by 10.6 [7.4-12.6] kg in the DJBL group 
(Fig. 3A). In comparison, the weight of the control group had decreased by 5.3 [1.9-10.6] kg (p<0.05, 
DJBL vs. control). Correspondingly, BMI decreased by 3.3 [2.2-4.2] kg/m2 in the DJBL group vs. 1.8 
[0.7-3.4] kg/m2 in the control group (Fig. 3B, p<0.05). In addition, excess weight loss was superior in 
the DJBL group; 32.0 [22.0-46.7] % in the DJBL vs. 16.4 [4.1-34.6] % in the control group respectively 
(p<0.05; Fig. 3C). In line, the percent total weight loss was greater in the DJBL group (DJBL: 10.0 [6.8-
12.3] vs. control: 4.7 [1.5-9.6] %; p<0.05; Fig. 3D).  
At month twelve, mean body weight of the DJBL patients was still 6.8 [3.3-12.0] kg lower than at 
baseline. In the control group, the weight difference was 4.0 [0.8-8.6] kg compared to baseline 
(p=0.07, DJBL vs. control). Accordingly, at this time point, BMI was 2.2 [1.2-3.4] kg/m2 lower 
compared to baseline in the DJBL group and 1.3 [0.3-2.8] kg/m2 lower in the control group (p=0.06). 
Importantly, DJBL patients still had an excess weight loss of 19.8 [10.6-45.0] % vs. 11.7 [1.4-25.4] % in 
the control group (p<0.05). The percent total weight loss was 5.8 [2.8-11.1] % in the DJBL group vs. 
3.5 [06-8.6] % in the control group (p<0.05). 
Figure 3. Effects of DJBL treatment vs. control treatment on weight parameters. Panel A displays weight changes over time 
for both the DJBL and the control group. Panel B shows the changes in BMI. Panel C depicts the percentage of excess weight 
loss over time whereas panel D shows the percentage of total body weight loss at all-time points for both the DJBL and 
control group. An asterisk (*) indicates p<0.05. 
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Effect of DJBL vs. control treatment on T2DM 
At baseline, the DJBL group was characterized by an HbA1c of 8.3 [7.7-9.0] vs. 8.3 [7.7-8.9] % in the 
control group (p=0.82). The fasting glucose level was 11.0 [9.4-13.0] mmol/L in the DJBL group and 
11.0 [9.3-13.1] mmol/L in the control group (p=0.87). Fasting insulin levels were 15.0 [9.0-21.0] and 
17.0 [13.0-36.0] mU/L in the DJBL and control group respectively (p=0.11, Table 1). At six months, 
HbA1c decreased to 7.0 [6.4-7.5] % in the DJBL group compared to 7.9 [6.6-8.3] % in the control group 
(Fig. 4A, p<0.05). Moreover, fasting glucose levels decreased to 8.5 [74-10.5] mmol/L in the DJBL 
group (Fig. 4B). In the control group, fasting glucose levels were 10.0 [7.6-11.5] mmol/L (Fig. 5D, 
p=0.10 DJBL vs. control). As shown in Figure 4F+H, fasting insulin levels decreased to 11.1 [7.0-17.8] 
and 14.0 [10.0-19.8] mU/L for the DJBL and control group respectively, p=0.40. In the DJBL group 85.3 
% of the patients achieved a decrease in postprandial glucose excursion vs. 48.7 % in the control 
group (p<0.05, Fig 4C+E). Additionally, changes in insulin levels as obtained during the meal tolerance 
tests are visualized in Figure 4F+H.  
At month twelve, mean HbA1c increased to 7.3 [6.6-8.0] % in the DJBL group vs. an increase to 8.0 
[6.8-8.8] in the control group (p=0.95, DJBL vs. control). Fasting glucose levels were 9.0 [7.4-11.1] and 
9.7 [8.4-12.3] mmol/L for the DJBL and control group respectively (p=0.41) and fasting insulin levels 
were 15.0 [8.0-19.5] and 15.7 [8.6-23.6] mU/L respectively (p=0.73).  
Changes in glucose lowering medication 
All participants used glucose lowering medication at baseline. In the DJBL group (n=38), 36 patients 
were on metformin, 28 patients were on sulfonylurea derivates (SU), and 17 patients were on insulin. 
In the control group (n=39), 33 patients were on metformin, 30 patients were on SU, and 19 patients 
were on insulin. Changes in glucose lowering medication evaluated at month six and month twelve 
are displayed in Table 2. Importantly, the daily insulin dosage was more often decreased or 
discontinued in the DJBL group compared to the control group (p<0.05 at month twelve). The same 
trend was observed for the usage of SUs (p< 0.05 at month twelve). 
Effect of DJBL vs. control treatment on cardiovascular parameters 
At baseline, 34% of the DJBL patients vs. 41% of the diet patients were on antihypertensive 
medication. During the course of the study, only minor medication changes were made. After six 
months of treatment, blood pressure decreased from 147 [139-156] / 92 [82-96] to 132 [122-140] / 
81 [72-90] mmHg in the DJBL group and from 152 [138-160] / 90 [82-96] to 137 [124-148] / 82 [79-90] 
mmHg in the control group (Table 2, p=0.25 for systolic blood pressure and p=0.29 for diastolic blood 
pressure). Total cholesterol levels decreased from 4.4 [3.-5.0] to 3.7 [3.4-4.2] mmol/L in the DJBL 
group. In the control group, no change was observed (4.4 [3.6-5.3] vs. 4.5 [3.9-5.1] mmol/L, p=0.02 
DJBL vs. control at month six).  
At the end of the study, after twelve months, blood pressure had stabilized; for DJBL patients the 
mean value was 130 [124-144] / 82 [77-90] vs. 140 [122-148] / 85 [78-90] mmHg in the control group 
(p=0.31 for systolic blood pressure and p=0.38 for diastolic blood pressure). The total cholesterol level 
of all patients was comparable to baseline (4.4 [4.0-5.3] vs. 4.4 [3.9-5.1] DJBL vs. control group 
respectively, p=0.79).  
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variables. Proportions between the two groups were compared using Fisher’s Exact test. Missing data 
were not imputed. A p-value <0.05 was considered statistically significant. 
Results 
DJBL vs. control: effect on weight 
Baseline characteristics of both groups are shown in table 1. At baseline, the mean body weight of the 
DJBL group was 105.4 [98.2-116.1] vs. 110.8 [99.7-129.0] kg in the control group (p=0.29). Mean BMI 
was 34.6 [32.4-38.1] kg/m2 in the DJBL group at baseline vs. 36.8 [32.6-42.0] kg/m2 in the control 
group (p=0.16). After six months, body weight had decreased by 10.6 [7.4-12.6] kg in the DJBL group 
(Fig. 3A). In comparison, the weight of the control group had decreased by 5.3 [1.9-10.6] kg (p<0.05, 
DJBL vs. control). Correspondingly, BMI decreased by 3.3 [2.2-4.2] kg/m2 in the DJBL group vs. 1.8 
[0.7-3.4] kg/m2 in the control group (Fig. 3B, p<0.05). In addition, excess weight loss was superior in 
the DJBL group; 32.0 [22.0-46.7] % in the DJBL vs. 16.4 [4.1-34.6] % in the control group respectively 
(p<0.05; Fig. 3C). In line, the percent total weight loss was greater in the DJBL group (DJBL: 10.0 [6.8-
12.3] vs. control: 4.7 [1.5-9.6] %; p<0.05; Fig. 3D).  
At month twelve, mean body weight of the DJBL patients was still 6.8 [3.3-12.0] kg lower than at 
baseline. In the control group, the weight difference was 4.0 [0.8-8.6] kg compared to baseline 
(p=0.07, DJBL vs. control). Accordingly, at this time point, BMI was 2.2 [1.2-3.4] kg/m2 lower 
compared to baseline in the DJBL group and 1.3 [0.3-2.8] kg/m2 lower in the control group (p=0.06). 
Importantly, DJBL patients still had an excess weight loss of 19.8 [10.6-45.0] % vs. 11.7 [1.4-25.4] % in 
the control group (p<0.05). The percent total weight loss was 5.8 [2.8-11.1] % in the DJBL group vs. 
3.5 [06-8.6] % in the control group (p<0.05). 
Figure 3. Effects of DJBL treatment vs. control treatment on weight parameters. Panel A displays weight changes over time 
for both the DJBL and the control group. Panel B shows the changes in BMI. Panel C depicts the percentage of excess weight 
loss over time whereas panel D shows the percentage of total body weight loss at all-time points for both the DJBL and 
control group. An asterisk (*) indicates p<0.05. 
A B 
D 
0 1 2 3 4 5 6 7 8 9 12
90
95
100
105
110
115
120
125
Treatment time (months)
W
ei
gh
t (
kg
)
0 1 2 3 4 5 6 7 8 9 12
30
32
34
36
38
40
Treatment time (months)
B
M
I (
kg
/m
2 )
0 1 2 3 4 5 6 7 8 9 12
0
10
20
30
40
50
Treatment time (months)
Ex
ce
ss
 W
ei
gh
t L
os
s 
(%
)
0 1 2 3 4 5 6 7 8 9 12
-15
-10
-5
0
Treatment time (months)
To
ta
l W
ei
gh
t L
os
s 
(%
)
C 
28   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
Effect of DJBL vs. control treatment on T2DM 
At baseline, the DJBL group was characterized by an HbA1c of 8.3 [7.7-9.0] vs. 8.3 [7.7-8.9] % in the 
control group (p=0.82). The fasting glucose level was 11.0 [9.4-13.0] mmol/L in the DJBL group and 
11.0 [9.3-13.1] mmol/L in the control group (p=0.87). Fasting insulin levels were 15.0 [9.0-21.0] and 
17.0 [13.0-36.0] mU/L in the DJBL and control group respectively (p=0.11, Table 1). At six months, 
HbA1c decreased to 7.0 [6.4-7.5] % in the DJBL group compared to 7.9 [6.6-8.3] % in the control group 
(Fig. 4A, p<0.05). Moreover, fasting glucose levels decreased to 8.5 [74-10.5] mmol/L in the DJBL 
group (Fig. 4B). In the control group, fasting glucose levels were 10.0 [7.6-11.5] mmol/L (Fig. 5D, 
p=0.10 DJBL vs. control). As shown in Figure 4F+H, fasting insulin levels decreased to 11.1 [7.0-17.8] 
and 14.0 [10.0-19.8] mU/L for the DJBL and control group respectively, p=0.40. In the DJBL group 85.3 
% of the patients achieved a decrease in postprandial glucose excursion vs. 48.7 % in the control 
group (p<0.05, Fig 4C+E). Additionally, changes in insulin levels as obtained during the meal tolerance 
tests are visualized in Figure 4F+H.  
At month twelve, mean HbA1c increased to 7.3 [6.6-8.0] % in the DJBL group vs. an increase to 8.0 
[6.8-8.8] in the control group (p=0.95, DJBL vs. control). Fasting glucose levels were 9.0 [7.4-11.1] and 
9.7 [8.4-12.3] mmol/L for the DJBL and control group respectively (p=0.41) and fasting insulin levels 
were 15.0 [8.0-19.5] and 15.7 [8.6-23.6] mU/L respectively (p=0.73).  
Changes in glucose lowering medication 
All participants used glucose lowering medication at baseline. In the DJBL group (n=38), 36 patients 
were on metformin, 28 patients were on sulfonylurea derivates (SU), and 17 patients were on insulin. 
In the control group (n=39), 33 patients were on metformin, 30 patients were on SU, and 19 patients 
were on insulin. Changes in glucose lowering medication evaluated at month six and month twelve 
are displayed in Table 2. Importantly, the daily insulin dosage was more often decreased or 
discontinued in the DJBL group compared to the control group (p<0.05 at month twelve). The same 
trend was observed for the usage of SUs (p< 0.05 at month twelve). 
Effect of DJBL vs. control treatment on cardiovascular parameters 
At baseline, 34% of the DJBL patients vs. 41% of the diet patients were on antihypertensive 
medication. During the course of the study, only minor medication changes were made. After six 
months of treatment, blood pressure decreased from 147 [139-156] / 92 [82-96] to 132 [122-140] / 
81 [72-90] mmHg in the DJBL group and from 152 [138-160] / 90 [82-96] to 137 [124-148] / 82 [79-90] 
mmHg in the control group (Table 2, p=0.25 for systolic blood pressure and p=0.29 for diastolic blood 
pressure). Total cholesterol levels decreased from 4.4 [3.-5.0] to 3.7 [3.4-4.2] mmol/L in the DJBL 
group. In the control group, no change was observed (4.4 [3.6-5.3] vs. 4.5 [3.9-5.1] mmol/L, p=0.02 
DJBL vs. control at month six).  
At the end of the study, after twelve months, blood pressure had stabilized; for DJBL patients the 
mean value was 130 [124-144] / 82 [77-90] vs. 140 [122-148] / 85 [78-90] mmHg in the control group 
(p=0.31 for systolic blood pressure and p=0.38 for diastolic blood pressure). The total cholesterol level 
of all patients was comparable to baseline (4.4 [4.0-5.3] vs. 4.4 [3.9-5.1] DJBL vs. control group 
respectively, p=0.79).  
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Figure 4. Effects of DJBL treatment on T2DM. A) HbA1c 
levels. B) Glucose concentrations of the DJBL group 
during the meal tolerance tests (MTT). C) AUC of 
glucose. D) Glucose concentrations of the control group 
during the MTT. E) AUC of glucose. F) Insulin levels 
during the MTT of the DJBL patients. G) AUC of insulin. 
H) Insulin concentrations of the control patients during 
the MTT. I) AUC of insulin. An asterisk (*) indicates 
p<0.05.  
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Table 2. Change in glucose lowering medication. The values given are percentages. 
 Month 6 Month 12 
 DJBL Control  DJBL Control  
Metformin     
Decreased  8.8 7.7 16.7 7.9 
Discontinued  2.9 -- 3.3 2.6 
Increased  -- -- 3.3 10.5 
SU derivatives      
Decreased  47.1 38.5 40.0 13.9 
Discontinued 14.7 23.1 13.3 13.9 
Increased 2.9 2.6 6.7 13.9 
Insulin     
Decreased  41.2 30.8 36.7 20.5 
Discontinued -- -- 13.3 -- 
Increased -- 10.3 -- 23.1 
 
In the DJBL group, there were eight adverse events requiring hospitalization. Five out of the eight 
events were device-related. One patient presented with melena and pain in the epigastric region, 
however no bleeding was found during endoscopic evaluation and complaints disappeared with 
conservative treatment. An additional patient presented with abdominal discomfort and subsequent 
dehydration due to insufficient fluid intake, which was also managed conservatively. In one patient, 
the DJBL got obstructed with food, making early removal necessary. One patient suffered from 
symptomatic gallstones during the study and was treated with a laparoscopic cholecystectomy. All 
device-related serious adverse events resolved without sequelae. Only one procedure-related serious 
adverse event occurred, an esophageal perforation during a scheduled DJBL removal at month six. 
After an apparent uncomplicated removal, final endoscopic evaluation revealed a 6-cm longitudinal, 
partially transmural tear of the esophagus. This was probably caused by one of the barbs on the 
anchor that was not fully covered by the removal hood. Treatment of the perforation was performed 
by endoscopic stenting and placement of a feeding tube. After three weeks, the tear had resolved 
without sequelae and the patient completed the study. During the study, only one DJBL patient 
withdrew consent due to an adverse event of abdominal pain at day 10. Two additional patients were 
lost to follow-up (at days 191 and 272 respectively, for more information see Figure 1). 
In the control group, there were also eight adverse events requiring hospitalization. By the end of the 
study five events had resolved without sequelae. The events that did not resolve without sequelae 
consisted of a myocardial infarction, a humerus fracture, a lower back hernia, diagnosis of cancer, and 
a non-specified psychiatric disorder. In this group, four patients withdrew informed consent. One at 
week one, month three, day 315, and one patient withdrew consent at day 273 when diagnosed with 
cancer. One patient was lost to follow-up at day 267.  
Discussion 
There is overwhelming evidence that bariatric surgery promotes weight loss and improves glucose 
homeostasis [20]. The Roux-en-Y gastric bypass and the biliopancreatic diversion seem to be the most 
effective procedures; both techniques cause significant weight loss and durable remission of T2DM 
[8,21-23]. Interestingly, the improvement of T2DM occurs rapidly within days following both types of 
surgery [23-25]. This rapid glycemic improvement is thought to be specifically attributable to the 
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Figure 4. Effects of DJBL treatment on T2DM. A) HbA1c 
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during the meal tolerance tests (MTT). C) AUC of 
glucose. D) Glucose concentrations of the control group 
during the MTT. E) AUC of glucose. F) Insulin levels 
during the MTT of the DJBL patients. G) AUC of insulin. 
H) Insulin concentrations of the control patients during 
the MTT. I) AUC of insulin. An asterisk (*) indicates 
p<0.05.  
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Table 2. Change in glucose lowering medication. The values given are percentages. 
 Month 6 Month 12 
 DJBL Control  DJBL Control  
Metformin     
Decreased  8.8 7.7 16.7 7.9 
Discontinued  2.9 -- 3.3 2.6 
Increased  -- -- 3.3 10.5 
SU derivatives      
Decreased  47.1 38.5 40.0 13.9 
Discontinued 14.7 23.1 13.3 13.9 
Increased 2.9 2.6 6.7 13.9 
Insulin     
Decreased  41.2 30.8 36.7 20.5 
Discontinued -- -- 13.3 -- 
Increased -- 10.3 -- 23.1 
 
In the DJBL group, there were eight adverse events requiring hospitalization. Five out of the eight 
events were device-related. One patient presented with melena and pain in the epigastric region, 
however no bleeding was found during endoscopic evaluation and complaints disappeared with 
conservative treatment. An additional patient presented with abdominal discomfort and subsequent 
dehydration due to insufficient fluid intake, which was also managed conservatively. In one patient, 
the DJBL got obstructed with food, making early removal necessary. One patient suffered from 
symptomatic gallstones during the study and was treated with a laparoscopic cholecystectomy. All 
device-related serious adverse events resolved without sequelae. Only one procedure-related serious 
adverse event occurred, an esophageal perforation during a scheduled DJBL removal at month six. 
After an apparent uncomplicated removal, final endoscopic evaluation revealed a 6-cm longitudinal, 
partially transmural tear of the esophagus. This was probably caused by one of the barbs on the 
anchor that was not fully covered by the removal hood. Treatment of the perforation was performed 
by endoscopic stenting and placement of a feeding tube. After three weeks, the tear had resolved 
without sequelae and the patient completed the study. During the study, only one DJBL patient 
withdrew consent due to an adverse event of abdominal pain at day 10. Two additional patients were 
lost to follow-up (at days 191 and 272 respectively, for more information see Figure 1). 
In the control group, there were also eight adverse events requiring hospitalization. By the end of the 
study five events had resolved without sequelae. The events that did not resolve without sequelae 
consisted of a myocardial infarction, a humerus fracture, a lower back hernia, diagnosis of cancer, and 
a non-specified psychiatric disorder. In this group, four patients withdrew informed consent. One at 
week one, month three, day 315, and one patient withdrew consent at day 273 when diagnosed with 
cancer. One patient was lost to follow-up at day 267.  
Discussion 
There is overwhelming evidence that bariatric surgery promotes weight loss and improves glucose 
homeostasis [20]. The Roux-en-Y gastric bypass and the biliopancreatic diversion seem to be the most 
effective procedures; both techniques cause significant weight loss and durable remission of T2DM 
[8,21-23]. Interestingly, the improvement of T2DM occurs rapidly within days following both types of 
surgery [23-25]. This rapid glycemic improvement is thought to be specifically attributable to the 
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intestinal bypass component [26-28] which, according to the foregut hypothesis, results in glycemic 
improvement by reduced secretion of diabetogenic factors in the proximal small intestine [29,30]. 
The hindgut hypothesis, on the other hand, attributes improved glycemic control to enhanced 
secretion of incretins in response to undigested nutrients in the distal small intestine [27, 31]. 
Interestingly, exclusion of the proximal small intestine by means of the surgical duodenal-jejunal 
bypass, rapidly improves T2DM, even in non-obese patients [32]. 
The DJBL is a non-surgical endoscopic device developed to create an intestinal bypass in a minimally 
invasive way [15, 33]. Previous studies have revealed positive effects of the DJBL on obesity, T2DM, 
and the metabolic syndrome [11,19]. The aim of the current study was to investigate the effect of the 
DJBL on obesity and T2DM in a randomized manner, comparing six months of DJBL treatment in 
combination with dietary intervention to dietary treatment alone. This study is the first to report on 
six months DJBL treatment compared to dietary intervention. Furthermore, our study included six 
months of post-DJBL-removal follow-up. 
Six months after treatment initiation, the DJBL group lost significantly more weight than the diet 
group. In addition, HbA1c decreased significantly compared to the control group. DJBL treatment was 
associated with a greater percentage of patients achieving a decrease in postprandial glucose levels. 
Furthermore, glucose lowering medication was reduced or discontinued in more DJBL patients than 
control patients. These results are in line with previous studies performed with the DJBL. Since the 
first report of a successful DJBL implantation in a patient for a period of three months, resulting in a 
total weight loss of 9 kg, [34] several studies have demonstrated positive effects of DJBL treatment on 
obesity [11,18]. In addition, a marked improvement of T2DM was observed [11, 18]. Previously 
performed randomized controlled trials, comparing DJBL treatment vs. sham or diet control 
treatment, have displayed superiority of the DJBL in weight control and improvement of T2DM [12-
15].  Taken together, DJBL treatment in combination with a diet is more effective in treating obesity 
and T2DM when compared to dietary intervention alone.  
Interestingly, the mechanisms responsible for the effectiveness of duodenal-jejunal exclusion are still 
unknown. Since postprandial insulin secretion seemed stable over the course of the study, it is 
tempting to speculate that the rapid changes in the glucose response to a meal may result from 
increased insulin sensitivity and / or decreased hepatic glucose production [35]. As previously shown, 
changes in glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon 
parallel this phenomenon [16].  
Intraluminal implants in the digestive tract can theoretically be the cause of serious complications. 
Migration, bleeding, perforation, or obstruction are potential drawbacks and are reported often in 
numerous studies on stent placement for colonic malignancy [36]. Although design, indication and 
placement behind the pylorus of the DJBL is unprecedented, safety has been a point of meticulous 
observation. However, DJBL treatment for six months has shown to have a favorable risk/benefit 
ratio. In the current study, one procedure related event occurred requiring only conventional 
treatment. Moreover, the early removal rate was low (1 out of 34) in this study. Adverse events were 
mild and most commonly consisted of abdominal discomfort and nausea. They typically occurred 
during the first few weeks following DJBL implantation and usually resolved without treatment and 
without sequelae. So far, no mortality has been reported after DJBL treatment with a published 
experience of around 300 patients worldwide. Therefore, the DJBL can be considered as a safe 
treatment option for obesity and T2DM. 
After removal of the device, weight and HbA1c increased slightly in the DJBL group. A similar trend for 
weight and HbA1c was observed in the control group. At month twelve, the percentage of excess 
weight loss and the percentage of total weight loss was still significantly greater in the DJBL group. 
Changes in weight and HbA1c were no longer statistically different between the groups. Importantly, 
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weight and T2DM control remained improved compared to baseline in both groups. At the time of 
study initiation, the maximally approved DJBL treatment duration was six months in the Netherlands. 
de Moura, et al. were the first to investigate one-year DJBL treatment and demonstrated the safety 
and efficacy of the DJBL in reducing obesity and T2DM on the longer term [17]. These positive effects 
have now been confirmed by two additional one-year prospective clinical studies [19,37]. Based on 
these results, it might be expected that the improvement of T2DM observed in the current study with 
a treatment duration of six months would be even more pronounced with a longer treatment 
duration. As DJBL is an innovative technique the maximum potential of this device is yet uncertain. 
One of the drawbacks could theoretically be migration of the device’s anchor further into the 
duodenum. As the chance of migration potentially increases when the device is left in place for a 
longer period, implantation time is extended only gradually in order not to compromise the patient’s 
safety. Next to longer implantation time, intermittent implantation could be a valid alternative to 
prolong the therapeutic effect of the DJBL and studies are now being performed to evaluate the 
feasibility and efficacy of reimplantation.  
Regarding cardiovascular risk profile, as already described by Cohen, et al., subtle changes in cardio 
vascular risk profile can be of major clinical importance. [37] In the current population, the 10-year 
risk for coronary heart disease according to the UK Prospective Diabetes Study Risk Engine would be, 
without intervention, approximately 14.0 % in the DJBL group vs. 12.5 % in the control group at 
twelve months. With the DJBL intervention, the estimated 10-year coronary heart disease risk 
decreased by approximately 2 % vs. 1 % decrease in the control group, [38] possibly indicating 
superiority of the DJBL over dietary treatment with respect to reducing risk for development of 
cardiovascular disease.  In the treatment algorithm for obese patients with type 2 diabetes, the DJBL 
can be positioned in between medical therapy and invasive bariatric techniques. In addition, it might 
be beneficial to combine DJBL treatment with the very promising glucose lowering therapies that 
have recently become available, such as glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 
inhibitors, or sodium/glucose cotransporter-2 inhibitors [39]. In the current study, no patients using 
these types of medication were included; however, studies including these drugs seem of great 
interest.  
In conclusion, the current data suggest that the DJBL is a valid alternative to invasive bariatric 
procedures in the treatment of obesity and T2DM. Six months of DJBL treatment plus dietary 
intervention leads to significant weight loss and improvement of T2DM compared to dietary 
treatment alone. 
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The hindgut hypothesis, on the other hand, attributes improved glycemic control to enhanced 
secretion of incretins in response to undigested nutrients in the distal small intestine [27, 31]. 
Interestingly, exclusion of the proximal small intestine by means of the surgical duodenal-jejunal 
bypass, rapidly improves T2DM, even in non-obese patients [32]. 
The DJBL is a non-surgical endoscopic device developed to create an intestinal bypass in a minimally 
invasive way [15, 33]. Previous studies have revealed positive effects of the DJBL on obesity, T2DM, 
and the metabolic syndrome [11,19]. The aim of the current study was to investigate the effect of the 
DJBL on obesity and T2DM in a randomized manner, comparing six months of DJBL treatment in 
combination with dietary intervention to dietary treatment alone. This study is the first to report on 
six months DJBL treatment compared to dietary intervention. Furthermore, our study included six 
months of post-DJBL-removal follow-up. 
Six months after treatment initiation, the DJBL group lost significantly more weight than the diet 
group. In addition, HbA1c decreased significantly compared to the control group. DJBL treatment was 
associated with a greater percentage of patients achieving a decrease in postprandial glucose levels. 
Furthermore, glucose lowering medication was reduced or discontinued in more DJBL patients than 
control patients. These results are in line with previous studies performed with the DJBL. Since the 
first report of a successful DJBL implantation in a patient for a period of three months, resulting in a 
total weight loss of 9 kg, [34] several studies have demonstrated positive effects of DJBL treatment on 
obesity [11,18]. In addition, a marked improvement of T2DM was observed [11, 18]. Previously 
performed randomized controlled trials, comparing DJBL treatment vs. sham or diet control 
treatment, have displayed superiority of the DJBL in weight control and improvement of T2DM [12-
15].  Taken together, DJBL treatment in combination with a diet is more effective in treating obesity 
and T2DM when compared to dietary intervention alone.  
Interestingly, the mechanisms responsible for the effectiveness of duodenal-jejunal exclusion are still 
unknown. Since postprandial insulin secretion seemed stable over the course of the study, it is 
tempting to speculate that the rapid changes in the glucose response to a meal may result from 
increased insulin sensitivity and / or decreased hepatic glucose production [35]. As previously shown, 
changes in glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon 
parallel this phenomenon [16].  
Intraluminal implants in the digestive tract can theoretically be the cause of serious complications. 
Migration, bleeding, perforation, or obstruction are potential drawbacks and are reported often in 
numerous studies on stent placement for colonic malignancy [36]. Although design, indication and 
placement behind the pylorus of the DJBL is unprecedented, safety has been a point of meticulous 
observation. However, DJBL treatment for six months has shown to have a favorable risk/benefit 
ratio. In the current study, one procedure related event occurred requiring only conventional 
treatment. Moreover, the early removal rate was low (1 out of 34) in this study. Adverse events were 
mild and most commonly consisted of abdominal discomfort and nausea. They typically occurred 
during the first few weeks following DJBL implantation and usually resolved without treatment and 
without sequelae. So far, no mortality has been reported after DJBL treatment with a published 
experience of around 300 patients worldwide. Therefore, the DJBL can be considered as a safe 
treatment option for obesity and T2DM. 
After removal of the device, weight and HbA1c increased slightly in the DJBL group. A similar trend for 
weight and HbA1c was observed in the control group. At month twelve, the percentage of excess 
weight loss and the percentage of total weight loss was still significantly greater in the DJBL group. 
Changes in weight and HbA1c were no longer statistically different between the groups. Importantly, 
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longer period, implantation time is extended only gradually in order not to compromise the patient’s 
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twelve months. With the DJBL intervention, the estimated 10-year coronary heart disease risk 
decreased by approximately 2 % vs. 1 % decrease in the control group, [38] possibly indicating 
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these types of medication were included; however, studies including these drugs seem of great 
interest.  
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procedures in the treatment of obesity and T2DM. Six months of DJBL treatment plus dietary 
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Koehestanie P, Dogan K, Janssen IM, Groenen M, Wahab P Berends FJ, Müller M, de Wit N 
Endosc Int Open. 2014; 2(1): E21-7. 
Abstract 
 
Background and study aims. Endoscopic implantation of a Duodenal-Jejunal Bypass Liner (DJBL) is a 
novel bariatric technique to induce remission of type 2 diabetes (T2DM) and weight loss. Placement 
of the DJBL mimics the bypass component of the Roux-en-Y gastric bypass (RYGB) procedure. In this 
observational study, we evaluated improvement of glycemic control and weight loss in the course of 
the treatment (0-24 weeks after DJBL implantation) and analyzed accompanying gut hormone 
responses.  
 
Patients and methods. Twelve obese T2DM subjects were selected for DJBL implantation. Body 
weight, fat mass and fasting plasma levels of glucose, insulin, C peptide and HbA1c, were analyzed at 
0, 1, 4 and 24 weeks post-implant. Fasting ghrelin, GIP and GLP-1 were determined at 0, 1 and 4 
weeks post-implant.  
 
Results. Next to significant weight loss, also fat mass, fasting insulin and HOMA-IR index were 
significantly decreased after DJBL implantation and a 42% reduction was found in diabetes 
medication (p<0.05). The fasting GLP-1 response in the first 4 weeks post-implant was significantly 
correlated to the fasting insulin and HOMA-IR response. Fasting ghrelin was found significantly 
elevated, which stands in contrast to the decrease in ghrelin that is found after RYGB surgery.  
 
Conclusions. DJBL implantation provoked significant weight loss, a decrease in fat mass and an early 
remission of T2DM, comparable to results seen after RYGB surgery. Gut hormone analyses revealed a 
potential role of fasting GLP-1 in early remission of T2DM. Interestingly, the DJBL-induced elevation of 
ghrelin contradicts the suggested role of reduced ghrelin levels after RYGB in improvement of 
glycemic control.  
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Introduction 
Overweight and obesity are major risk factors for a number of chronic diseases, including diabetes, 
cardiovascular diseases and cancer [1]. Once considered a problem only in economically developed 
countries, overweight and obesity are now dramatically on the rise in economically developing 
countries, particularly in urban settings [2]. It is well established that obesity promotes insulin 
resistance and in doing so, forms the most important risk factor in developing type 2 diabetes 
(T2DM). Today more than 60 million people worldwide face the dual challenge of managing T2DM 
and obesity [2,3].  
Weight loss improves insulin resistance and forms, next to medication, one of the most important 
treatment modalities. Although conservative therapy such as diets and lifestyle training are 
frequently successful in weight control in the short term, long term results are most often 
disappointing due to problems with compliance to diets and lifestyle [4]. Bariatric surgery, on the 
other hand, has proven its effectiveness in achieving and maintaining weight loss and improving 
obesity-related T2DM, quality of life and survival [5]. It has been recognized that Roux-en-Y gastric 
bypass (RYGB) surgery causes remission of T2DM in the majority of operated subjects within days 
after the surgery [6,7]. The latter suggests that weight loss independent mechanisms are responsible 
for the early remission. It has been proposed that the early improvement in glycemic control 
following RYGB partly depends on the changes in intestinal anatomy and circulating levels of gut 
hormones, especially ghrelin and the incretin hormones, gastric inhibitory peptide (GIP) and 
glucagon-like peptide-1 (GLP-1) [8,9]. Ghrelin and GIP are assumed to be main effectors in the 
‘foregut hypothesis’ that states that exclusion of the foregut from nutrient exposure is most 
responsible for the rapid improvement of hyperglycemia [10,11]. GLP-1 is the main candidate for the 
‘hindgut theory’ that explains improved glycaemia by a faster delivery of nutrients to the hindgut 
after RYGB surgery. Both theories are currently still debated [12]. Although RYGB surgery is an 
efficient bariatric intervention for remission of T2DM, this surgery is a rather drastic measure that not 
every patient or doctor would prefer as a first treatment. Among the reasons not to embark on 
bariatric surgery are: Obesity not reaching NIH criteria (BMI less than 35 kg/m2) and fear of 
(complications of) surgery.  
Recently, a novel non-surgical bariatric technique has been developed, the duodenal-jejunal bypass 
liner (DJBL). The DJBL consist of a 60cm long fluoropolymer sleeve which can be delivered into and 
retrieved from the duodenum endoscopically. Once placed in the duodenum it mimics the intestinal 
bypass component of the RYGB. Clinical experience to date in more than 600 patients has 
demonstrated the safety and efficacy and the ability of the DJBL to rapidly affect blood glucose 
control and weight loss, while also demonstrating improvements in metabolic functions over time 
including cholesterol, blood pressure, LDL and triglycerides [13-16].  
Our goal was to investigate the effect of the DJBL on body weight, fat mass and early remission of 
T2DM during 6 months after implantation and explore the potential role of gut hormones in DJBL-
induced effects on weight loss and improvement of glycemic control. Therefore, body weight, fat 
mass, fasting plasma levels of glucose, insulin, C peptide and HbA1c were analyzed pre-implantation 
and after 1, 4 and 24 weeks post-implant. Additionally, at the first three-time points fasting plasma 
levels of ghrelin, GIP and GLP-1 were determined.  
Methods 
The study was performed according to the principles of the declaration of Helsinki.  The study was 
approved by the research and ethics committee at Rijnstate Hospital Arnhem, the Netherlands 
(protocol number: 1141), functioning according to the 3rd edition of the Guidelines on the Practice of 
Ethical Committees in Medical Research issued by the Royal College of Physicians of London. Written 
Chapter 3: Effects of Duodenal-Jejunal Bypass   |   39 
Informed consent was obtained from all participants after full explanation of the purpose and nature 
of all procedures.  
Patients 
Patients were considered eligible for the study if they were between 18 and 60 years old; had a BMI 
between 28 and 35 kg/m2; and T2DM with an HbA1c level above 7% Patients could take metformin, 
sulfonylurea derivates and/or insulin. Exclusion criteria were: pregnancy or intention to become 
pregnant; use of NSAIDS, anticoagulation therapy, corticosteroids, weight loss medication or drugs 
known to affect gastrointestinal motility; substance abuse; active H. pylori infection; dysfunctional ß 
cells (C peptide of <0.75 nmol/L); iron deficiency or iron deficiency anemia; GI tract abnormalities or 
previous surgery in the gastrointestinal tract that could affect the ability to place the device; 
symptomatic gallstones or kidney stones; known infection; bleeding disorders; gastroesophageal 
reflux disorder; connective tissue disorders; severe liver of kidney failure (creatinine >180mmol/L).  
Study Protocol 
For this observational study, twelve (7 male, 5 female) obese T2DM subjects (BMI 33.5  0.8 kg/m2, 
duration of T2DM 7.4  1.4 years) were selected for implantation of a DJBL and followed for 24 weeks 
post-implantation. During this study, body weight and fat mass were assessed using a body 
composition analyzer. Before implantation of the DJBL and 1, 4 and 24 weeks post-implantation of 
the DJBL, blood was drawn in EDTA tubes (Greiner Bio-One B.V, Alphen a/d Rijn, The Netherlands) 
after an overnight fasting period (at least 12 hours). Fasting plasma levels of gut hormones were only 
analyzed pre-implantation and 1 and 4 weeks post-implantation. Ten microliter per milliliter of blood 
DPP4 inhibitor (Merck Millipore, Billerica, MA, USA) was added within seconds after blood withdrawal 
(at 0, 1 and 4 weeks after DJBL implantation) to prevent degradation of active GLP-1 and GIP. Blood 
was centrifuged (within 1 hour) at 1000 x g for 10 min at 4 0C. Plasma was then aliquoted, snap-frozen 
and stored at -80 0C. Glucose, HbA1c and C peptide levels were measured at Rijnstate Hospital 
Arnhem following a standardized clinical protocol. The medication score was based on medication use 
for hyperglycemia control and was assessed before and within the first week after DJBL implantation.. 
It was based on the scoring system reported by Dorman et al. [17] (i.e. one point for each oral 
diabetes medication, one point for exenatide injections, two points for insulin injections) in 
combination with a scoring system in which for each medication unit one additional point was added 
(medication units: Metformin 500mg, Glimepiride 2mg, Tolbutamide 500mg, Galvus 50mg, Lantus 
10eh, Novorapid 10eh, Byet 10eh). 
Gut Hormone Assays 
Total ghrelin, active GLP-1 and total GIP concentrations were measured in human EDTA plasma 
samples at 0, 1 and 4 weeks after DJBL implantation, using commercially available Enzymelinked 
immunosorbent assays (ELISA) assays (EZGRT-89K, EGLP-35K, EZHGIP-54K, respectively) from Merck 
Millipore (Billerica, MA, USA), according to the manufacturer’s protocol.  
DJBL Procedure 
The DJBL (Endobarrier®, GI Dynamics, Lexington, MA) is an endoscopic implant that mimics the 
intestinal bypass component of the RYGB (Figure 1A, B). The device is comprised of a 60cm long 
impermeable fluoropolymer liner and a Nitinol anchor, which is used to reversibly affix the device to 
the wall of the duodenum (Figure 1C). The anchor is located in the duodenal bulb and the liner 
stretches out through the duodenum and into the jejunum. The DJBL is open at both ends to allow 
food passage. As a result, food will pass through the interior of the DJBL while pancreatic and bile 
juices stay on the outside of the liner so that digestion and absorption of nutrients can only start at 
the end of the liner. The DJBL therefore creates a bypass of the proximal intestinal tract.  
38   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
Introduction 
Overweight and obesity are major risk factors for a number of chronic diseases, including diabetes, 
cardiovascular diseases and cancer [1]. Once considered a problem only in economically developed 
countries, overweight and obesity are now dramatically on the rise in economically developing 
countries, particularly in urban settings [2]. It is well established that obesity promotes insulin 
resistance and in doing so, forms the most important risk factor in developing type 2 diabetes 
(T2DM). Today more than 60 million people worldwide face the dual challenge of managing T2DM 
and obesity [2,3].  
Weight loss improves insulin resistance and forms, next to medication, one of the most important 
treatment modalities. Although conservative therapy such as diets and lifestyle training are 
frequently successful in weight control in the short term, long term results are most often 
disappointing due to problems with compliance to diets and lifestyle [4]. Bariatric surgery, on the 
other hand, has proven its effectiveness in achieving and maintaining weight loss and improving 
obesity-related T2DM, quality of life and survival [5]. It has been recognized that Roux-en-Y gastric 
bypass (RYGB) surgery causes remission of T2DM in the majority of operated subjects within days 
after the surgery [6,7]. The latter suggests that weight loss independent mechanisms are responsible 
for the early remission. It has been proposed that the early improvement in glycemic control 
following RYGB partly depends on the changes in intestinal anatomy and circulating levels of gut 
hormones, especially ghrelin and the incretin hormones, gastric inhibitory peptide (GIP) and 
glucagon-like peptide-1 (GLP-1) [8,9]. Ghrelin and GIP are assumed to be main effectors in the 
‘foregut hypothesis’ that states that exclusion of the foregut from nutrient exposure is most 
responsible for the rapid improvement of hyperglycemia [10,11]. GLP-1 is the main candidate for the 
‘hindgut theory’ that explains improved glycaemia by a faster delivery of nutrients to the hindgut 
after RYGB surgery. Both theories are currently still debated [12]. Although RYGB surgery is an 
efficient bariatric intervention for remission of T2DM, this surgery is a rather drastic measure that not 
every patient or doctor would prefer as a first treatment. Among the reasons not to embark on 
bariatric surgery are: Obesity not reaching NIH criteria (BMI less than 35 kg/m2) and fear of 
(complications of) surgery.  
Recently, a novel non-surgical bariatric technique has been developed, the duodenal-jejunal bypass 
liner (DJBL). The DJBL consist of a 60cm long fluoropolymer sleeve which can be delivered into and 
retrieved from the duodenum endoscopically. Once placed in the duodenum it mimics the intestinal 
bypass component of the RYGB. Clinical experience to date in more than 600 patients has 
demonstrated the safety and efficacy and the ability of the DJBL to rapidly affect blood glucose 
control and weight loss, while also demonstrating improvements in metabolic functions over time 
including cholesterol, blood pressure, LDL and triglycerides [13-16].  
Our goal was to investigate the effect of the DJBL on body weight, fat mass and early remission of 
T2DM during 6 months after implantation and explore the potential role of gut hormones in DJBL-
induced effects on weight loss and improvement of glycemic control. Therefore, body weight, fat 
mass, fasting plasma levels of glucose, insulin, C peptide and HbA1c were analyzed pre-implantation 
and after 1, 4 and 24 weeks post-implant. Additionally, at the first three-time points fasting plasma 
levels of ghrelin, GIP and GLP-1 were determined.  
Methods 
The study was performed according to the principles of the declaration of Helsinki.  The study was 
approved by the research and ethics committee at Rijnstate Hospital Arnhem, the Netherlands 
(protocol number: 1141), functioning according to the 3rd edition of the Guidelines on the Practice of 
Ethical Committees in Medical Research issued by the Royal College of Physicians of London. Written 
Chapter 3: Effects of Duodenal-Jejunal Bypass   |   39 
Informed consent was obtained from all participants after full explanation of the purpose and nature 
of all procedures.  
Patients 
Patients were considered eligible for the study if they were between 18 and 60 years old; had a BMI 
between 28 and 35 kg/m2; and T2DM with an HbA1c level above 7% Patients could take metformin, 
sulfonylurea derivates and/or insulin. Exclusion criteria were: pregnancy or intention to become 
pregnant; use of NSAIDS, anticoagulation therapy, corticosteroids, weight loss medication or drugs 
known to affect gastrointestinal motility; substance abuse; active H. pylori infection; dysfunctional ß 
cells (C peptide of <0.75 nmol/L); iron deficiency or iron deficiency anemia; GI tract abnormalities or 
previous surgery in the gastrointestinal tract that could affect the ability to place the device; 
symptomatic gallstones or kidney stones; known infection; bleeding disorders; gastroesophageal 
reflux disorder; connective tissue disorders; severe liver of kidney failure (creatinine >180mmol/L).  
Study Protocol 
For this observational study, twelve (7 male, 5 female) obese T2DM subjects (BMI 33.5  0.8 kg/m2, 
duration of T2DM 7.4  1.4 years) were selected for implantation of a DJBL and followed for 24 weeks 
post-implantation. During this study, body weight and fat mass were assessed using a body 
composition analyzer. Before implantation of the DJBL and 1, 4 and 24 weeks post-implantation of 
the DJBL, blood was drawn in EDTA tubes (Greiner Bio-One B.V, Alphen a/d Rijn, The Netherlands) 
after an overnight fasting period (at least 12 hours). Fasting plasma levels of gut hormones were only 
analyzed pre-implantation and 1 and 4 weeks post-implantation. Ten microliter per milliliter of blood 
DPP4 inhibitor (Merck Millipore, Billerica, MA, USA) was added within seconds after blood withdrawal 
(at 0, 1 and 4 weeks after DJBL implantation) to prevent degradation of active GLP-1 and GIP. Blood 
was centrifuged (within 1 hour) at 1000 x g for 10 min at 4 0C. Plasma was then aliquoted, snap-frozen 
and stored at -80 0C. Glucose, HbA1c and C peptide levels were measured at Rijnstate Hospital 
Arnhem following a standardized clinical protocol. The medication score was based on medication use 
for hyperglycemia control and was assessed before and within the first week after DJBL implantation.. 
It was based on the scoring system reported by Dorman et al. [17] (i.e. one point for each oral 
diabetes medication, one point for exenatide injections, two points for insulin injections) in 
combination with a scoring system in which for each medication unit one additional point was added 
(medication units: Metformin 500mg, Glimepiride 2mg, Tolbutamide 500mg, Galvus 50mg, Lantus 
10eh, Novorapid 10eh, Byet 10eh). 
Gut Hormone Assays 
Total ghrelin, active GLP-1 and total GIP concentrations were measured in human EDTA plasma 
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immunosorbent assays (ELISA) assays (EZGRT-89K, EGLP-35K, EZHGIP-54K, respectively) from Merck 
Millipore (Billerica, MA, USA), according to the manufacturer’s protocol.  
DJBL Procedure 
The DJBL (Endobarrier®, GI Dynamics, Lexington, MA) is an endoscopic implant that mimics the 
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Implantation of the DJBL was performed with the patient under conscious sedation using propofol. 
Initial access to the stomach and duodenum was achieved by a standard gastroduodenoscopy. Next, a 
guide wire was advanced into the duodenum and the encapsulated device on a custom catheter was 
tracked over the guide wire into the duodenum (Figure 1D). The capsule at the distal end holds the 
liner and anchor. The catheter has an atraumatic ball at the end which is advanced through the 
intestine deploying the liner behind it. After full extension of the liner, the anchor was deployed in the 
duodenal bulb, approximately 0.5 cm distal to the pylorus. Endoscopic and fluoroscopic guidance was 
used to verify the correct position of the DJBL. The DJBL was removed after 24 weeks. No 
complications due to implantation of the DJBL were reported and therefore none of the patients had 
to undergo removal of the DJBL before the 24-week time point. 
After placement of the DJBL, patients received dietary guidelines including a low-calorie diet (female 
1200, male 1500 kcal). Moreover, patients were advised to consume only liquids (e.g. water, tea, 
bouillon, milk, soup, yogurt drinks) and pureed fruit in the first 3 days post-implant and soft, moist, 
ground or pureed foods (e.g. yogurt, diced vegetables and fruit, smoothie, rice pudding, scrambled 
egg) on days 4-7 after DJBL implantation, after which they could resume a normal diet. Our 
nutritionists contacted the patients before and 1, 4, 12 and 24 weeks after DJBL implantation to check 
and stimulate compliance to the dietary guidelines. 
Statistical analysis 
Data are reported as the mean  the standard error (SE). The differences between the mean values 
were tested for statistical significance using a One-way ANOVA with LSD Post Hoc test or Paired 
Samples T test (PASW Statistics 19.0 software, SPSS Inc., Chicago, Illinois, USA). Pearson correlation 
analysis was performed using area under the curve (AUC) data of 0-4 weeks after DJBL implantation 
or 0-24 weeks post-implant (PASW Statistics 19.0 software, SPSS Inc., Chicago, Illinois, USA).  
 
 
Figure 1. Implantation of DJBL. (A, B) Schematic 
overview of RYGB surgery (A) and implantation of 
DJBL (B). The arrows designate the comparable 
duodenal-jejunal part of the intestine that is 
‘bypassed’ in both bariatric procedures. (C, D) 
Devices for implantation of DJBL. (C) Illustration 
of the DJBL (60cm long impermeable 
fluoropolymer sleeve and a nitinol anchor, (D) 
DJBL implantation system. 
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Results 
Effect of DJBL on weight loss and glycemic control 
Twelve obese T2DM patients (BMI  30), with an average age of 50.3  1.9 years, were selected for 
implantation of a DJBL. In these patients, placement of the DJBL accompanied by dietary guidelines 
resulted in a significant weight loss (Table 1 and Figure 2). This weight loss was already manifest 
within 1 week after DJBL implantation, but became even more pronounced after a prolonged post-
implant period. Fat mass did not change in the first week post-implant, but started declining in the 
following post-implant period, with a significant reduction from baseline after 6 months (Table 1 and 
Figure 2). Parameters linked to glycemic control, we found substantially changed after DJBL 
implantation. Fasting insulin levels and the calculated HOMA-IR index showed a significant decrease 
in the first 4 weeks post-implant. Between 4 weeks and 6 months post-implant, a subtle raise was 
seen for both parameters, however HOMA-IR was still significantly different from baseline levels 
(Table 1 and Figure 2). For fasting glucose, a significant reduction from baseline could be detected at 
4 weeks post-implant and HbA1c which reflects the average plasma glucose concentration over a 
prolonged period, showed a continuous decline during the 6 months after DJBL implantation (Table 
1). Next to these changes in plasma parameters that already indicate a substantial improvement in 
glycemic control, we observed a drastic reduction (~42%) in overall diabetes medication after 
placement of the DJBL (Figure 3). In table 2, the medication before and after DJBL implantation is 
presented in more detail, distinguishing between oral and insulin dosages. The substantial reduction 
in diabetes medication, already in the first week after implantation, emphasizes that the DJBL 
provokes a rapid and substantial improvement of glycemic control in obese T2DM patients.  
To assess whether the improvement of glycemic control seen after DJBL implantation could be linked 
to the decrease in body weight, BMI or fat mass, we performed Pearson’s correlation analysis. 
Therefore, we first calculated the area under curve (AUC) for the changes during the 6 months (0-24 
weeks) post-implant. Figure 5 demonstrates that only the decrease in BMI showed a moderate 
positive correlation with the reduction in HbA1c levels (r=0.662, p=0.026). This indicates that there 
might be a link between weight loss and improved glycemic control, but this relation is likely to be not 
very strong.  
Table 1. Patient characteristics before and after implantation of DJBL  
  Weeks post-implant   
  0 1 4 24   
  mean  SE mean  SE mean  SE mean  SE p-value 
Body weight (kg) 104.9 3.0 101.3 2.9 99.9 2.9 97.7 3.3 0.39 
Weight loss (kg) 0.0a 0.0 -3.6b 0.5 -5.1b 0.9 -7.2b 1.2 <0.05 
BMI (kg/m2) 33.5 0.8 32.3 0.8 31.9 0.8 31.2 1.0 0.24 
Fat mass (%) 40.3a 1.7 40.0a 1.9 35.0a,b 1.9 33.1b 1.8 <0.05 
Fasting glucose (mmol/L) 12.1 0.7 9.7 1.2 9.5* 0.3 10.6 0.7 0.21 
Fasting insulin (mU/L) 21.5a 6.0 11.4a,b 2.5 7.2b 1.1 15.5a,b 2.5 <0.05 
C peptide (nmol/L) 1.3 0.1 1.1 0.1 1.2 0.1 1.1 0.1 0.52 
HOMA-IR 12.4a 3.3 4.8b 0.9 4.1b 0.5 7.3b 1.4 <0.05 
HbA1c (mmol/mol) 73.7 4.5     67.6* 3.3 61.3* 4.0 0.39 
GIP (pg/ml) 206.5 37.2 142.9 16.6 136.5 13.4     0.20 
GLP-1 (pM) 6.1a 1.2 3.2b 0.5 4.8a,b 0.7     <0.05 
Ghrelin (pg/ml) 341.2a 51.0 651.5b 89.5 712.3b 95.8     <0.05 
Distinct letters indicate significant differences between time points by a One-way ANOVA with LSD Post Hoc test, p<0.05. * 
indicates significant differences compared to baseline (0 weeks post-implant) by a Paired samples T-test, (p<0.05). 
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Gut hormone responses to implantation of the DJBL 
The strongest effects of the DJBL were visible within the first 4 weeks post-implantation (Figure 2). 
This is especially true for parameters linked to glycaemic control, namely, fasting insulin and glucose 
and the calculated HOMA-IR. To evaluate the potential role of gut hormones in these early effects 
that are seen after implantation of the DJBL, we measured plasma levels of ghrelin, Gip and GLP-1, as 
these gut hormones are suggested to be involved in early improvement of glycemic control after 
RYGB surgery. Fasting plasma levels of ghrelin, GIP and GLP-1 were analysed before and at 1 and 4 
weeks post-implantation (Figure 4). No significant changes in GIP were found, although 4 weeks after 
implantation a tendency for a decrease in GIP levels could be detected (p=0.09). A remarkable pattern 
was found for the plasma GLP-1 response to DJBL implantation, as a significant GLP-1 decrease was 
found at 1 week post-implant with an elevation (nearly) back to baseline levels in the following 3 
weeks (Figure 4). For ghrelin, a significant elevation was seen after DJBL implantation, with the 
highest induction in the first week post-implant (Figure 4).  
 
Figure 2. Effect of DJBL implantation on weight loss, fat mass, fasting plasma insulin and HOMA-IR index. Weight loss, fat 
mass, fasting plasma insulin and HOMA-IR index were determined pre-implant and 1, 4 and 24 weeks after DJBL 
implantation in all 12 patients. Data are visualized as mean (  SE). Distinct letters indicate significant differences between 
time points, p<0.05 (One-way ANOVA with LSD Post Hoc test). 
 
 
 
Figure 3. Effect of DJBL implantation on diabetes 
medication score. Diabetes medication score was assessed 
for all 12 patients, before and after implantation of the 
DJBL. Data are visualized as mean (  SE). * p<0.01 (Paired 
samples T test) 
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Pearson’s correlation analysis using AUC data representing the changes during week 0-4 post-implant 
(Figure 5), showed that GLP-1 responses are highly correlated to the changes in fasting insulin levels 
and HOMA-IR index (r=0.703, p=0.016 and r=0.781, p=0.008, respectively). No correlation was found 
between the changes in gut hormones and the reduction in body weight, BMI and/or fat mass after 
placement of the DJBL. These data indicate that GLP-1 might play a role in the rapid improvement of 
glycaemic control induced by DJBL implantation, but that this role is probably independent of weight 
loss and/or reduction of fat mass.  
 
Table 2. Medication score 
T2DM Medication Average score before implantation* Reduction after DJBL (%) 
Oral Metformin 500mg 4,4 6 
  Glymeperide 2mg 2,9 57 
  Tolbutamide 500mg 4,0 100 
Insulin Lantus 10eh 4,4 69 
  Novorapid 10eh 6,7 66 
  Byet 10eh 3,0 100 
  Galvus 50mg 1,5 100 
* medication score calculated by adding one point for each medication unit (medication units: Metformin 500mg, 
Glymeperide 2mg, Tolbutamide 500mg, Galvus 50mg, Lantus 10eh, Novorapid 10eh, Byet 10eh). Visualized is the average 
medication score of 12 patients. 
Discussion 
Recent studies have suggested a positive effect of RYGB surgery on remission of T2DM over restrictive 
procedures and conventional therapy due to a direct effect on the hormonally active gut [5,8,18]. 
These early postoperative hormonal effects could be the result of the exclusion of the duodenal-
jejunal part of the gut in RYGB surgery [10,11]. DJBL is a novel bariatric technique that mimics RYGB 
surgery and covers the same duodenal-jejunal part of the gut [19].,Our study shows that DJBL 
implantation induces a beneficial effect on remission of T2DM in obese patients, at least up till 24 
weeks post-implant. So, our study indicates that DJBL implantation might be a novel and alternative 
bariatric procedure to induce remission of T2DM in obese patients, especially as it is a much less 
invasive technique. However, future clinical studies (e.g. randomized trials) are essential to directly 
compare and distinguish the effects of RYGB surgery, low calorie diets and placement of a DJBL. This 
must show the additive value of DJBL implantation and prove validity of the DJBL as a long-lasting 
treatment for the obese diabetic patient.  
In the study of de Jonge et al. changes in postprandial responses of GLP-1 and GIP are reported after 
placement of the DJBL [20]. These changes, and especially the increase in GLP-1 postprandial 
response, are highly similar to changes induced by RYGB surgery that are suggested to contribute to 
the early remission of T2DM [8]. Fasting GLP-1 and GIP levels in our study are more difficult to directly 
link to early remission of T2DM and more likely reflect the effect of caloric restriction that is induced 
by placement of the DJBL. For instance, the early ‘dip’ in GLP-1 levels at 1-week post-implant could be 
explained by the consumption of liquid and ground/pureed food in the first week post-implant. This 
food is probably more easily absorbed in the proximal gut and will therefore hardly reach the distal 
small intestine where GLP-1 is mainly expressed. Even though these changes in fasting hormone levels 
are expected to be normal physiological responses to restriction and deprivation of diet, fasting GLP-1 
shows a significant correlation with fasting insulin and HOMA-IR, indicating that also the changes in 
fasting GLP-1 might play a role in improvement of glycemic control.  
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Surprisingly, we found an increase in ghrelin levels after placement of the DJBL, whereas mostly a 
decrease in fasting ghrelin levels is reported after RYGB surgery. Ghrelin is often suggested to be the 
‘foregut factor’ that plays an important role in T2DM remission after RYGB surgery [8,11]. Decreased 
ghrelin levels would lower the levels of growth hormone, cortisol and epinephrine, hormones that are 
known to counter-regulate insulin action. Moreover, decreased ghrelin levels are supposed to 
stimulate secretion of the insulin-sensitizing hormone adiponectin and might have a direct effect on 
insulin secretion by reduced binding to the ghrelin-receptor expressed in the pancreatic islets. Our 
study, however, does not subscribe this potential role of ghrelin in improvement of glycemic control, 
as we found an elevation of ghrelin, but still a substantial remission of T2DM. The elevation of ghrelin 
that we found could be explained by the reduced food intake that is prescribed by the dietary 
guidelines that accompany the placement of the DJBL. Ghrelin is a well-known ‘hunger signal’ that is 
predominantly secreted by the stomach and under normal physiological conditions, a reduced 
consumption of nutrients leads to an increase in plasma ghrelin levels [21]. The reduced ghrelin levels 
that are often seen after RYGB surgery might be explained by a surgically-induced disruption of the 
Figure 4. Responses of gut hormones ghrelin, GIP 
and GLP-1 after implantation of the DJBL. Fasting 
plasma levels of GIP GLP-1 and ghrelin were 
determined before (day 0) and at 1 and 4 weeks 
after implantation of the DJBL in all 12 patients. 
Data are visualized as mean (  SE). Distinct letters 
indicate significant differences between time 
points, p<0.05 (One-way ANOVA with LSD Post Hoc 
test). 
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vagal input to most ghrelin-producing cells during creation of the gastric pouch and bypass of the 
gastric fundus. Blockade of vagal impulses has been reported- to reduce circulation ghrelin levels 
[21,22]. Our data indicate that these reduced ghrelin levels after RYGB surgery have probably no or 
minimal effect on remission of T2DM. Remarkably, despite the rise in levels of the hunger-hormone 
ghrelin after implantation of the DJBL, patients also reported a reduced hunger-feeling (non-validated 
subjective observation) as is seen after RYGB surgery. So, together we conclude that the role of 
ghrelin in hunger sensation and remission of T2DM after bariatric surgery remains unclear. Moreover, 
our data suggest that other ‘foregut factors’ than ghrelin must be involved in these processes. 
 
 
Figure 5. Pearson correlation analysis using AUC data. For body weight, BMI, fat mass, fasting glucose, fasting insulin, C 
peptide, HOMA-IR and HbA1c, Pearson correlation analysis was performed using AUC data of 0-24 weeks after DJBL 
implantation. For gut hormones GIP, GLP-1 and ghrelin AUC data of 0-4 weeks post-implant were used. Light grey boxes 
indicate moderate correlation; dark grey boxes indicate a high correlation. Empty boxes mean no significant correlation was 
found. 
 
In summary, implantation of a DJBL results in significant weight loss and a rapid and substantial 
improvement of glycemic control. As for gut hormone responses, in contrast to RYGB surgery, 
implantation of the DJBL seems to preserve normal physiological responses of gut hormones linked to 
nutrient deprivation and dietary restriction, as elevated levels of ghrelin were found after reduced 
calorie intake and a ‘dip’ in GLP-1 levels was found after temporary consumption of ground/pureed 
food. Most interestingly, our study provides indications that the reduced ghrelin levels that are found 
after RYGB surgery cannot be a contributing ‘foregut factor’ in the early improvement of glycemic 
control. This is an intriguing finding, which must be further explored in future research.  
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known to counter-regulate insulin action. Moreover, decreased ghrelin levels are supposed to 
stimulate secretion of the insulin-sensitizing hormone adiponectin and might have a direct effect on 
insulin secretion by reduced binding to the ghrelin-receptor expressed in the pancreatic islets. Our 
study, however, does not subscribe this potential role of ghrelin in improvement of glycemic control, 
as we found an elevation of ghrelin, but still a substantial remission of T2DM. The elevation of ghrelin 
that we found could be explained by the reduced food intake that is prescribed by the dietary 
guidelines that accompany the placement of the DJBL. Ghrelin is a well-known ‘hunger signal’ that is 
predominantly secreted by the stomach and under normal physiological conditions, a reduced 
consumption of nutrients leads to an increase in plasma ghrelin levels [21]. The reduced ghrelin levels 
that are often seen after RYGB surgery might be explained by a surgically-induced disruption of the 
Figure 4. Responses of gut hormones ghrelin, GIP 
and GLP-1 after implantation of the DJBL. Fasting 
plasma levels of GIP GLP-1 and ghrelin were 
determined before (day 0) and at 1 and 4 weeks 
after implantation of the DJBL in all 12 patients. 
Data are visualized as mean (  SE). Distinct letters 
indicate significant differences between time 
points, p<0.05 (One-way ANOVA with LSD Post Hoc 
test). 
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vagal input to most ghrelin-producing cells during creation of the gastric pouch and bypass of the 
gastric fundus. Blockade of vagal impulses has been reported- to reduce circulation ghrelin levels 
[21,22]. Our data indicate that these reduced ghrelin levels after RYGB surgery have probably no or 
minimal effect on remission of T2DM. Remarkably, despite the rise in levels of the hunger-hormone 
ghrelin after implantation of the DJBL, patients also reported a reduced hunger-feeling (non-validated 
subjective observation) as is seen after RYGB surgery. So, together we conclude that the role of 
ghrelin in hunger sensation and remission of T2DM after bariatric surgery remains unclear. Moreover, 
our data suggest that other ‘foregut factors’ than ghrelin must be involved in these processes. 
 
 
Figure 5. Pearson correlation analysis using AUC data. For body weight, BMI, fat mass, fasting glucose, fasting insulin, C 
peptide, HOMA-IR and HbA1c, Pearson correlation analysis was performed using AUC data of 0-24 weeks after DJBL 
implantation. For gut hormones GIP, GLP-1 and ghrelin AUC data of 0-4 weeks post-implant were used. Light grey boxes 
indicate moderate correlation; dark grey boxes indicate a high correlation. Empty boxes mean no significant correlation was 
found. 
 
In summary, implantation of a DJBL results in significant weight loss and a rapid and substantial 
improvement of glycemic control. As for gut hormone responses, in contrast to RYGB surgery, 
implantation of the DJBL seems to preserve normal physiological responses of gut hormones linked to 
nutrient deprivation and dietary restriction, as elevated levels of ghrelin were found after reduced 
calorie intake and a ‘dip’ in GLP-1 levels was found after temporary consumption of ground/pureed 
food. Most interestingly, our study provides indications that the reduced ghrelin levels that are found 
after RYGB surgery cannot be a contributing ‘foregut factor’ in the early improvement of glycemic 
control. This is an intriguing finding, which must be further explored in future research.  
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Abstract 
 
Background and study aims. The duodenal-jejunal bypass liner (DJBL) is an endoscopic device that 
induces weight loss and improves glycemic control in patients with type 2 diabetes mellitus (T2DM). 
The aim of the current study was to assess the effects of DJBL explantation on glycemic control and 
weight. 
 
Patients and methods. The study included T2DM patients who had the DJBL implanted for at least 6 
months and with a follow-up of at least 12 months after explantation. The primary endpoints were 
changes in HbA1c and body weight during the 12 months after explantation. Secondary endpoints 
were: changes in fasting plasma glucose (FPG), blood pressure, and plasma lipid levels. 
 
Results. In total 59 patients completed the 12-month follow-up after explantation. During this period 
body weight increased by 5.6 ± 6.4 kg (p<0.001) and HbA1 rose from 65 ± 17 to 70 ± 20 mmol/mol 
(p<0.001). However, body weight remained 8.0 ± 8.6 kg (p<0.001) lower than before implantation, i.e. 
corresponding to a net total body weight loss of 7.4 ± 7.6% (p<0.001). Although HbA1c was 
significantly increased 12 months after explantation compared to baseline, and the amount of insulin 
used was comparable, the number of patients using insulin was significantly decreased. 
 
Conclusions. Explantation of the DJBL is associated with weight gain and worsening of glycemic 
control, although some beneficial effects sustain 12 months after explantation. A change in strategy 
will be needed to preserve the beneficial effects of DJBL treatment. 
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Introduction 
The efficacy of the duodenal-jejunal bypass liner (DJBL) as a treatment to induce weight loss and 
improve glycemic control in obese patients with type 2 diabetes mellitus (T2DM) has now been 
studied for more than 5 years. Rapid Total Body Weight Loss (TBWL) of over 10% and early 
improvement of glucose control in the first months after implantation has been demonstrated in 
several randomized controlled trials (RCTs)(1-4) and cohort studies(5-10). In the hope to enhance the 
beneficial effects of the DJBL, the maximum implantation period has been gradually increased from 
12 to 52 weeks over time. It is generally advised to combine the implantation of the DJBL with efforts 
to induce lifestyle changes, such as a healthy diet and optimal physical exercise. This combination is 
considered to be essential to gain a maximal beneficial effect of the DJBL treatment and to prepare 
patients for a life after explantation with preservation of the benefits achieved during implantation. 
There is currently no consensus regarding the optimal approach for the treatment of T2DM during 
implantation and after explantation. Although a substantial number of studies have published the 
results of the DJBL treatment, little is known about the consequences of explantation of the DJBL. The 
aim of the current study is to assess the impact of DJBL explantation on T2DM parameters and body 
weight. 
Patients and Methods 
Patient selection and outcome 
This is a prospective observational single center study performed in the Rijnstate Hospital, Arnhem, 
the Netherlands. The study included all patients with T2DM who had received the DJBL for a period of 
at least 6 months and had a follow-up of at least 12 months after explantation. The primary endpoints 
were changes in glycosylated hemoglobin A1c (HbA1c) and body weight 12 months after explantation 
compared to the start of the DJBL treatment. Secondary endpoints were changes in fasting plasma 
glucose (FPG), blood pressure (BP), and plasma lipid levels.  
As of the start of this study, the DJBL was commercially available in the Netherlands. Patients received 
standard care, as described below. This study was approved by the local institutional review board 
(registration number 746\100111). Patients visited the outpatient clinic 1 week, and 1, 3, 6, and 9 
months after implantation. Explantation was performed after 12 months, however, in case of 
intolerability or adverse events (AEs), explantation was performed at an earlier stage. During the first 
three months of implantation T2DM treatment was centralized and carried out by a single center 
team of specialized diabetes nurses under supervision of an endocrinologist. Medication was adjusted 
according to predefined schedules. Thereafter, T2DM treatment was performed by their referring 
physicians. Additionally, each patient received individual dietary advice prior to, and 3 months after 
implantation of a dietician specialized in bariatric patients. After explantation, outpatient clinic visits 
were scheduled after 1 week, and 6 and 12 months. During each visit body weight and blood pressure 
(BP) were measured, and blood samples were taken to evaluate T2DM treatment and to determine 
serum lipid levels. To increase compliance and reduce the number of missing values, patients received 
a repeat appointment and were phoned after missing an outpatient visit. 
Statistical analysis 
Changes in body weight were analyzed as the difference in absolute total body weight, change in 
body mass index (BMI), excess weight loss (EWL), and total body weight loss (TBWL). Changes in 
T2DM were analyzed as the absolute change in HbA1c, FPG, and changes in T2DM medication. 
Differences in lipid levels and BP were analyzed as absolute differences.  
Analyses were conducted with IBM SPSS Statistics for Windows, version 20.0 (IBM Corp, Armonk, NY). 
Data are reported as mean ± standard deviation (SD) unless specified otherwise. A p-value of <0.05 
was considered statistically significant. Analyses between different time points in the same group 
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were conducted with a paired-sample t-test, or Wilcoxon signed rank test when not normally 
distributed. Analyses between different groups were performed with an independent-samples t-test 
for continuous variables, and with the Pearson Chi-Square or Fisher’s Exact Test for dichotomous 
variables. A complete case analysis was performed, despite the missing data, since intention to treat 
analysis with last observation carried forward would overestimate the real effects of the DJBL. 
Significance was only calculated at 12 months after explantation to reduce multiple testing. Figures 
were created using GraphPad Prism version 5.1 (GraphPad Software, Inc.). 
Results 
Patient selection 
In total 96 patients underwent an explantation of the DJBL at time of analysis. Follow-up of all 
explanted patients, including the number of patients who missed their outpatient visits, and those 
who received bariatric surgery after explantation of the DJBL, is illustrated in figure 1. Thirty patients 
(31%) were lost to follow-up at 12 months after explantation. An additional 7 (7%) patients were 
excluded because they chose to undergo bariatric surgery during the one-year post-explantation 
period. The 30 patients who were lost to follow-up were comparable to the 59 patient who 
completed the 12-month follow-up in all baseline characteristics and main outcome parameters at 
time of explantation (Table 1). 
 
Figure 1: Flow chart. 
 
50   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
Introduction 
The efficacy of the duodenal-jejunal bypass liner (DJBL) as a treatment to induce weight loss and 
improve glycemic control in obese patients with type 2 diabetes mellitus (T2DM) has now been 
studied for more than 5 years. Rapid Total Body Weight Loss (TBWL) of over 10% and early 
improvement of glucose control in the first months after implantation has been demonstrated in 
several randomized controlled trials (RCTs)(1-4) and cohort studies(5-10). In the hope to enhance the 
beneficial effects of the DJBL, the maximum implantation period has been gradually increased from 
12 to 52 weeks over time. It is generally advised to combine the implantation of the DJBL with efforts 
to induce lifestyle changes, such as a healthy diet and optimal physical exercise. This combination is 
considered to be essential to gain a maximal beneficial effect of the DJBL treatment and to prepare 
patients for a life after explantation with preservation of the benefits achieved during implantation. 
There is currently no consensus regarding the optimal approach for the treatment of T2DM during 
implantation and after explantation. Although a substantial number of studies have published the 
results of the DJBL treatment, little is known about the consequences of explantation of the DJBL. The 
aim of the current study is to assess the impact of DJBL explantation on T2DM parameters and body 
weight. 
Patients and Methods 
Patient selection and outcome 
This is a prospective observational single center study performed in the Rijnstate Hospital, Arnhem, 
the Netherlands. The study included all patients with T2DM who had received the DJBL for a period of 
at least 6 months and had a follow-up of at least 12 months after explantation. The primary endpoints 
were changes in glycosylated hemoglobin A1c (HbA1c) and body weight 12 months after explantation 
compared to the start of the DJBL treatment. Secondary endpoints were changes in fasting plasma 
glucose (FPG), blood pressure (BP), and plasma lipid levels.  
As of the start of this study, the DJBL was commercially available in the Netherlands. Patients received 
standard care, as described below. This study was approved by the local institutional review board 
(registration number 746\100111). Patients visited the outpatient clinic 1 week, and 1, 3, 6, and 9 
months after implantation. Explantation was performed after 12 months, however, in case of 
intolerability or adverse events (AEs), explantation was performed at an earlier stage. During the first 
three months of implantation T2DM treatment was centralized and carried out by a single center 
team of specialized diabetes nurses under supervision of an endocrinologist. Medication was adjusted 
according to predefined schedules. Thereafter, T2DM treatment was performed by their referring 
physicians. Additionally, each patient received individual dietary advice prior to, and 3 months after 
implantation of a dietician specialized in bariatric patients. After explantation, outpatient clinic visits 
were scheduled after 1 week, and 6 and 12 months. During each visit body weight and blood pressure 
(BP) were measured, and blood samples were taken to evaluate T2DM treatment and to determine 
serum lipid levels. To increase compliance and reduce the number of missing values, patients received 
a repeat appointment and were phoned after missing an outpatient visit. 
Statistical analysis 
Changes in body weight were analyzed as the difference in absolute total body weight, change in 
body mass index (BMI), excess weight loss (EWL), and total body weight loss (TBWL). Changes in 
T2DM were analyzed as the absolute change in HbA1c, FPG, and changes in T2DM medication. 
Differences in lipid levels and BP were analyzed as absolute differences.  
Analyses were conducted with IBM SPSS Statistics for Windows, version 20.0 (IBM Corp, Armonk, NY). 
Data are reported as mean ± standard deviation (SD) unless specified otherwise. A p-value of <0.05 
was considered statistically significant. Analyses between different time points in the same group 
Chapter 4: Effects of Duodenal-Jejunal Bypass explantation   |   51 
were conducted with a paired-sample t-test, or Wilcoxon signed rank test when not normally 
distributed. Analyses between different groups were performed with an independent-samples t-test 
for continuous variables, and with the Pearson Chi-Square or Fisher’s Exact Test for dichotomous 
variables. A complete case analysis was performed, despite the missing data, since intention to treat 
analysis with last observation carried forward would overestimate the real effects of the DJBL. 
Significance was only calculated at 12 months after explantation to reduce multiple testing. Figures 
were created using GraphPad Prism version 5.1 (GraphPad Software, Inc.). 
Results 
Patient selection 
In total 96 patients underwent an explantation of the DJBL at time of analysis. Follow-up of all 
explanted patients, including the number of patients who missed their outpatient visits, and those 
who received bariatric surgery after explantation of the DJBL, is illustrated in figure 1. Thirty patients 
(31%) were lost to follow-up at 12 months after explantation. An additional 7 (7%) patients were 
excluded because they chose to undergo bariatric surgery during the one-year post-explantation 
period. The 30 patients who were lost to follow-up were comparable to the 59 patient who 
completed the 12-month follow-up in all baseline characteristics and main outcome parameters at 
time of explantation (Table 1). 
 
Figure 1: Flow chart. 
 
52   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
Table 1. Baseline demographics and changes between baseline and explantation for patients who completed 
and who were lost to follow-up at the outpatient visit 12 months after explantation of the DJBL 
 12-month follow-up 
completers 
n= 59 
12 months lost to follow-up 
n= 30 
p-value* 
Baseline characteristics 
Age (years) 52 ± 8 50 ± 7 0.311 
Female 27 (46%) 12 (40%) 0.604ϯ 
Body weight (kg) 106.4 ± 15.6 108.9 ± 19.7 0.510 
BMI (kg/m2) 34.4 ± 3.5 35.8 ± 5.6 0.238 
Systolic BP (mm Hg) 139 ± 16 138 ± 20 0.942 
Diastolic BP (mm Hg) 87 ± 10 855 ± 10 0.508 
T2DM duration (years) 8 ± 5 9 ± 5 0.669 
Blood values 
Total cholesterol (mmol/L) 4.56 ± 1.29 4.86 ± 0.98 0.279 
HDL (mmol/L) 1.10 ± 0.27 1.10 ± 0.30 0.886 
Triglyceride (mmol/L) 2.38 ± 2.08 2.72 ± 1.54 0.430 
LDL (mmol/L) 2.41 ± 0.94 2.59 ± 0.79 0.425 
FPG (mmol/L) 10.8 ± 2.9 11.2 ± 4.1 0.595 
HbA1c (mmol/ mol) 65 ± 15 68 ± 20 0.570 
Insulin (mU/L) 33 ± 50 31 ± 40 0.895 
C-peptide (nmol/L) 1.15 ± 0.49 1.20 ± 0.70 0.765 
Explantation characteristics 
Implantation time (weeks) 48 ± 7 50 ± 9 0.293 
∆ Absolute weight (kg) -13.6 ± 9.4 -11.6 ± 6.5 0.316 
EWL (%) 49 ± 30 42 ± 26 0.330 
TBWL (%) 12.6 ± 7.7 10.6 ± 5.6 0.216 
∆ HbA1c (mmol/mol) -4.1 ± 14.7 -8.1 ± 13.3 0.218 
∆ FPG (mmol/L) -0.9 ± 3.0 -0.7 ± 3.7 0.777 
Values are means with standard deviation, or n with percents in parentheses. BMI, body mass index; BP, blood pressure; 
EWL, excess weight loss; FPG, fasting plasma glucose; HbA1c, Glycosated hemoglobin AIc, HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; T2DM, type 2 diabetes mellitus; TBWL, total body weight loss, ∆ Difference between baseline and 
explantation. * Independent-Samples T-Test; ϯ Pearson Chi-Square 
 
 
Table 1 shows that the total group of 59 patients who completed the outpatient visit 12 months after 
explantation, had a mean age of 52 ± 8 years and 46% was female. All patients were diagnosed with 
T2DM with a mean duration of disease of 8 ± 5 years at time of implantation of the DJBL. The mean 
implantation time was 48 ± 7. weeks. 18 patients (31%) had had an early explantation between 6 and 
12 months.  
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Body weight 
During the implantation period body weight decreased by 11.6 ± 7.8 kg at 6 months and by 13.6 ± 
9.4kg (p<0.001) at 12 months (table 2 and figure 2A). The latter is comparable with a TBWL of 12.6 ± 
7.7% (p<0.001). Twelve months after explantation body weight had increased by 5.6 ± 6.4 kg but 
remained 8.0 ± 8.6 kg lower (p<0.001) compared to baseline. This reduced in a nett reduction in TBWL 
of 7.4 ± 7.6%. In total 18 patients (31%) still had had a nett TBWL greater than 10% 12 months after 
explantation. 
Type 2 Diabetes 
During implantation HbA1c and FPG decreased from 65 ± 15 to 61 ± 17 mmol/mol (p=0.039) and from 
10.8 ± 2.9 to 9.9 ± 3.0 mmol/L (p=0.028), respectively. However, 6 months after explantation both 
parameters had increased to the same level as observed at baseline. Twelve months after 
explantation HbA1c and FPG had significantly increased to 70 ± 20 mmol/mol (p=0.025) and 11.7 ± 3.7 
mmol/L (p=0.033), respectively (Table 2 and Figure 2B). 
Metformin, glimepiride, GLP-1 agonists, and insulin were the main antidiabetics used in the study 
population. The trends observed seen in the use of these medication groups are summarized in Table 
3. Metformin median dose and number of users remained unchanged after implantation as well as 
explantation. Implantation was associated with a significant increase in the number of patients using 
glimepiride, although the mean daily dose remained stable ranging from 4.2 ± 2.2 to 5.2 ± 2.0 mg. The 
number of patients on GLP-1 agonist significantly rose from 8% at time of screening to 25% 12 
months after explantation, the median dose did not change with 2mg daily. Implantation was 
associated with a decrease in the number of patients on insulin and decrease in mean daily dose. 
However, after explantation the number of patients using insulin increased again, as well as their 
mean dose. One year after explanation an overall nett beneficial effect of the DJBL intervention was 
observed only for the number of patients treated with insulin. At 12 months after explantation the 
number of patients on insulin decreased significantly from 47% to 24%. Insulin dose 12 months after 
explantation was comparable with baseline (88 ± 62 versus 99 ± 68). In contrast, the number of 
patients on glimepiride and GLP-1 agonists increased significantly, as the dose remained comparable. 
Cardiovascular parameters 
Slight variations in blood pressure were observed during and after implantation with the DJBL (Table 
2). Both systolic and diastolic BP decreased non-significantly during implantation and rose to baseline 
levels again 12 months after explantation. During the DJBL implantation period no significant changes 
were observed in lipid levels. Explantation was associated with a rise in total cholesterol, HDL 
cholesterol, triglycerides, and LDL cholesterol. However, 12 months after explantation only total 
cholesterol and triglycerides were significantly higher than observed just before implantation, with 
increment of 0.35 ± 1.16 mmol/L and 0.77 ± 2.68 mmol/L, respectively.Discussion 
This is the first study to present the long-term follow-up after explantation of the DJBL. It shows that 
after the initial weight loss and improvement of diabetes parameters during implantation, there is a 
partial loss of benefit after explantation. Explantation was associated with weight regain and 
deterioration of glycemic control. Nevertheless, at 12 months after explantation body weight was still 
significantly lower than before implantation. Although the number of insulin users remained lower 
than at baseline, this is within a background of an increase in FPG and HbA1c levels and a greater 
number of patients on glimepiride and GLP-1 agonists. Most of all other cardiovascular parameters 
measured were comparable with start of treatment, except for total cholesterol and triglycerides, 
which had increased significantly one year after explantation. 
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Table 1. Baseline demographics and changes between baseline and explantation for patients who completed 
and who were lost to follow-up at the outpatient visit 12 months after explantation of the DJBL 
 12-month follow-up 
completers 
n= 59 
12 months lost to follow-up 
n= 30 
p-value* 
Baseline characteristics 
Age (years) 52 ± 8 50 ± 7 0.311 
Female 27 (46%) 12 (40%) 0.604ϯ 
Body weight (kg) 106.4 ± 15.6 108.9 ± 19.7 0.510 
BMI (kg/m2) 34.4 ± 3.5 35.8 ± 5.6 0.238 
Systolic BP (mm Hg) 139 ± 16 138 ± 20 0.942 
Diastolic BP (mm Hg) 87 ± 10 855 ± 10 0.508 
T2DM duration (years) 8 ± 5 9 ± 5 0.669 
Blood values 
Total cholesterol (mmol/L) 4.56 ± 1.29 4.86 ± 0.98 0.279 
HDL (mmol/L) 1.10 ± 0.27 1.10 ± 0.30 0.886 
Triglyceride (mmol/L) 2.38 ± 2.08 2.72 ± 1.54 0.430 
LDL (mmol/L) 2.41 ± 0.94 2.59 ± 0.79 0.425 
FPG (mmol/L) 10.8 ± 2.9 11.2 ± 4.1 0.595 
HbA1c (mmol/ mol) 65 ± 15 68 ± 20 0.570 
Insulin (mU/L) 33 ± 50 31 ± 40 0.895 
C-peptide (nmol/L) 1.15 ± 0.49 1.20 ± 0.70 0.765 
Explantation characteristics 
Implantation time (weeks) 48 ± 7 50 ± 9 0.293 
∆ Absolute weight (kg) -13.6 ± 9.4 -11.6 ± 6.5 0.316 
EWL (%) 49 ± 30 42 ± 26 0.330 
TBWL (%) 12.6 ± 7.7 10.6 ± 5.6 0.216 
∆ HbA1c (mmol/mol) -4.1 ± 14.7 -8.1 ± 13.3 0.218 
∆ FPG (mmol/L) -0.9 ± 3.0 -0.7 ± 3.7 0.777 
Values are means with standard deviation, or n with percents in parentheses. BMI, body mass index; BP, blood pressure; 
EWL, excess weight loss; FPG, fasting plasma glucose; HbA1c, Glycosated hemoglobin AIc, HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; T2DM, type 2 diabetes mellitus; TBWL, total body weight loss, ∆ Difference between baseline and 
explantation. * Independent-Samples T-Test; ϯ Pearson Chi-Square 
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explantation, had a mean age of 52 ± 8 years and 46% was female. All patients were diagnosed with 
T2DM with a mean duration of disease of 8 ± 5 years at time of implantation of the DJBL. The mean 
implantation time was 48 ± 7. weeks. 18 patients (31%) had had an early explantation between 6 and 
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Body weight 
During the implantation period body weight decreased by 11.6 ± 7.8 kg at 6 months and by 13.6 ± 
9.4kg (p<0.001) at 12 months (table 2 and figure 2A). The latter is comparable with a TBWL of 12.6 ± 
7.7% (p<0.001). Twelve months after explantation body weight had increased by 5.6 ± 6.4 kg but 
remained 8.0 ± 8.6 kg lower (p<0.001) compared to baseline. This reduced in a nett reduction in TBWL 
of 7.4 ± 7.6%. In total 18 patients (31%) still had had a nett TBWL greater than 10% 12 months after 
explantation. 
Type 2 Diabetes 
During implantation HbA1c and FPG decreased from 65 ± 15 to 61 ± 17 mmol/mol (p=0.039) and from 
10.8 ± 2.9 to 9.9 ± 3.0 mmol/L (p=0.028), respectively. However, 6 months after explantation both 
parameters had increased to the same level as observed at baseline. Twelve months after 
explantation HbA1c and FPG had significantly increased to 70 ± 20 mmol/mol (p=0.025) and 11.7 ± 3.7 
mmol/L (p=0.033), respectively (Table 2 and Figure 2B). 
Metformin, glimepiride, GLP-1 agonists, and insulin were the main antidiabetics used in the study 
population. The trends observed seen in the use of these medication groups are summarized in Table 
3. Metformin median dose and number of users remained unchanged after implantation as well as 
explantation. Implantation was associated with a significant increase in the number of patients using 
glimepiride, although the mean daily dose remained stable ranging from 4.2 ± 2.2 to 5.2 ± 2.0 mg. The 
number of patients on GLP-1 agonist significantly rose from 8% at time of screening to 25% 12 
months after explantation, the median dose did not change with 2mg daily. Implantation was 
associated with a decrease in the number of patients on insulin and decrease in mean daily dose. 
However, after explantation the number of patients using insulin increased again, as well as their 
mean dose. One year after explanation an overall nett beneficial effect of the DJBL intervention was 
observed only for the number of patients treated with insulin. At 12 months after explantation the 
number of patients on insulin decreased significantly from 47% to 24%. Insulin dose 12 months after 
explantation was comparable with baseline (88 ± 62 versus 99 ± 68). In contrast, the number of 
patients on glimepiride and GLP-1 agonists increased significantly, as the dose remained comparable. 
Cardiovascular parameters 
Slight variations in blood pressure were observed during and after implantation with the DJBL (Table 
2). Both systolic and diastolic BP decreased non-significantly during implantation and rose to baseline 
levels again 12 months after explantation. During the DJBL implantation period no significant changes 
were observed in lipid levels. Explantation was associated with a rise in total cholesterol, HDL 
cholesterol, triglycerides, and LDL cholesterol. However, 12 months after explantation only total 
cholesterol and triglycerides were significantly higher than observed just before implantation, with 
increment of 0.35 ± 1.16 mmol/L and 0.77 ± 2.68 mmol/L, respectively.Discussion 
This is the first study to present the long-term follow-up after explantation of the DJBL. It shows that 
after the initial weight loss and improvement of diabetes parameters during implantation, there is a 
partial loss of benefit after explantation. Explantation was associated with weight regain and 
deterioration of glycemic control. Nevertheless, at 12 months after explantation body weight was still 
significantly lower than before implantation. Although the number of insulin users remained lower 
than at baseline, this is within a background of an increase in FPG and HbA1c levels and a greater 
number of patients on glimepiride and GLP-1 agonists. Most of all other cardiovascular parameters 
measured were comparable with start of treatment, except for total cholesterol and triglycerides, 
which had increased significantly one year after explantation. 
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Table 2. Characteristics at baseline, at the time of explanation, and 6 and 12 months after explantation. 
 Implantation 
N= 59 
Explantation* 
N= 59 
6 months PE* 
N= 54 
12 months PE* 
N= 59 
Weight, kg 
  ∆ baseline 
  ∆ explantation 
106.4 ± 15.6 92.8 ± 14.5 
  -13.6 ± 9.4#  
97.2 ± 16.0 
  -9.1 ± 9.9 
  +4.9 ± 4.8 
98.4 ± 15.3 
  -8.0 ± 8.6# 
  +5.6 ± 6.4# 
BMI, kg/m2 
  ∆ baseline 
  ∆ explantation 
34.4 ± 3.5 30.1 ± 3.5 
  -4.4 ± 3.2# 
 
  31.4 ± 3.6 
  -3.0 ± 3.4 
  +1.5 ± 1.4 
31.8 ± 3.4 
  -2.6 ± 3.0# 
  +1.7 ± 2.0# 
EWL, % 
  ∆ baseline 
  ∆ explantation 
N/A 48.8 ± 30.0 
  +48.8 ± 30.0# 
32.0 ± 32.1 
  +32.0 ± 32.1 
  -18.3 ± 17.4 
27.7 ± 28.9 
  +27.7 ± 28.9# 
  -21.0 ± 24.0# 
TBWL, % 
  ∆ baseline 
  ∆ explantation 
N/A 12.6 ± 7.7 
  +12.6 ± 7.7# 
8.4 ± 8.6 
  +8.4 ± 8.6 
  -4.6 ± 4.3 
7.4 ± 7.6 
  +7.4 ± 7.6# 
  -5.2 ± 5.8# 
HbA1c, mmol/mol 
  ∆ baseline 
  ∆ explantation 
65 ± 15 61 ± 17 
-4.1 ± 14.7 
(p=0.039) 
65 ± 17 
  -0.6 ± 13.9 
  +4.3 ± 11.2 
70 ± 20 
  +4.8 ± 16.0 (p=0.025) 
  +8.8 ± 15.4# 
FPG, mmol/L 
  ∆ baseline 
  ∆ explantation 
 
10.8 ± 2.9 9.9 ± 3.0 
  -0.9 ± 3.0 
(p=0.028) 
10.7 ± 3.6 
  -0.13 ± 3.73 
  +0.88 ± 2.69 
11.7 ± 3.7 
  +1.01 ± 3.50 (p=0.033) 
  +1.62 ± 3.47 (p=0.001) 
BP, systolic, mmHg 
  ∆ baseline 
  ∆ explantation 
139 ± 16 136 ± 21 
  -2.9 ± 21.6 
(p=0.358) 
132 ± 13 
  -7.3 ± 20.0 
  -0.2 ± 21.1 
140 ± 15 
  +0.4 ± 21.9 (p=0.913) 
  +4.0 ± 25.3 (p=0.284) 
BP, diastolic, mmHg 
  ∆ baseline 
  ∆ explantation 
87 ± 10 83 ± 12 
  -4.0 ± 14.0 
(p=0.054) 
85 ± 8 
  -1.5 ± 9.9 
  +2.7 ± 11.2 
87 ± 10 
  -0.4 ± 11.6 (p=0.836) 
  +3.6 ± 14.8 (p=0.101) 
Total cholesterol, 
mmol/L 
  ∆ baseline 
  ∆ explantation 
4.48 ± 1.17 4.31 ± 0.94 
  -0.17 ± 0.96 
(p=0.185) 
5.08 ± 1.08 
  +0.43 ± 1.16 
  +0.64 ± 0.91 
4.88 ± 1.06 
  +0.35 ± 1.16 (p=0.031) 
  +0.52 ± 1.01# 
HDL, mmol/L 
  ∆ baseline 
  ∆ explantation 
1.11 ± 0.27 1.08 ± 0.35 
  -0.02 ± 0.21 
(p=0.376) 
1.16 ± 0.35 
  +0.04 ± 0.21 
  +0.05 ± 0.20 
1.10 ± 0.32 
  -0.01 ± 0.20 (p=0.755) 
  +0.01 ± 0.19 (p=0.623) 
Triglycerides, mmol/L 
  ∆ baseline 
  ∆ explantation 
2.16 ± 1.25 2.04 ± 0.97 
  -0.11 ± 0.93 
(p=0.351) 
2.76 ± 2.13 
  +0.31 ± 1.83 
  +0.55 ± 1.59 
3.11 ± 3.03 
  +0.77 ± 2.68 (p=0.039) 
  +0.89 ± 2.32 (p=0.006) 
LDL, mmol/L 
  ∆ baseline 
  ∆ explantation 
2.44 ± 0.93 2.42 ± 0.81 
-0.02 ± 0.78 
(p=0.844) 
2.85 ± 0.91 
  +0.33 ± 1.01 
  +0.35 ± 0.69 
2.58 ± 0.91 
  +0.12 ± 0.82 (p=0.322) 
  +0.11 ± 0.75 (p=0.333) 
Values are means with standard deviation in parentheses. DJBL, duodenal-jejunal bypass liner; BMI, body mass index; BP, 
blood pressure; HbA1c, Glycosated hemoglobin AIc, HDL, high-density lipoprotein; LDL, low-density lipoprotein; PE, post 
explantation. ∆ baseline represents the comparison with values observed at the time of screening; ∆ explantation represents 
the comparison with data registered at the day of explantation. * Paired-Samples T-Test; # P<0.001 
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Figure 2. Changes in absolute body weight (A), and HbA1c 
(B) at baseline, during implantation with the DJBL, and till 
12 months after explantation (mean with 95% CI)  
So far, only a limited number of studies have reported changes after DJBL explantation. The number 
of patients included in the studies have been small (ranging from 8 to 31 patients) and follow-up after 
explantation was relatively short, ranging from 1 week up to 6 months (4, 7, 9-11). Moreover, 
implantation time varied among these studies. In two of the five studies, the DJBL was implanted for 
6 months, and only 3 studies considered a 12-month implantation time, which is currently the 
standard treatment. De Jonge et al. studied 16 patients after 6 months implantation and found a 
sustained decrease in glucose response after a meal test, 1 week after explantation. No changes in 
HOMA-IR or insulin response were observed (9). Two studies evaluated the effects on T2DM, 26 
weeks after explantation in 16 and 11 patients treated with the DJBL for 1 year (10, 11). Explantation 
was associated with an increase in HbA1c of 3 and 6 mmol/mol, respectively, but compared to 
baseline HbA1c levels remained 10 and 19 mmol/mol lower than before implantation. Unfortunately, 
changes in diabetic medication were not reported. This hampers the opportunity to separate the 
impact of adjustments in antidiabetic medication and that of the DJBL. The largest RCT published so 
far included 31 patients treated with the DJBL for 26 weeks with a follow-up of another 26 weeks 
after explantation(4). HbA1c increased by 4 mmol/mol and FPG by 0.5 mmol/L after explantation in 
the patients treated with the DJBL. A similar trend was observed in our study, although the 
increments in our patients were larger with an increment in HbA1c of 8.8 mmol/mol and FGP of 1.62 
mmol/L after explantation, respectively. Although a reduction in antidiabetic medication was also 
described in the RCT referred to above, the 50% reduction in insulin users in our study might explain 
the differences in glycemic control during implantation and after explantation. Additionally, since the 
HbA1c increased after explantation in most of our patients, it can be concluded that dose 
adjustments in antidiabetic medication have been inadequate. 
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Table 2. Characteristics at baseline, at the time of explanation, and 6 and 12 months after explantation. 
 Implantation 
N= 59 
Explantation* 
N= 59 
6 months PE* 
N= 54 
12 months PE* 
N= 59 
Weight, kg 
  ∆ baseline 
  ∆ explantation 
106.4 ± 15.6 92.8 ± 14.5 
  -13.6 ± 9.4#  
97.2 ± 16.0 
  -9.1 ± 9.9 
  +4.9 ± 4.8 
98.4 ± 15.3 
  -8.0 ± 8.6# 
  +5.6 ± 6.4# 
BMI, kg/m2 
  ∆ baseline 
  ∆ explantation 
34.4 ± 3.5 30.1 ± 3.5 
  -4.4 ± 3.2# 
 
  31.4 ± 3.6 
  -3.0 ± 3.4 
  +1.5 ± 1.4 
31.8 ± 3.4 
  -2.6 ± 3.0# 
  +1.7 ± 2.0# 
EWL, % 
  ∆ baseline 
  ∆ explantation 
N/A 48.8 ± 30.0 
  +48.8 ± 30.0# 
32.0 ± 32.1 
  +32.0 ± 32.1 
  -18.3 ± 17.4 
27.7 ± 28.9 
  +27.7 ± 28.9# 
  -21.0 ± 24.0# 
TBWL, % 
  ∆ baseline 
  ∆ explantation 
N/A 12.6 ± 7.7 
  +12.6 ± 7.7# 
8.4 ± 8.6 
  +8.4 ± 8.6 
  -4.6 ± 4.3 
7.4 ± 7.6 
  +7.4 ± 7.6# 
  -5.2 ± 5.8# 
HbA1c, mmol/mol 
  ∆ baseline 
  ∆ explantation 
65 ± 15 61 ± 17 
-4.1 ± 14.7 
(p=0.039) 
65 ± 17 
  -0.6 ± 13.9 
  +4.3 ± 11.2 
70 ± 20 
  +4.8 ± 16.0 (p=0.025) 
  +8.8 ± 15.4# 
FPG, mmol/L 
  ∆ baseline 
  ∆ explantation 
 
10.8 ± 2.9 9.9 ± 3.0 
  -0.9 ± 3.0 
(p=0.028) 
10.7 ± 3.6 
  -0.13 ± 3.73 
  +0.88 ± 2.69 
11.7 ± 3.7 
  +1.01 ± 3.50 (p=0.033) 
  +1.62 ± 3.47 (p=0.001) 
BP, systolic, mmHg 
  ∆ baseline 
  ∆ explantation 
139 ± 16 136 ± 21 
  -2.9 ± 21.6 
(p=0.358) 
132 ± 13 
  -7.3 ± 20.0 
  -0.2 ± 21.1 
140 ± 15 
  +0.4 ± 21.9 (p=0.913) 
  +4.0 ± 25.3 (p=0.284) 
BP, diastolic, mmHg 
  ∆ baseline 
  ∆ explantation 
87 ± 10 83 ± 12 
  -4.0 ± 14.0 
(p=0.054) 
85 ± 8 
  -1.5 ± 9.9 
  +2.7 ± 11.2 
87 ± 10 
  -0.4 ± 11.6 (p=0.836) 
  +3.6 ± 14.8 (p=0.101) 
Total cholesterol, 
mmol/L 
  ∆ baseline 
  ∆ explantation 
4.48 ± 1.17 4.31 ± 0.94 
  -0.17 ± 0.96 
(p=0.185) 
5.08 ± 1.08 
  +0.43 ± 1.16 
  +0.64 ± 0.91 
4.88 ± 1.06 
  +0.35 ± 1.16 (p=0.031) 
  +0.52 ± 1.01# 
HDL, mmol/L 
  ∆ baseline 
  ∆ explantation 
1.11 ± 0.27 1.08 ± 0.35 
  -0.02 ± 0.21 
(p=0.376) 
1.16 ± 0.35 
  +0.04 ± 0.21 
  +0.05 ± 0.20 
1.10 ± 0.32 
  -0.01 ± 0.20 (p=0.755) 
  +0.01 ± 0.19 (p=0.623) 
Triglycerides, mmol/L 
  ∆ baseline 
  ∆ explantation 
2.16 ± 1.25 2.04 ± 0.97 
  -0.11 ± 0.93 
(p=0.351) 
2.76 ± 2.13 
  +0.31 ± 1.83 
  +0.55 ± 1.59 
3.11 ± 3.03 
  +0.77 ± 2.68 (p=0.039) 
  +0.89 ± 2.32 (p=0.006) 
LDL, mmol/L 
  ∆ baseline 
  ∆ explantation 
2.44 ± 0.93 2.42 ± 0.81 
-0.02 ± 0.78 
(p=0.844) 
2.85 ± 0.91 
  +0.33 ± 1.01 
  +0.35 ± 0.69 
2.58 ± 0.91 
  +0.12 ± 0.82 (p=0.322) 
  +0.11 ± 0.75 (p=0.333) 
Values are means with standard deviation in parentheses. DJBL, duodenal-jejunal bypass liner; BMI, body mass index; BP, 
blood pressure; HbA1c, Glycosated hemoglobin AIc, HDL, high-density lipoprotein; LDL, low-density lipoprotein; PE, post 
explantation. ∆ baseline represents the comparison with values observed at the time of screening; ∆ explantation represents 
the comparison with data registered at the day of explantation. * Paired-Samples T-Test; # P<0.001 
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Figure 2. Changes in absolute body weight (A), and HbA1c 
(B) at baseline, during implantation with the DJBL, and till 
12 months after explantation (mean with 95% CI)  
So far, only a limited number of studies have reported changes after DJBL explantation. The number 
of patients included in the studies have been small (ranging from 8 to 31 patients) and follow-up after 
explantation was relatively short, ranging from 1 week up to 6 months (4, 7, 9-11). Moreover, 
implantation time varied among these studies. In two of the five studies, the DJBL was implanted for 
6 months, and only 3 studies considered a 12-month implantation time, which is currently the 
standard treatment. De Jonge et al. studied 16 patients after 6 months implantation and found a 
sustained decrease in glucose response after a meal test, 1 week after explantation. No changes in 
HOMA-IR or insulin response were observed (9). Two studies evaluated the effects on T2DM, 26 
weeks after explantation in 16 and 11 patients treated with the DJBL for 1 year (10, 11). Explantation 
was associated with an increase in HbA1c of 3 and 6 mmol/mol, respectively, but compared to 
baseline HbA1c levels remained 10 and 19 mmol/mol lower than before implantation. Unfortunately, 
changes in diabetic medication were not reported. This hampers the opportunity to separate the 
impact of adjustments in antidiabetic medication and that of the DJBL. The largest RCT published so 
far included 31 patients treated with the DJBL for 26 weeks with a follow-up of another 26 weeks 
after explantation(4). HbA1c increased by 4 mmol/mol and FPG by 0.5 mmol/L after explantation in 
the patients treated with the DJBL. A similar trend was observed in our study, although the 
increments in our patients were larger with an increment in HbA1c of 8.8 mmol/mol and FGP of 1.62 
mmol/L after explantation, respectively. Although a reduction in antidiabetic medication was also 
described in the RCT referred to above, the 50% reduction in insulin users in our study might explain 
the differences in glycemic control during implantation and after explantation. Additionally, since the 
HbA1c increased after explantation in most of our patients, it can be concluded that dose 
adjustments in antidiabetic medication have been inadequate. 
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Table 3. Dosage and number of users of the four most used diabetic medications at time of screening, 
explantation, and 12 months after DJBL explantation. Changes in diabetic medication; 12 months after 
explantation of the DJBL compared to prior to implantation of the DJBL. 
 At time of 
DJBL screening 
At time of 
DJBL explantation 
12 months after 
DJBL explantation 
 Dosage n (%) Dosage n (%) Dosage n (%) 
Metformin (mg) 2,000 ± 700 49 (83) 1,900 ± 800 52 (88) 1,900 ± 800 51 (86) 
Glimepiride (mg) 5.2 ± 2.0 22 (37) 4.2 ± 2.2 38 (64)* 4.5 ± 2.3 34 (58)* 
GLP agonist (mg) 1.9 ± 0.7 5 (8) 2.0 ± 0.7 11 (19)* 2.1 ± 0.5 15 (25)* 
Insulin (IU)       
Long acting 53 ± 27 23 (39) 30 ± 9 4 (7)* 42 ± 27 12 (20)* 
Short acting 65 ± 43 24 (41) 36 ± 23* 10 (17)* 61 ± 38 12 (20)* 
Total 99 ± 68 28 (47) 44 ± 28* 11 (19)* 88 ± 62 14 (24)* 
Values are mean with standard deviation and number of patients (with percents). DJBL, duodenal-jejunal bypass liner. 
*p<0.05 compared with time of DJBL screening, analyzed with Wilcoxon Signed Rank test 
 
Weight change in T2DM patients after explantation of the DJBL has been reported in 2 studies. After a 
reduction in body weight of 10.6 kg, induced by a DJBL implantation time of 26 weeks, body weight 
rose by 3.8 kg in 6 months after explantation [4]. However, compared to pre-implantation a nett 
effect 6.8kg remained, which was comparable with a nett TBWL of 5.8% (EWL of 19.8%) at 26 weeks 
after explantation. In the study reporting 26-week explantation follow-up after an implantation time 
of 12 months, body weight increased by 4.4 kg after explantation, but the overall effect was a nett 
loss in body weight of 17.7 kg compared to baseline. (7). In our study, the weight gain observed 6 
months after explantation was 4.9 kg, i.e. comparable to the findings in these previous studies. After 
6 months weight gain appears to level off. The nett effect at 12 months after explantation was a 
TBWL of 7.4% (EWL 27.7%). Although statistically significant, this is below the limit of 10% weight 
reduction now commonly used to evaluate the efficacy of anti-obesity interventions. In the present 
study 31% of patients had a TBWL > 10%, one year after explantation.  
The beneficial metabolic effects of the DJBL have been attributed to favorable hormonal changes of 
intestinal hormones such as GLP-1, ghrelin, PYY, and CKK, (9, 12). It was hoped that the new hormonal 
settings induced by the DJBL might remain after explantation. However, emerging evidence suggests 
that the effects of the DJBL are transient and disappear after removal. Recently, it has been reported 
that the delayed gastric emptying observed during implantation reverses to normal after 
explantation(13). Both mechanisms might explain why the majority of patients report to have a 
reduced satiety level again after explantation, and why glycemic control deteriorates after 
explantation. Specific measures to prevent these changes in satiety and glucose control will be 
needed to maintain the beneficial effects of DJBL implantation. We hypothesize that the use of high 
dose GLP-1 agonists may prove to be useful in this setting(14). It has been shown that high dose 
liraglutide slows gastric emptying, increases satiety and improves glycemic control. It appears to be a 
promising agent to combine with the DJBL. A potentiating effect during implantation is not unlikely, 
and continuation of the GLP-1 agonist after explantation may help to reduce the risk of relapse. 
Chapter 4: Effects of Duodenal-Jejunal Bypass explantation   |   57 
Relapse after a variable period seems to be an upcoming issue in all bariatric techniques. It is 
observed after minimal invasive techniques, such as the intragastric balloon, but also after varies 
types of bariatric surgery such as adjustable gastric banding or Roux-en-Y gastric bypass (RYGB)(15, 
16). Up to now literature describing this relapse is still limited.  However, the widespread occurrence 
seen in clinical practice may serve to underline the importance of intensified research focusing on 
relapse prevention. To improve the results of DJBL implantation and to prevent or reduce the degree 
of relapse several issues will need to be given attention. Optimization of patient selection and 
improved counseling to establish beneficial life style changes during the implantation period may 
improve the effects of DJBL and minimize relapse. We also believe that a strict protocol for diabetes 
management during and after the implantation is a key to improve the results. It is well known that 
the use of insulin in T2DM leads to major weight gain by stimulating lipogenesis and inhibiting 
lipolysis, and that these physiological effects also create a great barrier for any therapy directed at 
achievement of weight loss. Thus, if possible insulin therapy should be avoided during DJBL 
treatment. Based on their pharmacological characteristics metformin and GLP-1 agonist are the 
preferred candidate agents to be combined with the DJBL, at least in theory. Prevention or delay of 
relapse might be established by prolongation of the implantation time. The feasibility of re-
implantation has already demonstrated on a limited scale(17). 
Our study has several limitations. First of all, it concerns a cohort study in which confounding factors 
cannot be controlled for, such as diet. All patients received dietary advice which makes it unclear to 
determine the true effects of the DJBL on T2DM and weight. Another, more subjective factor which is 
hard to measure, is motivation. Patients who choose a temporarily treatment such as the DJBL, might 
me less motivated than patients who choose for a definitive treatment such as surgery. Therefore, 
these patients might be less motivated and show more relapse. Additionally, a considerable number 
of patients were lost to follow-up. In most patients, this was caused by lack of interest to fulfill the 
follow-up because patients received their therapy. It is possible that patient who had a greater 
relapse after explantation were less motivated to attend the follow-up visits and thereby have led to 
an overestimation of the beneficial effects of the DJBL.  
In conclusion, explantation of the DJBL is associated with weight regain and worsening of glycemic 
control, although some beneficial effects sustain 12 months after explantation. New strategies will be 
required to preserve the beneficial effects of DJBL treatment. 
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Table 3. Dosage and number of users of the four most used diabetic medications at time of screening, 
explantation, and 12 months after DJBL explantation. Changes in diabetic medication; 12 months after 
explantation of the DJBL compared to prior to implantation of the DJBL. 
 At time of 
DJBL screening 
At time of 
DJBL explantation 
12 months after 
DJBL explantation 
 Dosage n (%) Dosage n (%) Dosage n (%) 
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Short acting 65 ± 43 24 (41) 36 ± 23* 10 (17)* 61 ± 38 12 (20)* 
Total 99 ± 68 28 (47) 44 ± 28* 11 (19)* 88 ± 62 14 (24)* 
Values are mean with standard deviation and number of patients (with percents). DJBL, duodenal-jejunal bypass liner. 
*p<0.05 compared with time of DJBL screening, analyzed with Wilcoxon Signed Rank test 
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Safety Experience with the Duodenal-Jejunal Bypass Line: an endoscopic treatment for diabetes and 
obesity 
Betzel B, Koehestanie P, Dogan K, Janssen IM, Aarts E, Homan J, Groenen M, Wahab P, Berends FJ 
Gastrointest Endosc. Gastrointest Endosc. 2015;82(5):845-52 
Abstract 
 
Background and study aims. The duodenal-jejunal bypass liner (DJBL) is a new, device-based 
endoscopic treatment for type 2 diabetes (T2DM) and obesity. The aim of this study was to report 
serious safety events of subjects treated with the DJBL while offering a simple guideline to mitigate 
risk. 
 
Patients and methods. For commercial use patients were eligible for implantation of the DJBL when 
they met the following criteria: age 18–65 years, BMI 28–45 kg/m2, T2DM, and negative serum H. 
pylori test. 
 
Results. Between October 2007 and January 2014, 152 (92%) of 165 planned implantations, and 94 
explantations have been performed in our center. Significant weight loss and improvement in T2DM 
and other cardiovascular parameters were achieved. Early removal of the device occurred due to 
persistent gastro-intestinal symptoms in 16 (11%) patients. Serious adverse events were observed in a 
subset of patients: 7 gastro-intestinal bleeds, 5 of which required early removal, 2 cases of 
pancreatitis, 1 case of hepatic abscess, and one obstruction of the sleeve. Explantation resulted in an 
esophageal tear in 2 cases. 
 
Conclusions. The DJBL improves glycemic control while causing weight loss. The safety profile of the 
DJBL demonstrates a reasonable tolerability profile. However, serious safety adverse events can 
occur. Patient selection, expert use of the device at placement and removal, and the supportive care 
of an experienced multi-disciplinary team is key for safe and effective use of the DJBL. 
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Introduction  
It is well recognized that obesity and type 2 diabetes (T2DM) are at worldwide epidemic proportions. 
[1-2] Unfortunately, behavioral modification approaches and an array of pharmacological agents, 
both orally administered and injectable, fail to demonstrate a sustained and impactful means to 
combat this metabolic epidemic. [3] The beneficial effects of behavioral modification and 
pharmacology are impeded by an innate difficulty in patients adhering to a given regime for sustained 
periods. Additionally, some anti-diabetes pharmacological agents incur further weight gain, 
worsening already established obesity. Bariatric surgery has emerged as an important intervention in 
the treatment for obesity and T2DM, manifesting with potent effects to normalize glycaemia 
accompanied by robust weight loss. [4-6] According to international guidelines, bariatric surgery 
should only be considered for patients with a BMI ≥35 kg/m2 combined with comorbidities. [7] This 
leads to a narrowing of its utility to a high risk sub-population and creates a reticence from some 
patients to undergo a permanent surgical procedure for a metabolic disorder. In recent years, a new 
therapeutic approach has emerged in the form of the duodenal-jejunal bypass liner (DJBL; 
EndoBarrier™, GI Dynamics, MA USA), a device placed temporarily in the gastrointestinal tract. It is 
placed endoscopically with minimal disruption to normal anatomy, [8-9] rendering it less invasive 
than bariatric surgery. After a recommended 12-month implant time, the device is endoscopically 
removed. Metabolic effects are seen in obese patients with T2DM with a lowering of glycaemia to 
6.5-7.5%, an excess weight loss of 39-47%, and positive effects on cardio-metabolic parameters. [10-
16] Its effects on glycaemia are at least as competitive as optimized pharmacology approaches and 
weight loss effects are beyond that seen with pharmacology. Therefore, the DJBL is emerging as an 
intervention that may complement certain pharmacological treatments in a setting where bariatric 
surgery is unattractive or unavailable. [13]  
The Rijnstate hospital, Arnhem, the Netherlands, is one of the centers pioneering the use of the DJBL 
as a treatment for obesity and T2DM, first in earlier prototype forms, then in formal clinical trials, [17-
18] and currently commercially. With increasing numbers, the experience and expertise in the use of 
the device continues to mature. The DJBL is considered to be a safe therapeutic option which is well 
tolerated by patients. However, early explantations have been reported. [8, 10, 11, 13, 16, 17, 19, 20] 
Additionally, patients experienced gastrointestinal bleeding due to the device [21] and a laparoscopic 
intervention due to perforation has been reported. [22]  
The aim of this report is to leverage the expertise gathered at the Arnhem center by summarizing the 
overall safety experience using the DJBL thus far, while discussing methods to optimize safe use of the 
device for the future. In view of the study design, only limited efficacy data is presented here. 
Design  
Between October 2007 and January 2014, a total of 165 implantations and 94 removals of the DJBL 
were performed in the Rijnstate Hospital, Arnhem, the Netherlands. All patients who were approved 
for implantation in the Rijnstate Hospital were prospectively followed. These patients were selected 
from 3 studies: two clinical trials [17, 18] and one prospectively followed cohort study. All studies 
were approved by the institutional review board. 
Inclusion criteria  
The inclusion criteria were different between the studies. Patients had to meet the following inclusion 
criteria for the commercial device: age 18–70 years, BMI 28–45 kg/m2, fasting plasma C-peptide >0.27 
nmol/L (normal range 0.27–1.28 nmol/L), negative serum H. pylori test, and use at least two different 
types of oral anti-diabetic medication or the use of insulin. With growing experience, inclusion criteria 
were adjusted and patients who used anticoagulant medication (e.g. acetylsalicylic acid and 
acenocoumarol) or non-steroidal anti-inflammatory drugs (NSAIDs) were excluded to reduce the risk 
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of gastrointestinal bleeding. Additional exclusion criteria included: abdominal surgery that disrupted 
gastrointestinal anatomy, severe gastro-esophageal reflux disease, active gastric or duodenal ulcer 
disease, coagulopathies, and severe systemic or end-organ disease. No gastric swallow tests or 
esophagogastroduodenoscopy (EGD) were performed prior to implantation. The main differences in 
inclusion criteria for the study of Schouten et al. [17] were age between 18 and 55 years, and BMI 
between 40 and 60 kg/m2, or above 35 kg/m2 with obesity related comorbidities. In the study of 
Koehestanie et al. [18] Patients were eligible with an age between 18 and 65 years, a BMI 30-50 
kg/m2, and had T2DM for less than 10 years with a glycated hemoglobin A1c (HbA1c) level between 
7.5% and 10.0%. 
Follow-up  
Detailed information concerning DJBL procedure delivery and removal were captured prospectively 
with clinical follow-up of patients for up to 2 years post-device removal. Patients receiving the 
commercial device were assessed by the clinician responsible for implantation prior to procedure and 
after placement. They were assessed clinically at 1 week and 1, 3, 6, 9 and 12 months thereafter. 
After removal, visits were scheduled at 1 week, and 6, 12 and 24 months. Clinical assessment 
included: symptom check, adverse event capture, physical examination, and blood draw for standard 
diabetes management purposes. Patients were instructed to contact our Center if experiencing any 
unanticipated symptoms. Additionally, if admitted to another hospital, patients were instructed to 
immediately inform their treating doctor about their DJBL. An adverse event was defined as any event 
that had negative consequences for the patient during device delivery, during the period the device 
was in place, or during removal. 
DJBL placement (implantation)  
Placement of the device is performed endoscopically with fluoroscopic guidance. In earlier use of the 
DJBL, the endoscopic procedure was performed under general anesthesia, however, with increasing 
experience and familiarity with the procedure, implantation is now performed under conscious 
sedation.23 The anchor of the DJBL is placed in the duodenum, and when positioned, the proximal 61 
cm of the small bowel is covered with an impermeable fluoropolymer sleeve that is open at both 
ends.9, 24 During delivery, liner and anchor are in a collapsed form contained in a protective capsule 
which is passed to the duodenum, just distal to the pylorus. The device folds out of the capsule and 
the proximal part of the sleeve is fixed to the wall of the duodenum with help from the pressure of 
the self-expanding Nitinol anchor. This anchor contains 20 short barbs positioned in two directions 
that affix the device to the duodenal wall to prevent the DJBL from migrating either distally or 
proximally. The fluoropolymer liner is then passed distally from the anchor point. As food passes 
though the inner portion of the liner, bile and pancreatic fluids pass outside, only mixing after passing 
61 cm from the anchor position in the duodenum. 
DJBL removal (explantation) 
Removal of the device is also performed endoscopically with fluoroscopic guidance and is now also 
performed under conscious sedation [23]. The DJBL is removed with the use of a customized retrieval 
device. One of the draw-strings located at the crown of the device is secured and pulled, thus 
collapsing the device crown. Subsequently, the device is retracted onto the endoscope, which is 
equipped with a hood to cover the anchor barbs. After the anchor is collapsed and the barbs are 
secured inside the hood, confirmed by fluoroscopy, the DJBL is removed by pulling it gently out of the 
duodenum, into the stomach and then through the esophagus and mouth. 
Statistical analysis 
Data were analyzed using IBM® SPSS® for Windows, version 21.0. Results are presented as mean 
values with standard deviation (SD), unless specified otherwise. Differences between two time points 
within patients were analyzed with a paired t-test. A p-value <0.05 was considered statistically 
significant. All tests were two-tailed. 
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Introduction  
It is well recognized that obesity and type 2 diabetes (T2DM) are at worldwide epidemic proportions. 
[1-2] Unfortunately, behavioral modification approaches and an array of pharmacological agents, 
both orally administered and injectable, fail to demonstrate a sustained and impactful means to 
combat this metabolic epidemic. [3] The beneficial effects of behavioral modification and 
pharmacology are impeded by an innate difficulty in patients adhering to a given regime for sustained 
periods. Additionally, some anti-diabetes pharmacological agents incur further weight gain, 
worsening already established obesity. Bariatric surgery has emerged as an important intervention in 
the treatment for obesity and T2DM, manifesting with potent effects to normalize glycaemia 
accompanied by robust weight loss. [4-6] According to international guidelines, bariatric surgery 
should only be considered for patients with a BMI ≥35 kg/m2 combined with comorbidities. [7] This 
leads to a narrowing of its utility to a high risk sub-population and creates a reticence from some 
patients to undergo a permanent surgical procedure for a metabolic disorder. In recent years, a new 
therapeutic approach has emerged in the form of the duodenal-jejunal bypass liner (DJBL; 
EndoBarrier™, GI Dynamics, MA USA), a device placed temporarily in the gastrointestinal tract. It is 
placed endoscopically with minimal disruption to normal anatomy, [8-9] rendering it less invasive 
than bariatric surgery. After a recommended 12-month implant time, the device is endoscopically 
removed. Metabolic effects are seen in obese patients with T2DM with a lowering of glycaemia to 
6.5-7.5%, an excess weight loss of 39-47%, and positive effects on cardio-metabolic parameters. [10-
16] Its effects on glycaemia are at least as competitive as optimized pharmacology approaches and 
weight loss effects are beyond that seen with pharmacology. Therefore, the DJBL is emerging as an 
intervention that may complement certain pharmacological treatments in a setting where bariatric 
surgery is unattractive or unavailable. [13]  
The Rijnstate hospital, Arnhem, the Netherlands, is one of the centers pioneering the use of the DJBL 
as a treatment for obesity and T2DM, first in earlier prototype forms, then in formal clinical trials, [17-
18] and currently commercially. With increasing numbers, the experience and expertise in the use of 
the device continues to mature. The DJBL is considered to be a safe therapeutic option which is well 
tolerated by patients. However, early explantations have been reported. [8, 10, 11, 13, 16, 17, 19, 20] 
Additionally, patients experienced gastrointestinal bleeding due to the device [21] and a laparoscopic 
intervention due to perforation has been reported. [22]  
The aim of this report is to leverage the expertise gathered at the Arnhem center by summarizing the 
overall safety experience using the DJBL thus far, while discussing methods to optimize safe use of the 
device for the future. In view of the study design, only limited efficacy data is presented here. 
Design  
Between October 2007 and January 2014, a total of 165 implantations and 94 removals of the DJBL 
were performed in the Rijnstate Hospital, Arnhem, the Netherlands. All patients who were approved 
for implantation in the Rijnstate Hospital were prospectively followed. These patients were selected 
from 3 studies: two clinical trials [17, 18] and one prospectively followed cohort study. All studies 
were approved by the institutional review board. 
Inclusion criteria  
The inclusion criteria were different between the studies. Patients had to meet the following inclusion 
criteria for the commercial device: age 18–70 years, BMI 28–45 kg/m2, fasting plasma C-peptide >0.27 
nmol/L (normal range 0.27–1.28 nmol/L), negative serum H. pylori test, and use at least two different 
types of oral anti-diabetic medication or the use of insulin. With growing experience, inclusion criteria 
were adjusted and patients who used anticoagulant medication (e.g. acetylsalicylic acid and 
acenocoumarol) or non-steroidal anti-inflammatory drugs (NSAIDs) were excluded to reduce the risk 
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of gastrointestinal bleeding. Additional exclusion criteria included: abdominal surgery that disrupted 
gastrointestinal anatomy, severe gastro-esophageal reflux disease, active gastric or duodenal ulcer 
disease, coagulopathies, and severe systemic or end-organ disease. No gastric swallow tests or 
esophagogastroduodenoscopy (EGD) were performed prior to implantation. The main differences in 
inclusion criteria for the study of Schouten et al. [17] were age between 18 and 55 years, and BMI 
between 40 and 60 kg/m2, or above 35 kg/m2 with obesity related comorbidities. In the study of 
Koehestanie et al. [18] Patients were eligible with an age between 18 and 65 years, a BMI 30-50 
kg/m2, and had T2DM for less than 10 years with a glycated hemoglobin A1c (HbA1c) level between 
7.5% and 10.0%. 
Follow-up  
Detailed information concerning DJBL procedure delivery and removal were captured prospectively 
with clinical follow-up of patients for up to 2 years post-device removal. Patients receiving the 
commercial device were assessed by the clinician responsible for implantation prior to procedure and 
after placement. They were assessed clinically at 1 week and 1, 3, 6, 9 and 12 months thereafter. 
After removal, visits were scheduled at 1 week, and 6, 12 and 24 months. Clinical assessment 
included: symptom check, adverse event capture, physical examination, and blood draw for standard 
diabetes management purposes. Patients were instructed to contact our Center if experiencing any 
unanticipated symptoms. Additionally, if admitted to another hospital, patients were instructed to 
immediately inform their treating doctor about their DJBL. An adverse event was defined as any event 
that had negative consequences for the patient during device delivery, during the period the device 
was in place, or during removal. 
DJBL placement (implantation)  
Placement of the device is performed endoscopically with fluoroscopic guidance. In earlier use of the 
DJBL, the endoscopic procedure was performed under general anesthesia, however, with increasing 
experience and familiarity with the procedure, implantation is now performed under conscious 
sedation.23 The anchor of the DJBL is placed in the duodenum, and when positioned, the proximal 61 
cm of the small bowel is covered with an impermeable fluoropolymer sleeve that is open at both 
ends.9, 24 During delivery, liner and anchor are in a collapsed form contained in a protective capsule 
which is passed to the duodenum, just distal to the pylorus. The device folds out of the capsule and 
the proximal part of the sleeve is fixed to the wall of the duodenum with help from the pressure of 
the self-expanding Nitinol anchor. This anchor contains 20 short barbs positioned in two directions 
that affix the device to the duodenal wall to prevent the DJBL from migrating either distally or 
proximally. The fluoropolymer liner is then passed distally from the anchor point. As food passes 
though the inner portion of the liner, bile and pancreatic fluids pass outside, only mixing after passing 
61 cm from the anchor position in the duodenum. 
DJBL removal (explantation) 
Removal of the device is also performed endoscopically with fluoroscopic guidance and is now also 
performed under conscious sedation [23]. The DJBL is removed with the use of a customized retrieval 
device. One of the draw-strings located at the crown of the device is secured and pulled, thus 
collapsing the device crown. Subsequently, the device is retracted onto the endoscope, which is 
equipped with a hood to cover the anchor barbs. After the anchor is collapsed and the barbs are 
secured inside the hood, confirmed by fluoroscopy, the DJBL is removed by pulling it gently out of the 
duodenum, into the stomach and then through the esophagus and mouth. 
Statistical analysis 
Data were analyzed using IBM® SPSS® for Windows, version 21.0. Results are presented as mean 
values with standard deviation (SD), unless specified otherwise. Differences between two time points 
within patients were analyzed with a paired t-test. A p-value <0.05 was considered statistically 
significant. All tests were two-tailed. 
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Results 
Until January 2014, a total of 165 patients met the inclusion criteria for implantation at our center: 9 
cases in a clinical study utilizing an earlier device prototype, [17]  36 cases in a subsequent clinical 
study with the eventual commercial prototype, [18]  and 120 commercial cases. Eight of the 36 cases 
in the second clinical trial were added to the 120 commercial cases in the analysis, since their 
implantation period was prolonged from 6 months to 12 months during the trial (Table 1). Of the 165 
attempted implantations, 152 (92.1%) were successfully conducted and, at time of analysis, 94 
devices have been removed. In total, 70 (46.1%) patients completed their intended implantation 
period and a further 58 (38.2%) patients had yet to complete their intended implant period with the 
device still in place (mean implantation duration of 26 ± 1.7 weeks). The remaining 24 (15.8%) 
patients had the device removed early (mean implantation duration of 22 ± 3.9 weeks) (Table 1). Of 
the 152 patients who received the DJBL, 123 (80.9%) patients reported no major adverse events. 
Sixteen patients experienced gastro-intestinal symptoms leading to early removal of the device, but 
without evidence of other adverse events. However, more significant adverse events were noted in 
other patients resulting in early removal of the device in some (Table 2). Table 3 shows patient 
characteristics and efficacy data for all 3 groups, divided by the length of the implantation period. 
Only descriptive statistics have been performed for the group of patients implanted for 12 weeks 
because of the small patient numbers. Body weight and BMI decreased statistically significant 
between baseline and explantation, as well in the 6 as 12-month group (p<0.001). HbA1c and fasting 
glucose decreased in all groups, but a significant decrease was only reached in the group implanted 
for 6 months. Total cholesterol and triglyceride decreased statistical significantly in both groups, as 
the changes in LDL cholesterol varied between the groups. Finally, the HDL cholesterol decreased in 
all groups, of which significantly in the 6-month group. 
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Results 
Until January 2014, a total of 165 patients met the inclusion criteria for implantation at our center: 9 
cases in a clinical study utilizing an earlier device prototype, [17]  36 cases in a subsequent clinical 
study with the eventual commercial prototype, [18]  and 120 commercial cases. Eight of the 36 cases 
in the second clinical trial were added to the 120 commercial cases in the analysis, since their 
implantation period was prolonged from 6 months to 12 months during the trial (Table 1). Of the 165 
attempted implantations, 152 (92.1%) were successfully conducted and, at time of analysis, 94 
devices have been removed. In total, 70 (46.1%) patients completed their intended implantation 
period and a further 58 (38.2%) patients had yet to complete their intended implant period with the 
device still in place (mean implantation duration of 26 ± 1.7 weeks). The remaining 24 (15.8%) 
patients had the device removed early (mean implantation duration of 22 ± 3.9 weeks) (Table 1). Of 
the 152 patients who received the DJBL, 123 (80.9%) patients reported no major adverse events. 
Sixteen patients experienced gastro-intestinal symptoms leading to early removal of the device, but 
without evidence of other adverse events. However, more significant adverse events were noted in 
other patients resulting in early removal of the device in some (Table 2). Table 3 shows patient 
characteristics and efficacy data for all 3 groups, divided by the length of the implantation period. 
Only descriptive statistics have been performed for the group of patients implanted for 12 weeks 
because of the small patient numbers. Body weight and BMI decreased statistically significant 
between baseline and explantation, as well in the 6 as 12-month group (p<0.001). HbA1c and fasting 
glucose decreased in all groups, but a significant decrease was only reached in the group implanted 
for 6 months. Total cholesterol and triglyceride decreased statistical significantly in both groups, as 
the changes in LDL cholesterol varied between the groups. Finally, the HDL cholesterol decreased in 
all groups, of which significantly in the 6-month group. 
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Unsuccessful implantations 
In 13 (7.9%) patients, implantation of the device was unsuccessful. This was mostly related to local 
anatomy of the small intestine. Three patients had a short duodenal bulb that offered too little space 
to position the anchor of the DJBL. Six patients had a sharp angle in the course of their proximal 
jejunum that led to folding of the DJBL. A tubular adenoma was seen in two patients which made it 
unwise to implant the DJBL; one in the duodenal bulb and one in the horizontal part of the 
duodenum. Abnormal anatomy of the stomach due to previous surgery and severe gastritis were the 
cause of unsuccessful implantation in two other patients. All other implantations were performed 
without any major difficulties.  
Procedural adverse events 
Three patients experienced an adverse event due to the procedure. During the implantation 
procedure of one patient, after delivering the sleeve, the anchor unfolded incompletely. When 
manipulating the anchor, the capsule went back into the esophagus together with the endoscope. A 
superficial mucosal lesion was visible which was closed with three endoscopic clips. A swallow test 
showed no leakage of contrast and the patient recovered well. 
During DJBL removal, damage to the esophagus occurred in two patients. This concerned our 21st and 
49th explantation procedure. In the first patient, at planned removal after 6 months, the endoscopic 
check after removal showed a longitudinal, partial full thickness transmural tear of the last 6 cm of 
the esophagus, which was confirmed by CT scan. This was likely caused by an exposed barb outside 
the hood at the time of retrieval. The lesion was treated with an esophageal stent for 3 weeks 
resulting in uneventful healing. In the second patient, the DJBL was explanted due to pancreatitis 11 
months post-implantation. The DJBL was collapsed and placed into the hood, and then retracted into 
the stomach. After repositioning the collapsed barbs the DJBL was explanted without any problems. 
Outside the body it appeared that due to torsion of the sleeve the barbs were intertwined. 
Endoscopic assessment showed three sites of superficial mucosa damage which were treated with a 
stent and feeding tube. Both were removed, after 7 and 10 days respectively, followed by an 
uneventful recovery.  
Adverse events during the implantation period 
(i) Abdominal pain  
After implantation, approximately 50% of the patients complain of mild to moderate abdominal 
symptoms, including pain, nausea and vomiting during the first two weeks. In all cases, a standard 
regimen of tramadol, butylscopolamine and metoclopramide was prescribed to mitigate these 
symptoms. Persisting abdominal complaints during the complete implantation period which could not 
be cured with life style changes or medication, lead to early explantation in 16 (10.5%) patients. 
Abdominal symptoms quickly improved post-removal. 
(ii) Gastrointestinal bleeding  
Seven patients suffered from gastro-intestinal bleeding after implantation, of which 5 led to early 
explantation (Table 2). Two patients complained of haematemesis and melena 3 and 6 weeks after 
implantation of the DJBL, respectively. In both cases there was no evidence of a lowered haemoglobin 
or haemocrit, and no signs of hypovolemia. Endoscopy showed slight erosions of the duodenal 
mucosa in one patient, and three longitudinal ulcers with two blood clots below the anchor in the 
other patient. As no active bleeding was apparent in these patients, the DJBL was not removed. The 
patients were treated with additional proton-pump inhibitors (PPIs) and sucralfate. No further 
bleeding was noted during follow-up. One patient complained of fatigue and dizziness 40 weeks after 
implantation. Blood results showed a microcytic anemia. Endoscopy showed migration of the DJBL 
with superficial ulcerations without active blood loss. After removal of the DJBL, anemia resolved.  
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A fourth patient presented with melena and a lowered haemoglobin 2 weeks after implantation. This 
patient had continued acetylsalicylic acid therapy due to a previous cerebrovascular event. No active 
bleeding was seen, but the degree of blood loss resulted in device removal after which subsequent 
endoscopic coagulation of the bleeding ulcer was necessary. No further problems occurred. A fifth 
patient was treated with active anticoagulation (two types of platelet aggregation inhibitors and 
heparin) 11 months after device implantation owing to a myocardial infarction requiring coronary 
artery bypass graft (CABG). A few days after initiating anti-coagulation, the patient suffered from 
melena and a fall in haemoglobin, requiring transfusion. The DJBL was removed without adverse 
event, bleeding ceased and CABG was carried out.  There were two further cases of significant 
gastrointestinal bleed. One patient presented with clear evidence of hypovolaemia and 
haematemesis 6 weeks after implantation. Computed tomography (CT) angiography showed active 
blood loss from the gastroduodenal artery. After transfusion, and embolization of the artery, the 
patient stabilized and the DJBL was removed the next day without additional further adverse event. 
The other patient presented also with clear evidence of hypovolaemia and melena 6 weeks after 
implantation, requiring transfusion. No active bleeding in the surroundings of the anchor was visible 
on endoscopy. When removing the device, on separating the anchor from its position in the duodenal 
bulb, arterial bleeding ensued. This resulted in significant blood loss that could not be managed 
endoscopically and surgical removal of the DJBL was carried out through emergency laparotomy. 
Uneventful recovery followed and the patient was discharged 8 days after surgery.  
(iii) Pancreatitis  
Two patients developed mild pancreatitis 8.5 and 11 months after implantation, respectively. The first 
patient presented with severe abdominal pain and vomiting. Blood tests showed serum amylase of 
>1300 U/L (normal range 1–220 U/L). A CT scan showed migration of the DJBL, which passed the 
major duodenal papilla (Figure 1A). Additionally, an EGD confirmed migration of the DJBL past the 
swollen major duodenal papilla (Figure 1B) with linear ulcerations in the duodenal mucosa (Figure 
1C). Residual food at the entrance of the DJBL had blocked the papilla (Figure 1D). After retrieval of 
the DJBL, the patient recovered quickly with a serum amylase of 642 U/L the next day. The second 
patient presented with three days of abdominal pain and an elevated serum amylase >14.000 U/L. 
EGD showed migration of the DJBL distally and hypertrophic tissue surrounding the major duodenal 
papilla. After removal of the DJBL, the patient quickly recovered.  
(iv) Hepatic abscess 
One patient who suffered from anemia due to gastrointestinal bleeding, checked in with the 
emergency room in another hospital. After transportation of the patient to our canter, the DJBL could 
be removed normally. During admission, the patient presented with hepatic abscesses. The patient 
was treated with antibiotics for 8 weeks (4 weeks intravenous and 4 weeks oral) and made a full 
recovery.  
(v) Perforation of the anchor of the DJBL 
Twelve months after implantation, during explantation, EGD showed in one patient a perforation of 
one of the barbs of the anchor through the duodenal wall next to the pylorus into the stomach 
(Figure 2). The DJBL could be explanted endoscopically with help of the explantation set. The patient 
reported no pain and no complaints afterwards. 
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Figure 1. Migration of the DJBL. Migration of the DJBL through the duodenum was confirmed with help of a CT scan (A), 
where it had passed the major duodenal papilla (B). The duodenum showed linear ulcerations of the duodenal mucosa 
because of the migrating DJBL (C) where food residues at the entrance of the DJBL had blocked the papilla (D). 
Discussion 
The DJBL is a promising, minimally invasive, treatment for patients with T2DM and obesity. This study 
is the first in its kind that highlights the safety aspects of the DJBL. Therefore, the efficacy data 
presented in this article needs to be carefully interpreted. Although significant improvements are 
seen in weight, diabetes, and other cardiovascular parameters in all 3 groups, this study is not 
designed to completely evaluate these effects. In the group of patients implanted with the DJBL for 12 
months, half of the patients did not yet reach explantation. Therefore additional research focusing on 
efficacy of the DJBL is needed. The intended 12-month use occurs in most patients through a straight 
forward placement and removal of the device, and a manageable tolerability profile, particularly in 
the early weeks after placement. There is the need for strong expertise and a multi-disciplinary team 
to be in place to allow safe and effective use of this new device. However, unintended safety events 
can still arise. Additionally, there is a learning curve regarding how the device is implemented; from 
the training of the endoscopist at the outset, the right selection of appropriate patients, the 
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Figure 2. Perforation of the anchor of the DJBL into the 
stomach. EGD showed a perforation of one of the barbs of 
the anchor of the DJBL. The barb perforated through the 
duodenal wall, next to the pylorus, into the stomach. 
knowledge of the multi-disciplinary team gathered over time, and the accumulation of experience as 
more device placements are conducted. The device platform in its earlier experimentation was 
studied with different prototypes and for shorter implant times to assure some level of efficacy and 
safety. This allowed optimization to its current form and a recommended implant time of 12 months. 
Although the pioneering work was conducted at a small number of centers initially, the device is now 
being used in an expanding number of sites, reaching over 2,000 devices placements worldwide 
currently. It is important at this stage to therefore take stock of the early learnings with the device 
and to review its safety profile and how unintended safety matters may be mitigated. 
 
 
 
Procedural damage 
It is possible that with poor technique, faulty equipment or very abnormal anatomy damage may 
occur to the local anatomy, most typically the esophagus. Initial training is of utmost importance and 
having experienced proctors and trainers on-site in the early stages of use is critical. An important 
step at removal is to assure that the barbs of the anchor must be fully covered by the removal hood 
as they can damage the esophagus. Fluoroscopic assistance is of utmost importance. After the anchor 
is collapsed, it is first pulled into the stomach where more space is available to reposition the anchor 
in the hood. Once secured, it is then removed from the stomach and esophagus. Recently, the hood 
has been modified and is now slightly larger, further facilitating safe removal. It is important to realize 
that although removal can be a quicker procedure than placement, it can also be more challenging. 
The two esophageal ruptures caused while explanting the DJBL with the short protection hood, 
occurred within our first fifty cases. Although familiarity with the procedure facilitates safer removal, 
it remains of utmost importance to carefully remove the DJBL by an experienced endoscopist. 
Abdominal symptoms  
It would be expected with the intended use of the DJBL that gastro-intestinal symptoms are likely 
after placement. Adhering to a low residue, semi-liquid diet in the two weeks post-implantation 
seems to mitigate these symptoms, and the consult of a dietician pre- and post-placement is highly 
impactful. Complaints such as acid reflux can be mitigated and is the rationale for treating with high 
dosage of PPIs (twice a day 40 mg) during the time of implantation. When insufficient, a switch to a 
different PPI can be made and sucralfate can be added. Mild to severe constipation is also observed. 
Therefore, maintaining a minimum of 2 liters of fluid a day is necessary. Occasional use of laxatives 
and enemas might be useful. However, in some cases gastro-intestinal symptoms are persistent and 
excessive, leading to early removal of the device. 
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Bleeding  
We observed gastro-intestinal bleeding in 7 cases. The foreign presence of the device, the anchor 
crown and barbs, and the possible alteration of local acid production might all be contributing factors 
for inflammation of the mucosa and potential bleeding. Two of the 7 cases we report may have been 
avoided as anti-coagulation complicated the given case. When a medical condition requiring anti-
coagulation during the implantation period supersedes, the device should be removed as soon as 
possible. Additionally, we advise excluding patients known to have a past or current history of gastric 
or duodenal complaints such as severe acid reflux disease not responding to PPI treatment and peptic 
or duodenal ulcers. When gastrointestinal blood loss is suspected, an endoscopy should be 
performed. When blood loss has been significant or there is evidence of active bleeding, we advise to 
remove the DJBL. The uncommon, but very important, adverse event of an apparent arterial bleed, 
likely caused by the barbs of the anchor, needs to be managed promptly. The ability to treat this 
adverse event endoscopically is low and angiographic detection and embolization, or even surgical 
intervention may be needed. Therefore, implantation and explantation should always be performed 
in a hospital with sufficiently trained personnel and equipment that can manage such serious adverse 
events. 
Pancreatitis, hepatic abscess  
Two patients suffered from pancreatitis without a complicated course. Although it is understood that 
this target population, obese subjects with T2DM, are predisposed to pancreatitis, the foreign 
presence of the device may independently put patients at risk of episodes of pancreatitis. As example, 
it is feasible that migration of the DJBL distally may cover the major duodenal papilla or cause local 
irritation and edema of the papilla. One method to reduce migration to the papilla is to implant the 
DJBL proximal into the duodenal bulb so the distance to the papilla is increased. However, the 
anatomy of the patient, especially a short duodenal bulb, might make it necessary to advance the 
anchor distally during implantation.  We observed one case of hepatic abscess. The exact pathology is 
still unclear, but the foreign presence of the device might cause local seeding of infection that may 
pass to the liver bed. Further experience is necessary to better understand the potential causal 
relationship and pathology. 
In conclusion, the DJBL is a new treatment platform for patients with T2DM with obesity. The device 
is relatively easy to deliver and remove in most patients and it is therefore able to manifest its 
beneficial effects in most patients without major tolerability or safety issues. However, more serious 
adverse events can occur, especially on removal of the DJBL. Therefore, an expert multi-disciplinary 
team should be on hand for both implants and, more importantly, explants. There is a low rate of 
adverse events during the implantation period, most importantly, gastro-intestinal bleeding. 
Clinicians should be mindful of symptoms and signs of blood loss from the gastro-intestinal tract so 
that appropriate measures may be taken. A surgical team and interventional radiologist should be 
available on demand for managing severe adverse events. One significant asset the device offers is 
that it is temporary in its design, such that if more severe adverse events manifest, they quickly 
resolve after device removal. Gaining experience with this new treatment approach will continue to 
allow safe and effective use of the DJBL. 
Take-home message  
The duodenal-jejunal bypass liner is a new endoscopic treatment for diabetes type 2 and obesity. 
Despite the minimal invasive nature of this treatment, serious adverse events may occur. Therefore, 
hospitals implanting and explanting the duodenal-jejunal bypass liner should be prepared for these 
events. 
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remove the DJBL. The uncommon, but very important, adverse event of an apparent arterial bleed, 
likely caused by the barbs of the anchor, needs to be managed promptly. The ability to treat this 
adverse event endoscopically is low and angiographic detection and embolization, or even surgical 
intervention may be needed. Therefore, implantation and explantation should always be performed 
in a hospital with sufficiently trained personnel and equipment that can manage such serious adverse 
events. 
Pancreatitis, hepatic abscess  
Two patients suffered from pancreatitis without a complicated course. Although it is understood that 
this target population, obese subjects with T2DM, are predisposed to pancreatitis, the foreign 
presence of the device may independently put patients at risk of episodes of pancreatitis. As example, 
it is feasible that migration of the DJBL distally may cover the major duodenal papilla or cause local 
irritation and edema of the papilla. One method to reduce migration to the papilla is to implant the 
DJBL proximal into the duodenal bulb so the distance to the papilla is increased. However, the 
anatomy of the patient, especially a short duodenal bulb, might make it necessary to advance the 
anchor distally during implantation.  We observed one case of hepatic abscess. The exact pathology is 
still unclear, but the foreign presence of the device might cause local seeding of infection that may 
pass to the liver bed. Further experience is necessary to better understand the potential causal 
relationship and pathology. 
In conclusion, the DJBL is a new treatment platform for patients with T2DM with obesity. The device 
is relatively easy to deliver and remove in most patients and it is therefore able to manifest its 
beneficial effects in most patients without major tolerability or safety issues. However, more serious 
adverse events can occur, especially on removal of the DJBL. Therefore, an expert multi-disciplinary 
team should be on hand for both implants and, more importantly, explants. There is a low rate of 
adverse events during the implantation period, most importantly, gastro-intestinal bleeding. 
Clinicians should be mindful of symptoms and signs of blood loss from the gastro-intestinal tract so 
that appropriate measures may be taken. A surgical team and interventional radiologist should be 
available on demand for managing severe adverse events. One significant asset the device offers is 
that it is temporary in its design, such that if more severe adverse events manifest, they quickly 
resolve after device removal. Gaining experience with this new treatment approach will continue to 
allow safe and effective use of the DJBL. 
Take-home message  
The duodenal-jejunal bypass liner is a new endoscopic treatment for diabetes type 2 and obesity. 
Despite the minimal invasive nature of this treatment, serious adverse events may occur. Therefore, 
hospitals implanting and explanting the duodenal-jejunal bypass liner should be prepared for these 
events. 
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The feasibility of delivering a duodenal–jejunal bypass liner (endobarrier) endoscopically with 
patients under conscious sedation 
Koehestanie P, Betzel B, Dogan K, Janssen IM , Aarts E, Groenen M, , Berends FJ, Wahab P 
Surg Endosc. 2014;28(1):325-30.  
Abstract 
 
Background and study aims. The endoscopically placed duodenal-jejunal bypass Liner (DJBL) or 
EndoBarrier® Gastrointestinal Liner has been designed to treat type 2 diabetes mellitus and 
simultaneously achieve weight loss in obese patients. This study was performed to determine the 
safety, efficacy and feasibility of delivering the DJBL under conscious sedation. The primary endpoints 
were safety and complications. Secondary endpoints were the delivery time (minutes) the amount of 
propofol (mg) used and total hospital stay (hours). 
 
Patients and methods. In this prospective study, we compared placement of the DJBL under propofol 
sedation with placement under general anaesthesia. Fifty-six patients were included with twenty-
eight patients in each group.   
 
Results. Both groups were comparable with respect to age, gender, and BMI. All devices were 
successfully placed and in both groups no complications occurred. Comparing the conscious sedation 
group with the general anesthesia group showed a mean total operation time of 29 minutes and 56 
minutes, mean propofol use of 170 mg and 258 mg, and mean hospital stay of 11 hours and 22 hours, 
respectively. 
 
Conclusions. Delivery of the DJBL under conscious sedation is feasible, safe and time and cost 
efficient. Because of possible complications during the procedure, we recommend placement of the 
DJBL under conscious sedation in the proximity of the operation room. 
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Introduction  
Today over 60 million people worldwide face the dual challenge of managing type 2 diabetes mellitus 
(T2DM) and obesity [1-3]. Weight loss improves insulin resistance and forms, next to medication, one 
of the most important treatment modalities. Although conservative therapy such as diet and lifestyle 
training are frequently successful in weight control in the short term, long term results are most often 
disappointing [4-5]. Bariatric surgery on the other hand has proven its effectiveness in achieving and 
maintaining weight loss and improving obesity-related T2DM, quality of life and survival in the long 
term [5-8]. Although mortality and morbidity of bariatric surgery are decreasing [9], there is demand 
for less invasive methods to treat morbid obesity and T2DM with less discomfort, risk and costs. 
Recently, endoscopic interventional techniques for the treatment of obesity have been introduced as 
possible minimally invasive alternatives to surgery. These techniques are promising and might 
eventually provide additional approaches to treat obesity [12-14]. Such interventions may offer 
economic benefits and minimally invasive outpatient options for the growing numbers of obese and 
diabetic patients. The development of endoluminal therapies may extend the current indications for 
intervention to those with multiple comorbidities, older age and those with overweight or obesity 
(BMI 28-35 kg/m2). An example of such an endoscopic technique is the Duodenal-Jejunal Bypass Liner 
(DJBL, EndoBarrier, GI Dynamics, Lexington, MA). The DJBL is an endoscopic implant mimicking a 
surgical duodenal-jejunal bypass. The first multi-center trial with the DJBL dates from 2007 [15]. Since 
then, our center has placed over 100 DJBL’s to treat obesity and T2DM. To date, clinical experience in 
over 500 patients has demonstrated the ability of the DJBL to rapidly affect blood glucose control and 
induce weight loss. It also promotes improvements in metabolic functions including lowered blood 
pressure, cholesterol, LDL and triglycerides [15-22]. At present the DJBL has been introduced in 
several countries in Europe, Latin America, the Middle East and Australia. The device is placed under 
endoscopic visualization and fluoroscopic guidance. In these trials, placement has been performed 
under general anesthesia in the operating theatre. The ability to move the DJBL procedure out of the 
OR and to conscious sedation may reduce time, expense and simplify logistics.  After four years of 
experience delivering and removing the DJBL in our clinic, the ability to place the DJBL under 
conscious sedation (CS) was explored. Previously, only one small case series has been reported on the 
use of CS during delivery of the DJBL in three patients [23]. Therefore, the aim of this prospective 
study was to compare delivery under CS, i.e. propofol sedation, without airway intubation to delivery 
under GA in terms of safety, feasibility and efficacy.  
Patients and Methods 
This prospective cohort study was conducted at the Department of Surgery and Gastroenterology at 
the Rijnstate Hospital Arnhem, The Netherlands. Between March 2010 and October 2012, the DJBL 
was delivered in 56 consecutive patients. Before these cases, over 50 DJBL placements and removals 
were performed in our facility by the same experienced team. The first 28 patients were implanted 
under GA and the second 28 under CS. The study was approved by the local institutional review board 
and informed consent was obtained from all participants.  
Inclusion and exclusion criteria 
Patients were eligible for DJBL if they met the following inclusion criteria: age 18 - 65 years and BMI 
between 30 and 50 kg/m2, a medical history of T2DM with HbA1c >7.0% and the use of metformin 
and insulin or sulfonylurea daily for at least one year. Exclusion criteria were pregnancy, use of 
NSAIDS, anticoagulation therapy, weight loss medication, substance abuse, active H. pylori infection, 
iron deficiency or iron deficiency anaemia, gastrointestinal tract abnormalities or previous surgery in 
the gastrointestinal tract that could make the implantation more difficult. There was no specific 
inclusion/exclusion anaesthetic criteria for both groups, however all patients underwent preoperative 
anaesthetic screening. 
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DJBL function 
The DJBL consists of a Nitinol anchor, which is used to reversibly affix the device to the wall of the 
duodenum, and a 60 cm, impermeable fluoropolymer liner (Figure 1). The DJBL is open at both ends 
to allow food to pass. After implantation, the anchor is located in the duodenal bulb, just distal to the 
pylorus and the liner stretches out into the duodenum and the proximal jejunum (Figure 2). As a 
result, pancreatic and bile juices mix with food only after it passes through the DJBL. The DJBL 
therefore creates a bypass of the proximal intestinal tract. 
Implantation technique 
Prior to the procedure, patients were not allowed to eat or drink fluids containing calories for 6 hours 
to prevent aspiration. Two hours prior to the delivery, patients stopped taking fluids and were given 
IV fluids. Peri-procedural diabetes medications were adjusted based on the medical advice of an 
endocrinologist. In the first group, delivery of the DJBL was performed under GA. Patients were 
sedated with propofol, sufentanyl and midazolam and had muscle relaxation (Suxamethonium) 
before intubation. In the second group, the delivery of the DJBL was performed solely under propofol 
sedation without airway intubation. In all procedures patients were positioned on their left side on 
the operating table. Initial access to the stomach and duodenum was achieved by a standard 
gastroduodenoscopy and the ampulla of Vater was identified. Next, a guide wire was advanced into 
the duodenum over which the encapsulated device on a custom catheter which was tracked into the 
duodenum. The capsule at the distal end holds the liner and anchor. The catheter has an atraumatic 
ball at the end which is advanced by pushing it slowly through the intestine deploying the liner behind 
it. After full extension of the liner, the anchor was deployed in the duodenal bulb, approximately 0.5 
cm behind the pylorus. Endoscopic and fluoroscopic guidance were used to verify the correct position 
of the DJBL and that the DJBL was open at both ends to allow food to pass. All patients were 
prescribed antiemetics (metoclopramide 10 mg three times daily), analgesics (paracetamol 1 gram 
four times daily and tramadol 50 mg three times daily) and an anti-spasmodic (buscopan 10 mg three 
times daily) for a maximum of ten days. These medications were only used by the patient when 
needed. Additionally, all patients used prophylactic 40 mg of Omeprazole twice daily to prevent 
peptic ulcer formation in the stomach and duodenum during the DJBL implant period. Patients were 
scheduled for visits at week 1, months 1, 3, 6 and 9. After device removal at month 12, patients 
returned for follow-up visits at 1 week and 3, 6, 9 and 12 months. During these visits, a set of safety 
and follow-up laboratory parameters were obtained, weight and blood pressure were measured, 
adverse events were assessed and nutritional and diabetes counselling was performed.  
Outcomes 
The primary endpoints were feasibility, safety and complications. Secondary endpoints were 
procedure time (minutes), i.e. OR time, total hospital stay (hours) and total amount of infused 
propofol per patient (mg). The procedure was considered successful when there were no procedural 
complications. All patients were brought to the recovery room in stable condition. During the 
recovery phase, patients’ vital signs were monitored.  Patients who received the DJBL under CS were 
discharged the same day of implantation if they could drink two glasses of water and one cup of 
thicker fluids such as yoghurt without complaints of abdominal pain, nausea or vomiting. 
Statistics 
Data were prospectively collected using a computerized database. Data were analyzed using SPSS 
20.0 for Windows. The means and standard deviations for each parameter were calculated. An 
independent t-test was performed to determine the difference between the two groups. A p-value of 
<0.05 was considered significant. Graphs were created using Graphpad Prism 5.02 (Graphpad 
Software, Inc.). 
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were performed in our facility by the same experienced team. The first 28 patients were implanted 
under GA and the second 28 under CS. The study was approved by the local institutional review board 
and informed consent was obtained from all participants.  
Inclusion and exclusion criteria 
Patients were eligible for DJBL if they met the following inclusion criteria: age 18 - 65 years and BMI 
between 30 and 50 kg/m2, a medical history of T2DM with HbA1c >7.0% and the use of metformin 
and insulin or sulfonylurea daily for at least one year. Exclusion criteria were pregnancy, use of 
NSAIDS, anticoagulation therapy, weight loss medication, substance abuse, active H. pylori infection, 
iron deficiency or iron deficiency anaemia, gastrointestinal tract abnormalities or previous surgery in 
the gastrointestinal tract that could make the implantation more difficult. There was no specific 
inclusion/exclusion anaesthetic criteria for both groups, however all patients underwent preoperative 
anaesthetic screening. 
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DJBL function 
The DJBL consists of a Nitinol anchor, which is used to reversibly affix the device to the wall of the 
duodenum, and a 60 cm, impermeable fluoropolymer liner (Figure 1). The DJBL is open at both ends 
to allow food to pass. After implantation, the anchor is located in the duodenal bulb, just distal to the 
pylorus and the liner stretches out into the duodenum and the proximal jejunum (Figure 2). As a 
result, pancreatic and bile juices mix with food only after it passes through the DJBL. The DJBL 
therefore creates a bypass of the proximal intestinal tract. 
Implantation technique 
Prior to the procedure, patients were not allowed to eat or drink fluids containing calories for 6 hours 
to prevent aspiration. Two hours prior to the delivery, patients stopped taking fluids and were given 
IV fluids. Peri-procedural diabetes medications were adjusted based on the medical advice of an 
endocrinologist. In the first group, delivery of the DJBL was performed under GA. Patients were 
sedated with propofol, sufentanyl and midazolam and had muscle relaxation (Suxamethonium) 
before intubation. In the second group, the delivery of the DJBL was performed solely under propofol 
sedation without airway intubation. In all procedures patients were positioned on their left side on 
the operating table. Initial access to the stomach and duodenum was achieved by a standard 
gastroduodenoscopy and the ampulla of Vater was identified. Next, a guide wire was advanced into 
the duodenum over which the encapsulated device on a custom catheter which was tracked into the 
duodenum. The capsule at the distal end holds the liner and anchor. The catheter has an atraumatic 
ball at the end which is advanced by pushing it slowly through the intestine deploying the liner behind 
it. After full extension of the liner, the anchor was deployed in the duodenal bulb, approximately 0.5 
cm behind the pylorus. Endoscopic and fluoroscopic guidance were used to verify the correct position 
of the DJBL and that the DJBL was open at both ends to allow food to pass. All patients were 
prescribed antiemetics (metoclopramide 10 mg three times daily), analgesics (paracetamol 1 gram 
four times daily and tramadol 50 mg three times daily) and an anti-spasmodic (buscopan 10 mg three 
times daily) for a maximum of ten days. These medications were only used by the patient when 
needed. Additionally, all patients used prophylactic 40 mg of Omeprazole twice daily to prevent 
peptic ulcer formation in the stomach and duodenum during the DJBL implant period. Patients were 
scheduled for visits at week 1, months 1, 3, 6 and 9. After device removal at month 12, patients 
returned for follow-up visits at 1 week and 3, 6, 9 and 12 months. During these visits, a set of safety 
and follow-up laboratory parameters were obtained, weight and blood pressure were measured, 
adverse events were assessed and nutritional and diabetes counselling was performed.  
Outcomes 
The primary endpoints were feasibility, safety and complications. Secondary endpoints were 
procedure time (minutes), i.e. OR time, total hospital stay (hours) and total amount of infused 
propofol per patient (mg). The procedure was considered successful when there were no procedural 
complications. All patients were brought to the recovery room in stable condition. During the 
recovery phase, patients’ vital signs were monitored.  Patients who received the DJBL under CS were 
discharged the same day of implantation if they could drink two glasses of water and one cup of 
thicker fluids such as yoghurt without complaints of abdominal pain, nausea or vomiting. 
Statistics 
Data were prospectively collected using a computerized database. Data were analyzed using SPSS 
20.0 for Windows. The means and standard deviations for each parameter were calculated. An 
independent t-test was performed to determine the difference between the two groups. A p-value of 
<0.05 was considered significant. Graphs were created using Graphpad Prism 5.02 (Graphpad 
Software, Inc.). 
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 Figure 1: Duodenal-Jejunal Bypass Liner. 
Results 
In total 56 patients were included. No significant differences were found in sex, age, weight and BMI.  
Table 1 shows the baseline characteristics of the patients. No procedure related complications 
occurred during implantation in either group. During the recovery, all patients remained stable and 
no case of clinically significant episodes of vomiting or adverse effects were observed. No patient in 
either group reported awareness of any part of the procedure afterwards. DJBL delivery time was 24 
± 1,3 minutes in the GA group compared to 14 ± 1,8 minutes in CS group (p=0.0001) (Figure 3). Total 
OR procedure time in the GA group was 57 ± 2,3 minutes comparing to 29±1,2 minutes in the CS 
group (p<0.0001) (Figure 4). Hospital stay in the GA group was 22 ± 0,4 hours compared to 12 ± 1,6 
hours (p=0.0001) in the CS group, in which all patients could be discharged the same day (Figure 5). 
The amount of propofol administered to the GA group was 258 ± 23 mg compared to 162 ± 12 mg in 
the CS group (p<0.0001) (Figure 6). 
 
 Figure 2: Implanted Duodenal-Jejunal Bypass Liner. 
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Figure 3: Implantation time in GA (general 
anesthesia) and CS (conscious sedation group) 
patients, Values are mean ± SD, p< 0,001. 
Figure 4: Total procedure time in GA (general 
anesthesia) and CS (conscious sedation group) 
patients, Values are mean ± SD, p< 0,001 
Table 1. Preoperative demographic data (mean ± SD) 
Parameter General anesthesia Conscious sedation 
Female/male 13/15 10/18 
Age (years) 50 ±1,5 48 ±1,5 
Weight (kg) 108 ± 3kg 105 ± 2 kg 
BMI (kg/m²) 35.6 ± 0.8 33.5 ± 0.5 
No significant differences were found. 
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Figure 5: Hospital stay in GA (general 
anesthesia) and CS (conscious sedation group) 
patients, Values are mean ± SD, p< 0,001. 
Figure 6. Propofol usage in GA (general 
anesthesia) and CS (conscious sedation group) 
patients, Values are mean ± SD, p< 0,001 
 
 
 
 
Discussion  
Delivery of the DJBL under CS is feasible and safe when compared to the use of GA.  In addition, 
delivering the DJBL under CS takes less time and results in a shorter hospital stay. By delivering the 
DJBL under CS, patients are not exposed to the potential risk and complications associated with GA 
[24]. General anesthesia holds certain risks, especially in obese patients [25]. These risk factors are 
categorized as respiratory disorders such as sleep apnea syndrome, hypoventilation syndrome, 
reduced lung volume and cardiovascular disorders such as hypertension, cardiac function and cardiac 
arrhythmias [26-30]. However, in the GA group no anesthetic complications occurred.  
Propofol is a short-acting, hypnotic, anesthetic agent, which is used for the induction and 
maintenance of general anesthesia and procedural sedation. Due to possible side effects on the 
respiratory and cardiovascular system, propofol should be administered only where appropriately 
trained staff and facilities for patient monitoring are available. Therefore, in both groups all deliveries 
took place in the OR. Propofol sedation requires intensive monitoring of the patient to maintain the 
adequate level of sedation and avoid waking up, agitation and gagging as well as sedating too deep 
causing respiratory insufficiency. Again, in our group, no procedural problems were met and not a 
single patient remembered any details of the procedure.  
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We believe that the DJBL team should have significant experience with delivery and removal 
procedures under GA before performing procedures under CS. Similar to other GI procedures, 
potential complications, although rare, include duodenal, pyloric or esophageal perforation, bleeding 
and respiratory and cardiovascular complications related to the sedation. Our team felt safe placing 
the DJBL under CS after we had performed more than 50 deliveries and removals and a clear protocol 
was developed. Only in high risk patients we do consider DJBL placement under general anesthesia. 
This includes BMI >45 kg/m2 and any anatomical anomalies of mouth and hypopharynx that may 
complicate the endoscopic procedure 
Conclusion 
Delivery of the DJBL under conscious sedation is feasible, safe and efficient in the hands of a team 
experienced in the procedure including gastroenterologists or surgeons, sedation team and using well 
developed protocols.  The use of CS may reduce costs of the DJBL procedures making the technology 
accessible to more diabetes and obesity patients. To further reduce costs, we are investigating 
performing procedures in the endoscopy suite, which remains in proximity to the OR if needed.  
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Abstract  
 
Background and study aims. To evaluate the feasibility, safety and effectiveness of duodenal-jejunal 
bypass liner (DJBL) re-implantation. The endoscopically implanted DJBL is a 60-cm impermeable 
fluoropolymer device, which prevents food from contacting the proximal intestine. It was designed to 
induce weight loss and treat Type 2 Diabetes Mellitus (T2DM).  
 
Patients and methods. Five obese patients with T2DM with BMI (Body Mass Index = Mass (kg)/ 
(height (m) 2), ranging from 30-35 kg/m2 who completed the follow-up after their first implant and 
underwent removal of the DJBL after 6 months, were selected for re-implantation after an additional 
18 months of follow-up. Weight loss, BMI and HbA1c were analyzed before and twelve months after 
re-implantation. 
 
Setting. Prospective, observational study was conducted at the department of surgery and 
gastroenterology of the Rijnstate hospital, Arnhem, the Netherlands. Between 2009 and 2011 
 
Results. In all five patients, the DJBL was implanted and explanted without any complications. Also, 
the re-implantation and re-explantation occurred without any complications. Median body weight 
decreased significantly from 105 kg to 95 kg, and BMI decreased from 33 to 29. The glycated 
hemoglobin (HbA1c) level decreased from 8.4% to 7.3% by the first implantation but it wasn’t 
significant. 
 
Conclusions. Re-implantation of DJBL is feasible, deemed safe, and showed additional weight loss. 
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Introduction  
Obesity has increased enormously over the last decade and is now a worldwide epidemic [1.2]. By 
2030, an estimated 2.2 billion people worldwide will be overweight and 1.1 billion will be obese. This 
accounts for over 30% of the entire world population. [3] Obesity is the most important risk factor for 
Type 2 Diabetes Mellitus (T2DM), hypertension, hypercholesterolemia, heart disease, osteoarthritis, 
obstructive sleep apnoea, and many more related co-morbidities. [2, 3] In particular the increased 
prevalence of T2DM is strongly related to the increase in obesity. Diets which lead to an improvement 
of T2DM by inducing weight loss are insufficient to establish sustainable weight loss over time. [4-6] 
currently, bariatric surgery is the only treatment which leads to sustainable weight loss and 
improvement of comorbidities in the long-term. [7-10] Even though morbidity and mortality of 
bariatric surgery has decreased tremendously [11], due to concerns among the physicians and 
patients, there is a demand for less invasive therapies. A number of endoscopic interventional 
techniques have been introduced with varying results. [12, 13] One of these devices is the duodenal-
jejunal bypass liner (DJBL, GI Dynamics, Lexington, MA, USA), which has shown promising results so 
far. [14, 16] 
The DJBL is a 60cm impermeable fluoropolymer device. The endoscopically-implanted DJBL prevents 
food from making contact with the proximal intestine, which results in considerable weight loss and 
metabolic improvement. [17-22] 
The DJBL has been evaluated in different clinical trials, including patients with (morbid) obesity and 
T2DM. The safety and effectiveness 12, 24 and 52 weeks after implantation have been established. 
[17, 21, 23, 24]  
These clinical trials are in favors of weight loss and glycaemic control in obese patients. To date, 
however, no results have been published of the DJBL (Duodenal-Jejunal Bypass Liner) exceeding 6 
months post-explant. Both weight and HbA1c levels have been reported to increase post-explant. The 
question remains whether it is possible to re-implant the DJBL and what the results will be in terms of 
BMI (Body Mass Index) change and T2DM control?  Therefore, the aim of this study is to investigate 
the safety and feasibility of re-implantation of the DJBL in patients. 
Patients and Methods 
This prospective, observational study was conducted at the department of surgery and 
gastroenterology of the Hospital in the Netherlands. Between 2009 and 2011, 32 DJBLs were 
implanted, which were in situ for 6 months. All patients were enrolled in a follow-up program of one 
year, including 6 months post-explant. The first five patients who completed the follow-up of 18 
months post-explantation and met the re-implantation criteria (see below) were selected for this 
study. The ethical board of the Rijnstate Hospital gave their permission to conduct this prospective 
study. When patients reached the 12th month follow-up, they were informed about the possibility of 
re-implanting the DJBL. All five patients were willing to participate and signed an informed consent. 
They were instructed to fully adhere to the recommended dietary advices once more to prevent 
weight gain. These dietary guidelines included a low-calorie diet (1200 kcal for females, 1500 kcal for 
males). 
Inclusion and exclusion criteria 
Patients were eligible for re-implantation of the DJBL when they met the following inclusion criteria: 
age between 18 and 65 years, BMI between 28 and 35 kg/m2, T2DM with two different oral 
medications or insulin, and previously experienced an uncomplicated implantation and explantation 
of the DJBL. Additionally, patients required a time-interval of at least 12 months between 
explantation and re-implantation and had shown full commitment to the follow-up schedule during 
the first implantation period. Informed consent had to be signed. Exclusion criteria were pregnancy, 
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use of NSAIDs, anticoagulation therapy, weight loss medication, substance abuse, active H. pylori 
infection, or gastrointestinal tract abnormalities seen during the first implantation or explantation. 
Patients were advised to only consume full liquids (e.g. water, tea, bouillon, milk, soup, yogurt drinks) 
and pureed fruit in the first five days after implantation and soft, moist or pureed foods (e.g. yogurt, 
diced vegetables and fruit, smoothies, rice pudding, scrambled egg) from days six to fourteen after 
DJBL re-implantation.  The patients also were advised to use less carbohydrate. All patients received a 
proton pump inhibitor (Omeprazole 40 mg twice daily) during the DJBL treatment to prevent 
ulceration.  All the patients were prescribed antiemetics (metoclopramide 10 mg three times daily), 
analgesics (paracetamol 1 g four times daily and tramadol 50 mg three times daily), and an 
antispasmodic (buscopan 10 mg three times daily) for a maximum of 10 days. These medications 
were only used by the patient when needed. Peri-procedural diabetes medications were adjusted 
based on the medical advice of a specialist endocrinologist. Both insulin and oral medication (except 
metformin) were reduced to at least 50% of the dose prior to re-implantation. Metformin was only 
reduced when all other oral medications were discontinued based on sober glucose and HbA1c levels. 
In patients in whom the insulin dosage was reduced, Glimepiride (2mg) was started to maintain 
glucose control which could be increased when needed. 
Follow-up 
After first implantation of the DJBL, regular follow-up visits were performed after 1, 2, 3 and 6 
months, after which explantation followed. Follow-up after explantation was conducted at months 
12, 18 and 24 post-explant. The DJBL was re-implanted at month 24 and patients were monitored 
again at months 25, 28, 30 and 36; at month 36, the DJBL was explanted for the second time. During 
these visits, a set of safety and follow-up laboratory parameters were obtained, weight and blood 
pressure was measured, adverse events were assessed and nutritional and diabetes counselling was 
performed. 
Statistics 
Data were prospectively collected using a computerized database. Data were analyzed using SPSS 
20.0 for Windows. Ideal BMI was set at 25kg/m2. Although only five patients were included, the 
mean, standard error and range for each parameter were calculated. A Bonferroni-adjusted 
significance calculated for multiple comparisons. The graphics were created using GraphPad Prism 
5.02 (GraphPad Software, Inc.)  
Results 
There were 5 patients included in this observational study, one female and four males, with a mean 
age of 45 (45-62) years and a mean weight of 106 kilograms. No procedure-related complications 
occurred during the (re-)implantation. All implantations were performed in the operating theatre. 
However, all first implantations were performed under general anaesthesia with tracheal intubation, 
whereas all re-implantations were done under conscious sedation without tracheal intubation22. On 
the first occasion, the DJBL was implanted in 26 (20-39) minutes; re-implantation time was 
significantly lower, with an average of 15 (10-17) minutes (p= 0.005). After re-implantation, all 
patients were discharged from the hospital on the same day. There were no complications during the 
re-implantation. After twelve months, all devices were explanted in the endoscopy room by using 
only midazolam. There was a gradual weight loss over time from 106 to 95 kg (p= 0.005) (Figure 1 and 
2), and BMI index decreased from 32 to 29.6 kg/m2 (p=0.005) (Table 1).  Also, there was a gradual 
excess weight loss (Figure 3). Initially, the HbA1c level decreased, but increased post-explantation. It 
decreased during the course of the re-implantation, this was not significant (Figure 4), (Table 1).  
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Figure 1: Mean weight 
over time. Overall weight 
change in time; A: 
Baseline, B: Explantation 1, 
C:  18 Months post ex-
plant and Re-implantation 
months, D: 6 Month post 
re-implantation, E: 
Explantation 2. 
Table 1. Weight, BMI, EWL and HbA1c change in different time intervals  
Time interval in 
months 
Mean weight in kg 
(±SEM, Range) 
p=0.005 
Mean BMI  
(±SEM) 
p=0.005 
EWL (%) 
(±SEM) 
NS 
Mean HbA1c in % 
(±SEM, Range) 
NS 
First implantation 
0 105 (6.1; 91-116) 33 (1.3) 0 8.4 (0.5; 7 – 9.7) 
6 98 (6.1; 80-115)* 31 (1.3)* 22  (2-52) 7.3 (0.5; 5.9 – 8.6) 
Second implantation 
24 106 (6.1; 82-116) 32 (1.3) 12  (2-63) 8.6 (0.5; 7.2 -9.7) 
30 96 (6.1; 78-113)* 29.9 (1.3)* 40  (9-85) 9.3 (0.5; 7.9 – 10.6) 
36 95 (6.1; 78-113)* 29.6 (1.3)* 40 (11-86) 8.5 (0.5; 7.3 – 9.9) 
All weight, BMI and HbA1c levels are mean (Standard Error of the Mean; Range), * the mean weight and BMI was 
statistically significant with Bonferroni's correction, but EWL and HbA1c were not. SEM: Standard error of the mean, EWL: 
Excess weight loss: (Initial weight – Follow up weight) / Ideal weight * 100, HbA1c:  Glycated haemoglobin; BMI: (Body 
mass index = Mass (kg)/ (height (m) 2) Ideal weight: BMI 25 kg/m2. 
Anatomical change in duodenal bulb per-implantation and post-explant 
The DJBL is comprised of a nitinol anchor, which is used to reversibly affix the device to the wall of the 
duodenal bulb12-15. Before re-implantation, all patients were examined with a gastroduodenoscopy to 
evaluate the state of the duodenal bulb, which was where the DJBL anchor was positioned. Figure 5A 
shows an implanted DJBL immediately after implantation. Figure 5B illustrates the DJBL six months 
post-implant just before explantation; the anchors are pressing on the tissue which creates pseudo 
polyps. These pseudo polyps immediately after explantation are shown in Figure 5C. The pseudo 
polyps decreased in size but were still visible in all five patients just before re-implantation after 12 
months Figure 5D. After the second explantation there were again the same degrees of polyps. We 
do not know whether these also disappear, while none of the patients got a second endoscopy after 
the second explantation, but theoretically they will also disappear. 
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Figure 2: Mean BMI. BMI 
change in time; A: First 
implantation, B: 
Explantation, C:18 months 
post ex-plant and Re-
implantation, D: 6 months 
post re-implantation E: 
Explantation. BMI: (Body 
mass index = Mass (kg)/ 
(height (m) 2) 
Figure 3: Excess weight loss. Overall Excess 
weight loss A: First implantation, B: first 
Explantation, C: 6 months post-explant, D: 12 
months post ex-plant and Re-implantation, E: 
6 months post re-implantation, F 12 months 
post re-implantation. (EWL is defined as the 
amount of weight that is in excess of the 
ideal body weight (IBW). Ideal body weight is 
conventionally determined by the 
Metropolitan Life Tables or as a BMI of 25 kg 
/m2 in time). 
Figure 4: Mean HbA1c. HbA1c 
change in time; A: First 
implantation, B: Explantation, 
C: 18 months post ex-plant 
and Re-implantation, D: 6 
months post re-implantation 
E: Explantation. HbA1c is the 
glycated haemoglobin. 
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Figure 5: Endoscopic illustrations of DJBL in position and pseudo polyps in duodenal bulb. A: First DJBL (Duodenal-Jejunal 
Bypass Liner) implantation: DJBL anchors positioned in the duodenum bulb, the white arrows show the nitinol anchors 
implanted in the duodenal bulb. B: 6 Months post-implant: The entrance of the DJBL six months post-implant, the white 
arrows show the nitinol anchors pressing on the tissue of the duodenal bulb. C: Explantation after six months: The white 
arrows show the pseudo polyps in the duodenum bulb. D: 24 months post-implant: The white arrows show the pseudo polyps 
in the duodenum bulb 
 
Discussion  
There is an urgent need for minimally invasive techniques which guarantee long-term weight loss. 
Although the DJBL works conceptually but there is weight regain after explantation. Re-implantation 
may be the answer to this problem. The aim of this study was to determine whether it is technically 
possible to re-implant the DJBL, and whether the re-implantation would have the same weight and 
metabolic effect as the first implantation. During evaluation of the duodenal bulb prior to re-
implantation, there were still some visible pseudo polyps (Figure 5D). This was the result of the first 
implantation when the DJBL was in place for six months. The DJBL held itself in position in the 
duodenal bulb by the anchors (Figure 5A). The pressure of anchors on the tissue of the duodenal bulb 
created pseudo polyps in that location (Figure 5B). Also, 18 months post-explant, these polyps had 
decreased in size. Nevertheless, it was possible to re-implant the DJBL and explant it after 12 months 
without any complications. After the DJBL was implanted for the first time, all five patients lost weight 
(Figure 1, 2,3), their BMI and HbA1c levels decreased (Table 1 and Figure 2,4). However, these good 
results seemed to fade somewhat over time. Immediately after explantation, all five patients’ 
regained weight (Figure 1,2,3), but even 12 months post-explant they had still not reached their 
baseline level (Figure 1). Post-explant, the HbA1c level also increased (Figure 4). At month 24, 
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immediately after the re-implantation, the mean weight decreased again. However, HbA1c levels 
were still high in month 30 but decreased in month 36. Due to the rapid decrease in the use of anti-
diabetic mediation compared to the first implantation period, the HbA1c level increased immediately 
after re-implantation. Our protocol to reduce insulin, for example, was too vigorous and should be 
reduced in the future based on sober glucose and HbA1c levels. At six months after re-implantation, 
the weight dropped below the minimum weight of the first implantation (Figure 1). Also, the BMI six 
months after re-implantation was decreased more (29.9 kg/m2) compared to six months post-implant 
during the first implantation (31 kg/m2) (Table 1). There is a difference between the patients when it 
comes to weight loss. Some patients were doing far better than others. In general, it could be stated 
that the patients who lost a reasonable amount of weight during the first implantation also did well 
after re-implantation and showed even better weight loss.   It should be stated that this study used a 
small group of patients. However, the first results show that re-implantation is feasible. From our 
point of view, DJBL should never been re-implanted in patients who did not show good results during 
their first DJBL implantation. However, in patients who lost weight, with a HbA1c level that dropped 
during the first period and had good glycaemic control, there could be a benefit of re-implantation. 
For this group of patients, DJBL re-implantation could be considered.  
Conclusion 
The results of this study show that re-implantation of the DJBL is save and feasible. After re-
implantation, the weight and HbA1c levels decreased once more.  However, the numbers of the 
included patients were too small. 
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arrows show the nitinol anchors pressing on the tissue of the duodenal bulb. C: Explantation after six months: The white 
arrows show the pseudo polyps in the duodenum bulb. D: 24 months post-implant: The white arrows show the pseudo polyps 
in the duodenum bulb 
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after re-implantation. Our protocol to reduce insulin, for example, was too vigorous and should be 
reduced in the future based on sober glucose and HbA1c levels. At six months after re-implantation, 
the weight dropped below the minimum weight of the first implantation (Figure 1). Also, the BMI six 
months after re-implantation was decreased more (29.9 kg/m2) compared to six months post-implant 
during the first implantation (31 kg/m2) (Table 1). There is a difference between the patients when it 
comes to weight loss. Some patients were doing far better than others. In general, it could be stated 
that the patients who lost a reasonable amount of weight during the first implantation also did well 
after re-implantation and showed even better weight loss.   It should be stated that this study used a 
small group of patients. However, the first results show that re-implantation is feasible. From our 
point of view, DJBL should never been re-implanted in patients who did not show good results during 
their first DJBL implantation. However, in patients who lost weight, with a HbA1c level that dropped 
during the first period and had good glycaemic control, there could be a benefit of re-implantation. 
For this group of patients, DJBL re-implantation could be considered.  
Conclusion 
The results of this study show that re-implantation of the DJBL is save and feasible. After re-
implantation, the weight and HbA1c levels decreased once more.  However, the numbers of the 
included patients were too small. 
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Introduction  
Our published articles have been critically and systematically reviewed using the CONSORT and 
STROBE guidelines (CONSORT 2010 Key Documents).  The shortcomings of our research has been 
highlighted to allow for further research. 
Critical appraisal of chapter 2: The Effect of the Endoscopic Duodenal-Jejunal Bypass Liner on Obesity 
and Type 2 Diabetes Mellitus, a Multicenter Randomized Controlled Trial. 
Introduction. I reviewed our published article systematically by using the CONSORT guidelines 
(CONSORT 2010 Key Documents). The shortcomings of our research have been highlighted to allow 
for further research.  
Results. The review of our (published) article led to identification of several areas that would benefit 
from improvement (Table 1). Were I to conduct new research with the same question, all mentioned 
improvements would be taken into account.  However, the question that remains is whether DJBL is a 
viable alternative for obese patients with type 2 diabetes. 
In light of the increasing prevalence of obesity, the outstanding questions are: Is bariatric surgery the 
only option to treat obesity? Or could a device such as the DJBL be a possible alternative? 
The study was not designed and was not in complete agreement with   the consort guidelines. If the 
study would have been designed according to the consort guidelines the precision of the answer 
would have been greater. 
Conclusion. In conclusion, the results of the randomized control trial have to be interpreted with 
more caution than initially indicated. Further research may be needed to generate data that support 
the effectiveness of DJBL as an alternative for patients with obesity and type 2 diabetes 
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Critical appraisal of chapter 3 
Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, 
accompanied by elevated fasting ghrelin levels 
 
Introduction  
I reviewed our published article systematically using STROBE Guidelines.  
 
Results  
I have reviewed our published article systematically by using the STROBE Guidelines. As follows from 
the table below there is ample room for improvement in this study. If I were to conduct a new study 
with a similar question, I would take all the mentioned improvements into consideration. To test our 
hypothesis in this study, a different and more appropriate study design should have been selected. 
For example, a prospective cohort study that would allow for comparison between the DJBL and diet 
group. The subjects could have been followed up for a longer period. The questions that still need to 
be answered are: How will the gut hormones response following removal of the DJBL?  Would the 
response be different in the group that was treated by diet only?  
 
Conclusion  
In conclusion, I believe that the hypothesis about the gut hormone has been partially answered.  
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Critical appraisal of chapter 5 
 
Safety Experience with the Duodenal-Jejunal Bypass Line: an endoscopic treatment for diabetes and 
obesity. 
 
Introduction. 
I reviewed chapter 5 systematically using STROBE Guidelines.  
Results  
In this chapter, we have attempted to share our experience of managing of the complications. It was 
a retrospective observational cohort study with both implantation and explantation of DJBL 
conducted at our hospital. In this study, it was difficult to follow the STROBE guidelines step-by-step. I 
would have been preferable to categorize adverse events in greater detail such as mild, moderate and 
severe and discern whether there were independent risk factors.  Some of our advices are expert 
based it would have been better to specifically mention it as an expert opinion in our paper.   
Conclusion  
In conclusion, we have provided insight into managing complications following DJBL implantations 
however, the adverse events could have been highlighted in more detail. 
 
110   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
Chapter 8: Methodology and Critical appraisal   |   111 
Critical appraisal of chapter 5 
 
Safety Experience with the Duodenal-Jejunal Bypass Line: an endoscopic treatment for diabetes and 
obesity. 
 
Introduction. 
I reviewed chapter 5 systematically using STROBE Guidelines.  
Results  
In this chapter, we have attempted to share our experience of managing of the complications. It was 
a retrospective observational cohort study with both implantation and explantation of DJBL 
conducted at our hospital. In this study, it was difficult to follow the STROBE guidelines step-by-step. I 
would have been preferable to categorize adverse events in greater detail such as mild, moderate and 
severe and discern whether there were independent risk factors.  Some of our advices are expert 
based it would have been better to specifically mention it as an expert opinion in our paper.   
Conclusion  
In conclusion, we have provided insight into managing complications following DJBL implantations 
however, the adverse events could have been highlighted in more detail. 
 
110   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
11
2 
  |
   T
he
sis
: T
he
 E
nd
os
co
pi
c D
uo
de
na
l-J
ej
un
al
 B
yp
as
s L
in
er
 in
 ty
pe
 2
 d
ia
be
te
s a
nd
 o
be
sit
y 
Se
ct
io
n/
To
pi
c 
Ite
m
 N
o 
Ch
ec
kl
ist
 it
em
 
Re
po
rte
d 
Im
pr
ov
em
en
ts
 
Ti
tle
 a
nd
 a
bs
tra
ct
 
1 
(a
) I
nd
ica
te
 th
e 
st
ud
y’
s d
es
ig
n 
w
ith
 a
 co
m
m
on
ly 
us
ed
 te
rm
 in
 
th
e 
tit
le
 o
r t
he
 a
bs
tr
ac
t d
es
ig
n 
 
Ye
s 
 
In
tro
du
ct
io
n 
 
 
 
 
Ba
ck
gr
ou
nd
/r
at
io
na
le
 
2 
Ex
pl
ai
n 
th
e 
sc
ie
nt
ifi
c b
ac
kg
ro
un
d 
an
d 
ra
tio
na
le
 fo
r t
he
 
in
ve
st
ig
at
io
n 
be
in
g 
re
po
rt
ed
 
Ye
s 
 
Ob
je
ct
iv
es
 
3 
St
at
e 
sp
ec
ifi
c o
bj
ec
tiv
es
, i
nc
lu
di
ng
 a
ny
 p
re
sp
ec
ifi
ed
 h
yp
ot
he
se
s 
Ye
s 
 
St
ud
y d
es
ign
 
4 
Pr
es
en
t k
ey
 e
le
m
en
ts
 o
f s
tu
dy
 d
es
ig
n 
ea
rly
 in
 th
e 
pa
pe
r S
tu
dy
 
de
sig
n 
 
Ye
s 
   
Se
tt
in
g 
5 
De
sc
rib
e 
th
e 
se
tt
in
g,
 lo
ca
tio
ns
, a
nd
 re
le
va
nt
 d
at
es
, i
nc
lu
di
ng
 
pe
rio
ds
 o
f r
ec
ru
itm
en
t, 
ex
po
su
re
, f
ol
lo
w
-u
p,
 a
nd
 d
at
a 
co
lle
ct
io
n 
Ye
s 
W
e 
sh
ou
ld
 h
av
e 
m
en
tio
ne
d 
th
at
 R
ijn
st
at
e 
ho
sp
ita
l i
s 
an
 
ex
pe
rt 
ce
nt
re
 o
n 
DJ
BL
 
Pa
rt
ici
pa
nt
s 
6 
(a
) C
oh
or
t s
tu
dy
—
Gi
ve
 th
e 
el
ig
ib
ili
ty
 cr
ite
ria
, a
nd
 th
e 
so
ur
ce
s 
an
d 
m
et
ho
ds
 o
f s
el
ec
tio
n 
of
 p
ar
tic
ip
an
ts
. D
es
cr
ib
e 
m
et
ho
ds
 o
f 
fo
llo
w
-u
p 
Ye
s 
 
Va
ria
bl
es
 
7 
Cl
ea
rly
 d
ef
in
e 
al
l o
ut
co
m
es
, e
xp
os
ur
es
, p
re
di
ct
or
s, 
po
te
nt
ia
l 
co
nf
ou
nd
er
s, 
an
d 
ef
fe
ct
 m
od
ifi
er
s. 
Gi
ve
 d
ia
gn
os
tic
 cr
ite
ria
, if
 
ap
pl
ica
bl
e 
Ye
s 
 
Da
ta
 so
ur
ce
s/
 
m
ea
su
re
m
en
t 
8*
 
 F
or
 e
ac
h 
va
ria
bl
e 
of
 in
te
re
st
, g
iv
e 
so
ur
ce
s o
f d
at
a 
an
d 
de
ta
ils
 o
f 
m
et
ho
ds
 o
f a
ss
es
sm
en
t (
m
ea
su
re
m
en
t).
 D
es
cr
ib
e 
co
m
pa
ra
bi
lit
y 
of
 a
ss
es
sm
en
t m
et
ho
ds
 if
 th
er
e 
is 
m
or
e 
th
an
 o
ne
 g
ro
up
 
Ye
s 
 
Bi
as
 
9 
De
sc
rib
e 
an
y e
ffo
rt
s t
o 
ad
dr
es
s p
ot
en
tia
l s
ou
rc
es
 o
f b
ia
s 
 
 
St
ud
y s
ize
 
10
 
Ex
pl
ai
n 
ho
w
 th
e 
st
ud
y s
ize
 w
as
 a
rr
iv
ed
 a
t 
Ye
s, 
 
 
Qu
an
tit
at
iv
e 
va
ria
bl
es
 
11
 
Ex
pl
ai
n 
ho
w
 q
ua
nt
ita
tiv
e 
va
ria
bl
es
 w
er
e 
ha
nd
le
d 
in
 th
e 
an
al
ys
es
. I
f a
pp
lic
ab
le
, d
es
cr
ib
e 
w
hi
ch
 g
ro
up
in
gs
 w
er
e 
ch
os
en
 
an
d 
w
hy
 
No
t 
re
le
va
nt
  
 
St
at
ist
ica
l m
et
ho
ds
 
12
 
(a
) D
es
cr
ib
e 
al
l s
ta
tis
tic
al
 m
et
ho
ds
, i
nc
lu
di
ng
 th
os
e 
us
ed
 to
 
co
nt
ro
l f
or
 co
nf
ou
nd
in
g 
Ye
s 
 
 
 
(b
) D
es
cr
ib
e 
an
y m
et
ho
ds
 u
se
d 
to
 e
xa
m
in
e 
su
bg
ro
up
s a
nd
 
No
t 
 
Ch
ap
te
r 8
: M
et
ho
do
lo
gy
 a
nd
 C
rit
ica
l a
pp
ra
isa
l  
 | 
  1
13
 
Se
ct
io
n/
To
pi
c 
Ite
m
 N
o 
Ch
ec
kl
ist
 it
em
 
Re
po
rte
d 
Im
pr
ov
em
en
ts
 
in
te
ra
ct
io
ns
 
re
le
va
nt
 
 
 
(c
) E
xp
la
in
 h
ow
 m
iss
in
g 
da
ta
 w
er
e 
ad
dr
es
se
d 
No
 
 
 
 
(d
) C
oh
or
t s
tu
dy
—
If 
ap
pl
ica
bl
e,
 e
xp
la
in
 h
ow
 lo
ss
 to
 fo
llo
w
-u
p 
w
as
 a
dd
re
ss
ed
 lo
ss
 to
 fo
llo
w
 u
p 
 
No
t 
re
le
va
nt
 
 
 
 
(e
) D
es
cr
ib
e 
an
y s
en
sit
iv
ity
 a
na
ly
se
s 
 
 
Re
su
lts
 
 
 
 
 
Pa
rt
ici
pa
nt
s 
13
* 
(a
) R
ep
or
t n
um
be
rs
 o
f i
nd
ivi
du
al
s a
t e
ac
h 
st
ag
e 
of
 st
ud
y—
eg
 
nu
m
be
rs
 p
ot
en
tia
lly
 e
lig
ib
le
, e
xa
m
in
ed
 fo
r e
lig
ib
ili
ty
, c
on
fir
m
ed
 
el
ig
ib
le
, i
nc
lu
de
d 
in
 th
e 
st
ud
y,
 co
m
pl
et
in
g 
fo
llo
w
-u
p,
 a
nd
 
an
al
ys
ed
 
ye
s 
 
 
 
(b
) G
iv
e 
re
as
on
s f
or
 n
on
-p
ar
tic
ip
at
io
n 
at
 e
ac
h 
st
ag
e 
No
t 
re
le
va
nt
 
 
 
 
(c
) C
on
sid
er
 u
se
 o
f a
 fl
ow
 d
ia
gr
am
 
No
 
It 
w
ou
ld
 h
av
e 
po
ss
ib
ly 
be
en
 m
or
e 
ap
pr
op
ria
te
 to
 h
av
e 
a 
flo
w
 ch
ar
t 
De
sc
rip
tiv
e 
da
ta
 
14
* 
(a
) G
iv
e 
ch
ar
ac
te
ris
tic
s o
f s
tu
dy
 p
ar
tic
ip
an
ts
 (e
g 
de
m
og
ra
ph
ic,
 
cli
ni
ca
l, 
so
cia
l) 
an
d 
in
fo
rm
at
io
n 
on
 e
xp
os
ur
es
 a
nd
 p
ot
en
tia
l 
co
nf
ou
nd
er
s 
No
t 
re
le
va
nt
  
 
 
 
(b
) I
nd
ica
te
 n
um
be
r o
f p
ar
tic
ip
an
ts
 w
ith
 m
iss
in
g 
da
ta
 fo
r e
ac
h 
va
ria
bl
e 
of
 in
te
re
st
 
Al
l d
at
e 
w
ar
e 
av
ai
la
bl
e 
 
 
 
(c
) C
oh
or
t s
tu
dy
 S
um
m
ar
ise
 fo
llo
w
-u
p 
tim
e 
(e
g,
 a
ve
ra
ge
 a
nd
 
to
ta
l a
m
ou
nt
) 
No
t 
re
le
va
nt
 
 
Ou
tc
om
e d
at
a 
15
* 
Co
ho
rt
 st
ud
y 
Re
po
rt
 n
um
be
rs
 o
f o
ut
co
m
e 
ev
en
ts
 o
r s
um
m
ar
y 
m
ea
su
re
s o
ve
r t
im
e 
Ye
s 
 
M
ai
n 
re
su
lts
 
16
 
(a
) G
ive
 u
na
dj
us
te
d 
es
tim
at
es
 a
nd
, i
f a
pp
lic
ab
le
, c
on
fo
un
de
r-
ad
ju
st
ed
 e
st
im
at
es
 a
nd
 th
ei
r p
re
cis
io
n 
(e
g,
 9
5%
 co
nf
id
en
ce
 
in
te
rv
al
). 
M
ak
e 
cle
ar
 w
hi
ch
 co
nf
ou
nd
er
s w
er
e 
ad
ju
st
ed
 fo
r a
nd
 
w
hy
 th
ey
 w
er
e 
in
clu
de
d 
No
 
 
112   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity Chapter 8: Methodology and Critical appraisal   |   113
Ch
ap
te
r 8
: M
et
ho
do
lo
gy
 a
nd
 C
rit
ica
l a
pp
ra
isa
l  
 | 
  1
13
 
Se
ct
io
n/
To
pi
c 
Ite
m
 N
o 
Ch
ec
kl
ist
 it
em
 
Re
po
rte
d 
Im
pr
ov
em
en
ts
 
in
te
ra
ct
io
ns
 
re
le
va
nt
 
 
 
(c
) E
xp
la
in
 h
ow
 m
iss
in
g 
da
ta
 w
er
e 
ad
dr
es
se
d 
No
 
 
 
 
(d
) C
oh
or
t s
tu
dy
—
If 
ap
pl
ica
bl
e,
 e
xp
la
in
 h
ow
 lo
ss
 to
 fo
llo
w
-u
p 
w
as
 a
dd
re
ss
ed
 lo
ss
 to
 fo
llo
w
 u
p 
 
No
t 
re
le
va
nt
 
 
 
 
(e
) D
es
cr
ib
e 
an
y s
en
sit
iv
ity
 a
na
ly
se
s 
 
 
Re
su
lts
 
 
 
 
 
Pa
rt
ici
pa
nt
s 
13
* 
(a
) R
ep
or
t n
um
be
rs
 o
f i
nd
ivi
du
al
s a
t e
ac
h 
st
ag
e 
of
 st
ud
y—
eg
 
nu
m
be
rs
 p
ot
en
tia
lly
 e
lig
ib
le
, e
xa
m
in
ed
 fo
r e
lig
ib
ili
ty
, c
on
fir
m
ed
 
el
ig
ib
le
, i
nc
lu
de
d 
in
 th
e 
st
ud
y,
 co
m
pl
et
in
g 
fo
llo
w
-u
p,
 a
nd
 
an
al
ys
ed
 
ye
s 
 
 
 
(b
) G
iv
e 
re
as
on
s f
or
 n
on
-p
ar
tic
ip
at
io
n 
at
 e
ac
h 
st
ag
e 
No
t 
re
le
va
nt
 
 
 
 
(c
) C
on
sid
er
 u
se
 o
f a
 fl
ow
 d
ia
gr
am
 
No
 
It 
w
ou
ld
 h
av
e 
po
ss
ib
ly 
be
en
 m
or
e 
ap
pr
op
ria
te
 to
 h
av
e 
a 
flo
w
 ch
ar
t 
De
sc
rip
tiv
e 
da
ta
 
14
* 
(a
) G
iv
e 
ch
ar
ac
te
ris
tic
s o
f s
tu
dy
 p
ar
tic
ip
an
ts
 (e
g 
de
m
og
ra
ph
ic,
 
cli
ni
ca
l, 
so
cia
l) 
an
d 
in
fo
rm
at
io
n 
on
 e
xp
os
ur
es
 a
nd
 p
ot
en
tia
l 
co
nf
ou
nd
er
s 
No
t 
re
le
va
nt
  
 
 
 
(b
) I
nd
ica
te
 n
um
be
r o
f p
ar
tic
ip
an
ts
 w
ith
 m
iss
in
g 
da
ta
 fo
r e
ac
h 
va
ria
bl
e 
of
 in
te
re
st
 
Al
l d
at
e 
w
ar
e 
av
ai
la
bl
e 
 
 
 
(c
) C
oh
or
t s
tu
dy
 S
um
m
ar
ise
 fo
llo
w
-u
p 
tim
e 
(e
g,
 a
ve
ra
ge
 a
nd
 
to
ta
l a
m
ou
nt
) 
No
t 
re
le
va
nt
 
 
Ou
tc
om
e d
at
a 
15
* 
Co
ho
rt
 st
ud
y 
Re
po
rt
 n
um
be
rs
 o
f o
ut
co
m
e 
ev
en
ts
 o
r s
um
m
ar
y 
m
ea
su
re
s o
ve
r t
im
e 
Ye
s 
 
M
ai
n 
re
su
lts
 
16
 
(a
) G
ive
 u
na
dj
us
te
d 
es
tim
at
es
 a
nd
, i
f a
pp
lic
ab
le
, c
on
fo
un
de
r-
ad
ju
st
ed
 e
st
im
at
es
 a
nd
 th
ei
r p
re
cis
io
n 
(e
g,
 9
5%
 co
nf
id
en
ce
 
in
te
rv
al
). 
M
ak
e 
cle
ar
 w
hi
ch
 co
nf
ou
nd
er
s w
er
e 
ad
ju
st
ed
 fo
r a
nd
 
w
hy
 th
ey
 w
er
e 
in
clu
de
d 
No
 
 
112   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity Chapter 8: Methodology and Critical appraisal   |   113
11
4 
  |
   T
he
sis
: T
he
 E
nd
os
co
pi
c D
uo
de
na
l-J
ej
un
al
 B
yp
as
s L
in
er
 in
 ty
pe
 2
 d
ia
be
te
s a
nd
 o
be
sit
y 
Se
ct
io
n/
To
pi
c 
Ite
m
 N
o 
Ch
ec
kl
ist
 it
em
 
Re
po
rte
d 
Im
pr
ov
em
en
ts
 
 
 
(b
) R
ep
or
t c
at
eg
or
y 
bo
un
da
rie
s w
he
n 
co
nt
in
uo
us
 v
ar
ia
bl
es
 w
er
e 
ca
te
go
riz
ed
 
No
t 
re
le
va
nt
  
 
 
 
(c
) I
f r
el
ev
an
t, 
co
ns
id
er
 tr
an
sla
tin
g 
es
tim
at
es
 o
f r
el
at
ive
 ri
sk
 in
to
 
ab
so
lu
te
 ri
sk
 fo
r a
 m
ea
ni
ng
fu
l t
im
e 
pe
rio
d 
No
 
Th
e 
ad
ve
rs
e 
ev
en
ts
 w
hi
ch
 o
cc
ur
re
d 
co
ul
d 
ha
ve
 b
ee
n 
de
fin
ed
 m
or
e 
th
or
ou
gh
ly.
 F
or
 e
xa
m
pl
e,
 c
at
eg
or
isi
ng
 in
to
 
m
ild
, m
od
er
at
e 
an
d 
se
ve
re
 a
dv
er
se
 e
ve
nt
s. 
W
ith
 th
is 
da
ta
, 
w
e 
co
ul
d 
ha
ve
 c
al
cu
la
te
d 
th
e 
pe
rc
en
ta
ge
 o
cc
ur
re
nc
e 
of
 
ea
ch
 a
nd
 in
ve
st
ig
at
ed
 if
 o
th
er
 fa
ct
or
s 
(s
uc
h 
as
 a
ge
, B
M
I, 
di
ab
et
es
 m
el
lit
us
 a
nd
 g
en
de
r) 
in
flu
en
ce
d 
it.
 
Ot
he
r a
na
lys
es
 
17
 
Re
po
rt 
ot
he
r a
na
ly
se
s d
on
e—
eg
 a
na
ly
se
s o
f s
ub
gr
ou
ps
 a
nd
 
in
te
ra
ct
io
ns
, a
nd
 se
ns
iti
vit
y 
an
al
ys
es
 
No
t 
re
le
va
nt
 
to
 th
is 
st
ud
y  
 
Di
sc
us
sio
n 
 
 
 
 
Ke
y 
re
su
lts
 
18
 
Su
m
m
ar
ise
 k
ey
 re
su
lts
 w
ith
 re
fe
re
nc
e 
to
 st
ud
y o
bj
ec
tiv
es
 
Ye
s 
 
Lim
ita
tio
ns
 
19
 
Di
sc
us
s l
im
ita
tio
ns
 o
f t
he
 st
ud
y,
 ta
kin
g 
in
to
 a
cc
ou
nt
 so
ur
ce
s o
f 
po
te
nt
ia
l b
ia
s o
r i
m
pr
ec
isi
on
. D
isc
us
s b
ot
h 
di
re
ct
io
n 
an
d 
m
ag
ni
tu
de
 o
f a
ny
 p
ot
en
tia
l b
ia
s 
No
 
 
In
te
rp
re
ta
tio
n 
20
 
Gi
ve
 a
 ca
ut
io
us
 o
ve
ra
ll 
in
te
rp
re
ta
tio
n 
of
 re
su
lts
 co
ns
id
er
in
g 
ob
je
ct
ive
s, 
lim
ita
tio
ns
, m
ul
tip
lic
ity
 o
f a
na
ly
se
s, 
re
su
lts
 fr
om
 
sim
ila
r s
tu
di
es
, a
nd
 o
th
er
 re
le
va
nt
 e
vi
de
nc
e.
 
Ye
s 
Al
th
ou
gh
 s
om
e 
of
 o
ur
 a
dv
ice
s 
w
er
e 
ex
pe
rt 
ba
se
d 
th
er
e 
w
as
 i
ns
uf
fic
ie
nt
 d
at
a 
to
 b
ac
k 
th
is.
 W
e 
sh
ou
ld
 h
av
e 
em
ph
as
ize
d 
th
at
 o
ur
 c
en
tre
 h
as
 s
o 
fa
r 
ha
d 
th
e 
m
os
t 
ex
pe
rie
nc
e 
w
ith
 D
JB
L i
nt
er
na
tio
na
lly
 
Ge
ne
ra
lis
ab
ili
ty
 
21
 
Di
sc
us
s t
he
 g
en
er
al
isa
bi
lit
y (
ex
te
rn
al
 v
al
id
ity
) o
f t
he
 st
ud
y 
re
su
lts
 
No
 
Bu
t i
t c
ou
ld
 b
e 
ge
ne
ra
liz
ed
  
Ot
he
r i
nf
or
m
at
io
n 
 
 
 
 
Fu
nd
in
g 
22
 
Gi
ve
 th
e 
so
ur
ce
 o
f f
un
di
ng
 a
nd
 th
e 
ro
le
 o
f t
he
 fu
nd
er
s f
or
 th
e 
pr
es
en
t s
tu
dy
 a
nd
, i
f a
pp
lic
ab
le
, f
or
 th
e 
or
ig
in
al
 st
ud
y o
n 
w
hi
ch
 
th
e 
pr
es
en
t a
rti
cle
 is
 b
as
ed
 
Ye
s, 
th
er
e 
w
as
 n
o 
fu
nd
in
g 
 
 
 
Chapter 8: Methodology and Critical appraisal   |   115 
Critical appraisal of chapter 6 
 
The feasibility of delivering a duodenal–jejunal bypass liner (endobarrier) endoscopically with patients 
under conscious sedation 
 
Introduction  
I reviewed chapter 6 systematically using the STROBE Guidelines.  
 
Results  
The study design was a prospective cohort. To be able to answer the question more accordingly a RCT 
trial would have been a better study design.  Nevertheless, we have been able to answer the cost-
effectiveness of the device delivering under conscious sedation.  
 
Conclusion  
In conclusion, the most appropriate study design to answer the question would be a randomised 
clinical trial instead of a prospective cohort study.  
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Critical appraisal of chapter 7 
Is Re-implantation of the Duodenal-Jejunal Bypass Liner Feasible? 
 
Introduction  
I reviewed chapter 7 systematically using STROBE Guidelines. Based on the guidelines I can state that 
the effect of the study needs to be interpreted with caution. The aim of the study was safety, 
feasibility and effectiveness. Based on the study design and small study population it is difficult to 
draw conclusions. In view of the small number of the study and the study design it is difficult to 
provide a definitive answer. 
Conclusion  
The results of this study are interesting but the reader must be warned that the results must be 
interpreted with caution. 
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Introduction  
I reviewed chapter 7 systematically using STROBE Guidelines. Based on the guidelines I can state that 
the effect of the study needs to be interpreted with caution. The aim of the study was safety, 
feasibility and effectiveness. Based on the study design and small study population it is difficult to 
draw conclusions. In view of the small number of the study and the study design it is difficult to 
provide a definitive answer. 
Conclusion  
The results of this study are interesting but the reader must be warned that the results must be 
interpreted with caution. 
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Discussion  
One could argue that the advance in healthcare in recent years is due the advent of evidence based 
medicine. Evidence based medicine is accurate, explicit, and judicious. Therefore, every physician 
should, one way or another, be involved in research. It does not mean that every physician needs to 
be a scientist. But every physician should have the skills to integrate the external clinical evidence 
from systematic research in his or her daily practice. The efforts will lead to good clinical practice and 
eventually improve clinical decision-making. Considering these thoughts, I have tried to enhance my 
understanding from the published papers. I have reviewed the published articles systematically by 
using CONSORT and STROBE guidelines (CONSORT 2010 Key Documents) and highlighted the 
shortcomings of our research to allow for further research.  
The second chapter of this thesis has been reviewed systematically using the CONSORT guideline. The 
shortcomings of this study have been listed here. If I would have another opportunity to conduct the 
same study again, I would have defined the primary and secondary outcomes in greater detail. Based 
on the chosen primary and secondary outcomes, the appropriate design will follow eventually; this 
will result to a more defined answer and an accurate conclusion. The most crucial question in our 
published study was the effect of the Endoscopic Duodenal-Jejunal Bypass Liner on Obesity and Type 2 
Diabetes Mellitus. Was this question answered accurately? I believe we partially answered this 
question. We observed significant weight loss in the DJBL group compared to the diet group during 
the study. The HbA1c level decreased by 1.3% with the DJBL in place, this decreased by 1.3% 
significantly but only when DJBL was in place. The results show that DJBL has a positive effect when it 
is placed, but that this effect disappears when it is explanted. Patient will still have diabetes and 
obesity when the device is explanted. Thus, a number of important questions remain to be answered:  
Could this device, with its temporary effect, be the answer to this burden? 
How could we maximize the positive effect of the DJBL?  
Which type of subjects could maximally benefit from this device?  
How safe is DJBL?  
How does our published paper contribute to the answer to these questions? After reviewing our 
paper based on CONSORT guidelines, I am not convinced whether and how my papers add to the 
outstanding issues. It is clear that treatment of obesity requires a multidisciplinary approach. I am 
convinced that bariatric or endoscopic procedures are not the answer to stem the obesity tide. Which 
type of procedure or approach must be chosen to treat type 2 diabetes and obesity? It is important to 
pursue a long-term effect of the procedure. It is worth mentioning that when this study was 
conducted the DJBL was only allowed to be implanted for a period of six months. As far as diet and 
exercise go there is room for improvement. The diet used could have been documented in greater 
detail; same could have been done for exercise. This could have provided us with insight into inter-
individual difference between the subjects and possible effect on the results. Also, the safety data 
could have been documented in more detail in both groups. Safety was one of the primary questions. 
The safety data should have been analyzed in more detail. In this paper only the percentage of 
adverse events were presented. A randomized sham controlled trial would be a better model to 
answer the above questions.  
The following chapters of this thesis have been reviewed using the STROBE guideline. There was 
ample room for improvement in chapter 3. There is still little known about the mechanism of action 
of DJBL. In this chapter, we evaluated the effect of the DJBL on the gut hormones. The gut hormones 
GLP-1, GIP and Ghrelin were measured on 0-1-4 weeks post implant in 12 consecutively subjects. As 
the primary and secondary outcomes were not stated evidently, it makes the interpretation of the 
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results difficult. If I could conduct the same study again I would select a different study design. Ideally, 
the study design would entail a controlled cohort with two different groups such as comparing the 
DJBL and diet group. Moreover, the gut hormones can be measured in further detail. For example, 
before implantation, during implantation in different intervals of 4 weeks and post explantations in 
different interval for at least one-year post explant. As well as measuring the subject’s weights, HbA1c 
and anti-diabetic medication. Because of the short-term measurements and single DJBL group our 
question remains unanswered.  
In chapter 4 we have tried to collect similar data 12 months post explant. This study was conducted 
according to the STROBE guidelines. Even though the weight was still significantly lower than the 
baseline, the question about the anti-diabetic effect of DJBL remains. There was almost 30% lost to 
follow-up. This can be interpreted in two ways. Due to failing to follow-up the subjects we cannot be 
certain whether they performed better or worse than our presented results.  This could either be an 
under or overestimation of the DJBL effect. If we had a more effective and stricter follow-up program 
we would have been able to give a more detailed answer.  
Chapter 5 is about managing complications. In this chapter, we share our experience with DJBL. The 
data were collected from three different study periods. In each period, different types of DJBL were 
used. It would have been more advantageous to mention to mention which adverse events occurred 
in which period and with which type of DJBL. This would have provided greater insight whether 
certain adverse events occurred more in certain type of DJBL. Furthermore, this would have enabled 
us to measure whether an improvement in the design of DJBL would help to reduce the adverse 
events. This study lists the type of complications that may occur and how we are coming from a 
tertiary centre have handled the complications. In this study, we share our experience with DJBL. This 
could be viewed as an expert opinion.  
Chapter 6 shows our experience with implantation of the DJBL under conscious sedation. However, to 
answer the questions, regard the safety, efficacy and cost-effectiveness, a randomized controlled trial 
is required. Our study was a prospective cohort study with the same baseline characteristics in both 
groups. Both groups have shown efficiency in time and use of medications. However, issues regarding 
cost-effectiveness and safety remain unanswered. There are limitations inherent to this study that 
needs attention. Before the DJBL was implanted under conscious sedation, the gastroenterologist had 
gained enough experience with the device. This could influence the data. We need a randomized 
controlled trial study, to answer the questions, whether DJBL could be implanted under conscious 
sedation in the endoscopy room. 
After explantation of the DJBL the body weight and HbA1c level increased. In chapter 7 we conducted 
a study to see if re-implantation of the device was safe and possible. Could we draw firm conclusions 
based on this study after all? The answer is no. In order to answer this question fully detail we need 
to use a different study design with more subjects. In a feasibility study to answer the most important 
questions like: Can it work? Does it work? Will it work? 
The best option would be a prospective observational cohort study. The subjects then enter the study 
in consecutive order. Here, we have chosen for a cohort of 5 subjects who were willing to participate 
in this extension cohort of the chapter 2. Not only the limited number of subjects but also their 
motivation could have influenced the results. 
In conclusion, we could state that there is a demand for less invasive endoscopic bariatric therapies as 
obesity is increasing. DJBL could be a suitable intervention for certain type of patients. Further 
research is necessary to evaluate the full effect of the DJBL on type 2 diabetes and obesity.
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groups. Both groups have shown efficiency in time and use of medications. However, issues regarding 
cost-effectiveness and safety remain unanswered. There are limitations inherent to this study that 
needs attention. Before the DJBL was implanted under conscious sedation, the gastroenterologist had 
gained enough experience with the device. This could influence the data. We need a randomized 
controlled trial study, to answer the questions, whether DJBL could be implanted under conscious 
sedation in the endoscopy room. 
After explantation of the DJBL the body weight and HbA1c level increased. In chapter 7 we conducted 
a study to see if re-implantation of the device was safe and possible. Could we draw firm conclusions 
based on this study after all? The answer is no. In order to answer this question fully detail we need 
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9.1 General discussion  
According to the world health organization’s worldwide obesity has more than doubled since 1980. In 
2014, more than 1.9 billion adults, 18 years and older, were overweight [1]. Obesity seems to be a 
hard to conquer disease and for many years doctors and pharmaceutical companies have tried to 
come up with a solution. Some promising medicines have come and gone, with good short-term 
results but often with serious related morbidity and mortality. Other more conservative treatments, 
like for example Weight Watchers or specific sport programs are too much depending on the patient’s 
internal motivation. As with medication, short term results are often stunning, but in the long term 
only a very small percentage is able to maintain their lowered bodyweight. Weight regain is due to 
many factors, most of which are patient related. The best solution available today to achieve good 
long-term weight loss and related co-morbidity reduction is more radical than just medication or 
reduction of calorie intake. Bariatric surgery, combined with a good follow up program, has proven its 
effectiveness in achieving and maintaining weight loss and improving obesity-related co-morbidities, 
quality of life, and survival [2]. Also, the International Diabetes Federation stated that bariatric 
surgery, especially the Roux-en-Y Gastric Bypass should be incorporated as a treatment for type 2 
diabetes [3]. Although RYGB surgery is an efficient intervention for T2DM, it carries the risk of 
complications, and although rare, mortality (0.1-0.04%) [4,5]. When a patient undergoes RYGB 
surgery, the stomach and small intestine are permanently surgically changed, and besides the 
operative risks, many patients do not dare to take such a drastic measure. It seems logical that for the 
treatment of T2DM in patients with relative mild obesity one should seek a solution which holds a 
lesser risk of complications, no permanent change in abdominal anatomy and with good result in 
terms of T2DM reduction or even resolution. The high prevalence of (morbid) obese T2DM patients 
requiring treatment demands a relatively simple and safe technique that can be available and 
implemented in a large population. 
There is great interest in new, safe, simple, other nonsurgical procedures for weight loss. Gastric 
Balloons, Suturing – plication/partition and modifying gastric motor function are a few examples of 
minimally invasive endoscopic procedures [6-9]. However, most of these procedures are only 
temporarily solutions and still inferior to bariatric surgery. When looking at the RYGB, the working 
mechanism on T2DM reduction is based on fast passage of foods and bypassing the duodenum for 
food and calories [10-12]. This can also in part be realized by placing endoscopic devices into the 
duodenum.  One example is the Duodenal-Jejunal Bypass Liner or DJBL. The DJBL consists of a 60 cm 
long impermeable fluoropolymer sleeve with a nitinol anchor, which is used to reversibly affix the 
device to the wall of the duodenal bulb. Once in place, the DJBL excludes the proximal small intestine 
from food contact, thereby mimicking the bypass component of the RYGB [13,14]. In the current 
thesis, we aimed to investigate the effect of this endoscopic bariatric technique on obesity and its 
comorbidities and managing of the complications. And address the hypothesis which has been stated 
at the begin of this thesis.  
The duodenal jejunal bypass liner will improve type 2 diabetes and obesity comparing diet alone.  The 
best way to address this hypothesis is through randomized controlled trail. In this thesis in Chapter 2 
the effect and feasibility of the DJBL on subject with type 2 diabetes and obesity is studied in a 
multicenter randomized controlled trial. Seventy-seven patients were included and randomized; 38 
patients were allocated to the DJBL group of which 34 patients were successfully implanted and 39 
control patients started a dietary intervention. This study showed that in both groups the weight and 
HbA1c levels decreased, however, significantly more so in the DJBL group compared to the diet 
group, which was comparable with the previous studies [13,15,16]. Also, the patients in the DJBL 
group decreased their use of medication. However, the weight and HbA1c levels increased in both 
group during the follow up period when the DJBL was explanted. This was, however, less in the DJBL 
group compared to the diet group. Interestingly, patients in the DJBL group required immediate 
lowering of their medication the first week after implantation. This is similar to the rapid 
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control patients started a dietary intervention. This study showed that in both groups the weight and 
HbA1c levels decreased, however, significantly more so in the DJBL group compared to the diet 
group, which was comparable with the previous studies [13,15,16]. Also, the patients in the DJBL 
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improvement of glycemic control after surgical procedures such as the RYGB [17,18].  To explain this 
effect there are two hypotheses: the foregut and the hindgut hypothesis. The “hindgut hypothesis” 
states that diabetes control results from the expedited delivery of nutrient chyme to the distal 
intestine, enhancing a physiologic signal that improves glucose metabolism [19,20]. Glucagon-like 
peptide 1 (GLP-1) is one of the gut hormones which most likely is involved in this process. GLP-1 is an 
incretin hormone secreted by L cells of the distal bowel in response to intestinal nutrients. It 
stimulates insulin secretion and exerts proliferative and anti-apoptotic effects on pancreatic beta 
cells. Nowadays, the incretins are very much of interest to treat type 2 diabetes.  The GLP-1 analogs 
and Dipeptidyl Peptidase-4 (DPP-IV) inhibitors are the examples of such medications. DPP-IV is a 
peptidase that rapidly degrades GLP-1. Administration of DPP-IV inhibitor slows down GLP-1 
degradation, thereby increasing the endogenous GLP-1 concentration, whereas a GLP-1 agonist 
directly stimulates the GLP-1 receptor [21,22,23]. To investigate the mechanism of action and role of 
the incretins after implantation of DJBL we conducted a prospective trail. In Chapter 3 we measured 
different types of the incretins (GLP-1, GIP and Ghrelin) before and after DJBL implantation and 
determined its correlation with fast insulin, HbA1c, HOMA-IR and weigh loss. A week after 
implantation the patients used 40% less medication.  At the same time, the fasting glucose level was 
decreased significantly. After one month, the HbA1c levels and HOMA-IR decreased as well. The GLP-
1 level decreased the first week post-implant but increased thereafter. The fact that the patients used 
less medication even the first week post-implant while the fasting glucose level was decreased could 
be attributed to the gut hormones. This was in line with the earlier studies with RYGB [24,25,26] and 
DJBL and its effect on type 2 diabetes [27]. The limitation of our study was lacking a control group and 
no measurement of the incretins after explantation of DJBL. However, in the period when the DJBL 
was in place there was a tremendous improvement of the type 2 diabetes. This device can only be in 
situ for a period of twelve months.  We were very interested in the effect of the DJBL when it was 
removed.  
The important question we had was, how long will the positive effect of the DJBL endure when it is 
removed?  We tried to answer this question in Chapter 4. We collected a prospective data of all 
patients who were treated with DJBL. The duration of the study was twelve months post-explant. In 
total, 59 patients completed the 12-month follow-up after explantation. During this period body 
weight increased by 5.6 (standard deviation, 6.4) kg (P < .001) and HbA1c rose from 65 (SD 17) to 70 
(SD 20) mmol/mol (P < .001). However, body weight remained 8.0 (SD 8.6) kg (P < .001) lower than 
before implantation, that is, corresponding to a net total body weight loss of 7.4% (SD 7.6) (P < .001). 
Although HbA1c was significantly higher 12 months after explantation compared with baseline and 
the mean daily dose of insulin used was comparable, the number of patients on insulin remained 
significantly lower than before implantation.  This is the first ‘long term’ follow up internationally.  We 
evaluated that the explantation of the DJBL is associated with weight gain and worsening of glycemic 
control, although some beneficial effects sustain 12 months after explantation. A change in strategy 
will be needed to preserve the beneficial effects of DJBL treatment. Different studies have shown the 
positive effect of the DJBL when it is in place. But when it’s removed the patients gain weight and 
HbA1c level is going to increase.  So still its temporarily management of the type 2 diabetes and 
obesity. We should find better selection criteria for the patients who will benefit the most from this 
device. Until now there are not such criteria for this device. 
The DJBL consists of a 60 cm long impermeable fluoropolymer sleeve with a five-sharp anchor from 
nitinol. These anchors affix the device to the wall of the duodenal bulb. There is constant of a 
peristaltic movement in the duodenum, this could increase the chance of complications. In a 
retrospective observational study, we evaluated the complications with the DJBL so far. In Chapter 5 
we share our experience with the DJBL from a safety perspective. Between October 2007 and January 
2014, 152 (92%) of 165 planned implantations, and 94 explantations have been performed in our 
center. Significant weight loss and improvement in T2DM and other cardiovascular parameters were 
achieved. Early removal of the device occurred due to persistent gastro-intestinal symptoms in 16 
130   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
(11%) patients. Serious adverse events were observed in a subset of patients: 7 gastro-intestinal 
bleeds, 5 of which required early removal, 2 cases of pancreatitis, 1 case of hepatic abscess, and one 
obstruction of the sleeve. Explantation resulted in an esophageal tear in 2 cases. The device is 
relatively easy to deliver and remove in the majority of patients and it is therefore able to manifest its 
beneficial effects in the majority of patients without major tolerability or safety issues. However, 
more serious adverse events can occur, especially on removal of the DJBL. Therefore, an expert multi-
disciplinary team should be on hand for both the implant and, more importantly, explant procedure. 
There is a low rate of adverse events during the implantation period, most importantly, gastro-
intestinal bleeding. Clinicians should be mindful of symptoms and signs of blood loss from the gastro-
intestinal tract, so that appropriate measures may be taken. A surgical team and interventional 
radiologist should be available on demand for managing severe adverse events. One significant asset 
the device offers is that it is temporary in its design, such that if more severe adverse events manifest, 
they quickly resolve after device removal. DJBL seemed safe, but in inexperience hands, there is a 
chance of serious complications, like perforations, bleeding and pancreatitis. At our center, all the 
complications were managed without serious damage. 
After four years of experience delivering and removing the DJBL in our clinic, the ability to place the 
DJBL under conscious sedation (CS) was explored. In Chapter 6 we described our experience so far. 
The DJBL was implanted and explanted under conscious sedation and compared with the group under 
general anaesthesia. The parameters which were studied were total operation time, propofol usage, 
safety and hospital stay. The total operation time in patients under conscious sedation was 29 
minutes, mean propofol use of 170 mg and mean hospital stay of 11 hours. This was significantly less 
than de group under general anaesthesia.   Both techniques showed no procedural complications. By 
the time that this study was done, there were over 100 DJBL implanted under conscious sedation. We 
could state that the delivery of the DJBL under conscious sedation is feasible, safe and time and cost 
efficient. Because of possible complications during the procedure, we recommend placement and 
especially explantation of the DJBL under conscious sedation in the proximity of the operation room. 
The DJBL team should have significant experience with delivery and removal procedures under GA 
before performing procedures under CS. Similar to other GI procedures, potential complications, 
although rare, include duodenal, pyloric or esophageal perforation, bleeding and respiratory and 
cardiovascular complications related to the sedation. Our team felt safe placing the DJBL under CS 
after we had performed over 50 deliveries and removals under general anesthesia and a clear 
protocol was developed. Only in high risk patients we do consider DJBL placement under general 
anesthesia. This includes BMI >45 kg/m2 and any anatomical anomalies of mouth and hypopharynx 
that may complicate the endoscopic procedure. This study showed that after enough experience, the 
implantation and explantation of the DJBL under conscious sedation is safe and feasible.  DJBL is an 
endoscopic device which could be placed in the endoscopy room by using only propofol. This will 
reduce the cost of the device, which make this device available for more patients to treat with.  
As we discussed in Chapter 4 there is weight regain after explantation. Due to the CE mark, it’s 
impossible to prolong the treatment beyond twelve months. Re-implantation may be the answer to 
the observed weight regain. 
We conducted a prospective observational study in a small group of patients. In Chapter 7 we studied 
whether it is technically possible to re-implant the DJBL, and whether the re-implantation would have 
the same weight and metabolic effect as the first implantation. These were the first re-implantations 
internationally so far. There was a gradual weight loss over time from 106 to 95 kg (p= 0.005), and 
BMI index decreased from 32 to 29.6 kg/m2 (p=0.005). Also, there was a gradual excess weight loss. 
Initially, the HbA1c level decreased, but increased post-explantation. It decreased during the re-
implantation, this was not significant. The results of this study show that re-implantation of the DJBL 
is save and feasible. After re-implantation, the weight and HbA1c levels decreased once more. The 
first results of this small interventional study show that re-implantation is feasible. From our point of 
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(11%) patients. Serious adverse events were observed in a subset of patients: 7 gastro-intestinal 
bleeds, 5 of which required early removal, 2 cases of pancreatitis, 1 case of hepatic abscess, and one 
obstruction of the sleeve. Explantation resulted in an esophageal tear in 2 cases. The device is 
relatively easy to deliver and remove in the majority of patients and it is therefore able to manifest its 
beneficial effects in the majority of patients without major tolerability or safety issues. However, 
more serious adverse events can occur, especially on removal of the DJBL. Therefore, an expert multi-
disciplinary team should be on hand for both the implant and, more importantly, explant procedure. 
There is a low rate of adverse events during the implantation period, most importantly, gastro-
intestinal bleeding. Clinicians should be mindful of symptoms and signs of blood loss from the gastro-
intestinal tract, so that appropriate measures may be taken. A surgical team and interventional 
radiologist should be available on demand for managing severe adverse events. One significant asset 
the device offers is that it is temporary in its design, such that if more severe adverse events manifest, 
they quickly resolve after device removal. DJBL seemed safe, but in inexperience hands, there is a 
chance of serious complications, like perforations, bleeding and pancreatitis. At our center, all the 
complications were managed without serious damage. 
After four years of experience delivering and removing the DJBL in our clinic, the ability to place the 
DJBL under conscious sedation (CS) was explored. In Chapter 6 we described our experience so far. 
The DJBL was implanted and explanted under conscious sedation and compared with the group under 
general anaesthesia. The parameters which were studied were total operation time, propofol usage, 
safety and hospital stay. The total operation time in patients under conscious sedation was 29 
minutes, mean propofol use of 170 mg and mean hospital stay of 11 hours. This was significantly less 
than de group under general anaesthesia.   Both techniques showed no procedural complications. By 
the time that this study was done, there were over 100 DJBL implanted under conscious sedation. We 
could state that the delivery of the DJBL under conscious sedation is feasible, safe and time and cost 
efficient. Because of possible complications during the procedure, we recommend placement and 
especially explantation of the DJBL under conscious sedation in the proximity of the operation room. 
The DJBL team should have significant experience with delivery and removal procedures under GA 
before performing procedures under CS. Similar to other GI procedures, potential complications, 
although rare, include duodenal, pyloric or esophageal perforation, bleeding and respiratory and 
cardiovascular complications related to the sedation. Our team felt safe placing the DJBL under CS 
after we had performed over 50 deliveries and removals under general anesthesia and a clear 
protocol was developed. Only in high risk patients we do consider DJBL placement under general 
anesthesia. This includes BMI >45 kg/m2 and any anatomical anomalies of mouth and hypopharynx 
that may complicate the endoscopic procedure. This study showed that after enough experience, the 
implantation and explantation of the DJBL under conscious sedation is safe and feasible.  DJBL is an 
endoscopic device which could be placed in the endoscopy room by using only propofol. This will 
reduce the cost of the device, which make this device available for more patients to treat with.  
As we discussed in Chapter 4 there is weight regain after explantation. Due to the CE mark, it’s 
impossible to prolong the treatment beyond twelve months. Re-implantation may be the answer to 
the observed weight regain. 
We conducted a prospective observational study in a small group of patients. In Chapter 7 we studied 
whether it is technically possible to re-implant the DJBL, and whether the re-implantation would have 
the same weight and metabolic effect as the first implantation. These were the first re-implantations 
internationally so far. There was a gradual weight loss over time from 106 to 95 kg (p= 0.005), and 
BMI index decreased from 32 to 29.6 kg/m2 (p=0.005). Also, there was a gradual excess weight loss. 
Initially, the HbA1c level decreased, but increased post-explantation. It decreased during the re-
implantation, this was not significant. The results of this study show that re-implantation of the DJBL 
is save and feasible. After re-implantation, the weight and HbA1c levels decreased once more. The 
first results of this small interventional study show that re-implantation is feasible. From our point of 
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view, DJBL should never be re-implanted in patients who did not show good results during their first 
DJBL implantation. However, in patients who lost weight, with an HbA1c level that dropped during 
the first period and had good glycaemic control, there could be a benefit of re-implantation. The 
limitation of this study was the small group of patients. The only thing what we could conclude is the 
feasibility of the re-implantation. Twelve months post-explant will be the time to re-implant again. 
This because of the damage what barbs caused to the tissue in the duodenum bulb. There were 
pseudopolyps in the duodenum bulb by the explantations. These pseudopolyps were completely 
disappeared at least twelve months after explantation. 
In Chapter 8 the methodologies of the published articles were reviewed retrospectively using 
CONSORT and STROBE guidelines.  Based on the shortcomings of the study designs, it is difficult to 
draw firm conclusions. For instance, in Chapter 2 the primary and secondary outcomes are not fully 
apparent. The study design was based on HbA1c and this was the primary outcome. The secondary 
outcome was weight loss and should thus be addressed as one. The HbA1c level decreased 
significantly but only when the DJBL was in place. This result only shows that DJBL has a positive 
effect when it is placed, but that this effect disappears when it is explanted. We fail to provide the 
reader with sufficient detail about the safety parameters and adverse events. In this study, we only 
mentioned the percentage of the adverse events without comparison with the control group. 
Diabetes and obesity will still present upon explantation of the device. This study has been unable to 
answer the questions about the effectiveness and safety of DJBL successfully. Therefore, we propose 
a randomized sham controlled trial to answer these questions 
In Chapter3 we investigated the mechanism of action and role of the incretins after implantation of 
DJBL. A prospective cohort study design with diet group as the control group would be a better study 
design to implement. Such study design would allow us to answer the question about the mechanism 
of action. Moreover, this study the primary and secondary outcomes were unclear. This makes 
interpreting the results difficult. And the question remains unanswered. Based on this study we only 
could speculate about the potential working mechanism of DJBL. Chapter 5 is about managing 
complications. In this chapter, we share our experience with DJBL. This study shows the type of 
complications which could occur and how we as a tertiary centre have handled the complications. 
This could be viewed as an expert opinion.  
Chapter 6 shows our experience with implantation of the DJBL under conscious sedation. However, to 
answer the questions about the safety, efficiency and cost-effectiveness, we need a randomized 
controlled trial. This study shows efficiency regarding the time and use of medications. However, 
issues regarding cost-effectiveness and safety remain unanswered.  
In Chapter 7 we conducted a study to see if re-implantation of the device is safe and possible. Could 
we draw a firm conclusion based on this study after all? The answer is no. This could be a pilot study. 
In order to answer this question adequately we need to use a different study design with more 
subjects.  
Only Chapter 4 which describes the data 12 months post explant was conducted according to the 
STROBE guidelines. In conclusion, taking chapter 8 into account we have to interpret the results of the 
studies with more caution 
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answer the questions about the effectiveness and safety of DJBL successfully. Therefore, we propose 
a randomized sham controlled trial to answer these questions 
In Chapter3 we investigated the mechanism of action and role of the incretins after implantation of 
DJBL. A prospective cohort study design with diet group as the control group would be a better study 
design to implement. Such study design would allow us to answer the question about the mechanism 
of action. Moreover, this study the primary and secondary outcomes were unclear. This makes 
interpreting the results difficult. And the question remains unanswered. Based on this study we only 
could speculate about the potential working mechanism of DJBL. Chapter 5 is about managing 
complications. In this chapter, we share our experience with DJBL. This study shows the type of 
complications which could occur and how we as a tertiary centre have handled the complications. 
This could be viewed as an expert opinion.  
Chapter 6 shows our experience with implantation of the DJBL under conscious sedation. However, to 
answer the questions about the safety, efficiency and cost-effectiveness, we need a randomized 
controlled trial. This study shows efficiency regarding the time and use of medications. However, 
issues regarding cost-effectiveness and safety remain unanswered.  
In Chapter 7 we conducted a study to see if re-implantation of the device is safe and possible. Could 
we draw a firm conclusion based on this study after all? The answer is no. This could be a pilot study. 
In order to answer this question adequately we need to use a different study design with more 
subjects.  
Only Chapter 4 which describes the data 12 months post explant was conducted according to the 
STROBE guidelines. In conclusion, taking chapter 8 into account we have to interpret the results of the 
studies with more caution 
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9.2 Conclusions and future perspectives 
In this thesis, we have discussed the different aspect of the DJBL as a treatment for the type 2 
diabetes and obesity. DJBL Treatment is safe and already more than 4000 DJBLs have been implanted 
worldwide with manageable complications and no reported mortality.  The patients who were 
included in this thesis were obese, with a BMI between 30 and 50 kg/m2, and were diagnosed with 
T2DM. From recent studies, we know that bariatric surgery in T2DM patients with BMI less than 35 
km/m2 is also very promising [1,2], especially because the eligibility of the bariatric surgery in this 
group is still matter of debate.  Cohen et al has already published two studies with DJBL including 
patients with low BMI and T2DM with good effect [3,4]. 
Because DJBL is a reversible noninvasive endoscopic procedure, it’s a good alternative for some 
diabetic patients with a low BMI index compared to bariatric surgery. It must however be kept in 
mind that strict follow up and good patient motivation is imminent to achieve a good T2DM 
reduction. We confirmed the weight independent improvement of T2DM, which can be attributed to 
the gut hormones according to the earlier study [5]. In the first comparative study of gastric bypass 
and DJBL, the preliminary data demonstrated that both procedures have a similar impact on diabetes 
remission and significant impact on body weight. With this in mind we do not have to expose patients 
with low BMI to the potential complications of the bariatric surgery.  Some endocrinologists and 
bariatric surgeons might disagree, but in our eyes another important group are young patient’s that 
might be better off with a reversible noninvasive procedure like DJBL in younger life than treating 
them with a definitive procedure like a RYGB or sleeve gastrectomy. Although we do know little about 
the results of the DJBL, we also still know very little about the very long-term complications of 
bariatric surgery.  However, it is questionable if the implantation of the DJBL for only 12 months is 
sufficient to treat a chronic disease such as obesity and T2DM. Furthermore, implantation alone will 
not lead to the results presented in this thesis. There is a need for an intensive lifestyle program and 
dietary support with optimal conservative treatment.  At the start of the current thesis, DJBL 
treatment duration was limited to only six months. Later, the treatment duration was extended to 
one year [6,7]. For this period results are good in terms of weight loss and T2DM, but still too short. 
When explanted and after the end of the intense follow up program many patients go back to their 
old habits. So, patients should still be followed up and in our opinion a second DJBL can be placed 
when either weight or T2DM increases again in patients who have shown to have done well with a 
DJBL the first time. As shown in this thesis, these patients do very well after re-implantation. The 
most common complaint after implantation is abdominal discomfort and nausea. With proper 
medication, these complaints seem to fade in a few weeks, but in some patients the complaints 
persist and in a few patients the DJBL was removed. These explantations seem, even with good 
instructions, not preventable. Although most complications associated with the DJBL are minor, they 
do occur. Especially in the beginning of our learning curve up to one in five DJBL seemed difficult to 
implant. After having completed this curve, nowadays this does not often seem to occur any more. 
Only in patients with a very short bulbus, implantation can be challenging. 
A grave complication is a liver abscess, which was seen in a few patients and was treated successfully 
with antibiotics. These abscesses can develop as a result of translocation of bacteria through the 
duodenal wall due to perforations of the sharp barbs of the anchor of the DJBL. In our series, we have 
seen two patients with a liver abcess so far.  The most critical part of the DJBL is the removal. 
Although it seems simple, it can result in perforation of the esophagus or arterial bleeding of the 
arteria duodenalis. When the latter occurs, it is sometimes necessary to perform emergency surgery. 
Thus, removal should be performed by an experienced professional and team in the proximity of a 
good (intervention) radiological and a surgical facility. To make DJBL placement more effective and 
(financially) available for more patients the DJBL implantation and explantation was performed under 
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conscious sedation our daycare facility.  This brings the possibility of implanting DJBL in de Endoscopy 
room nearby, which will reduce the cost and makes DJBL available for more patients.  
Future of the DJBL 
As it comes to the future perspective of the DJBL, few adjustments could maximize the DJBL effect on 
weight loss and type 2 diabetes. We have learned from our experience with the DJBL that extension 
of the implantation duration of the DJBL maximizes the effect of the device. The implant duration of 
the DJBL can theoretically be extended from twelve months to two years, three years or even five 
years.  Possibly the weight loss will remain stable preventing the progression of type 2 diabetes and 
decreasing cardiovascular risks. However, longer implant duration carries a new set of risk factors:  
The risks of migration will increase and with this the chance of bowel perforation will increase as well. 
Also, it becomes harder to withdraw the device from the bulbus. To prevent migration and 
perforation risk, the anchor design will play a very important role. A possible regimen is to remove 
and directly re-implant a DJBL with intervals of one year. This results, as shown in a stable weight loss, 
but unfortunately adds to the total costs of the treatment. 
There are also some other adjustment which will help the patient to reduce more weight after 
implantation. The introduction of a diaphragm membrane in the entrance of the DJBL, which was 
developed earlier, could theoretically add to the weight loss. This will ensure longer stay of the food 
in the stomach, and as such adds a restrictive component to the bypass mechanism. This was tested 
and resulted in a small patient group to more passage problems and thus was not introduced so far. 
This problem might be overcome by better instruction to the patient. 
Previous studies and one of our own have shown that the DJBL has a positive effect on the production 
gut hormones, for example GLP-1. Today, GLP-1 agonists are being used as a treatment for type 2 
diabetes patients. Combining the DJBL with this hormone will theoretically have a positive effect in 
achieving glycemic control. This requires more research but might add to the results on T2DM 
regression. The complications that occur with DJBL treatment are most often mild, but with the 
possible serious complications one should have proper training before starting implantation. Also, the 
proper facilities should be available and a good treatment and complication protocol must be at 
hand. With the current technique, the technical changes that should be made are mainly concerning 
the anchor. Improvement of the design should focus on explantation after one year (minimal tissue 
ingrowth at that point), minimal chance on translocation of bacteria and thus liver abscesses. We 
think that the proper adjustments have already been made for the removal device, but adding a 
larger silicone protection hood seems good advice. The biggest challenge for the future still is the 
total price of one year of DJBL treatment.  With a price of roughly € 8000,- per year it’s very expensive 
right now, especially when considering that a RYGB has a similar price for the total treatment.  
In conclusion, the DJBL is a promising (non-surgical) endoscopic treatment option for obese patients 
with type 2 diabetes. This device is not perfect yet, but might just fill the gap between medical 
therapy and a surgical bariatric treatment. In the future, the role of gastroenterologists in the 
treatment of obesity will increase due to the various endoscopic techniques that are currently being 
developed. 
Research agenda  
In this thesis, we have only studied a few aspects of the DJBL. From the research point of view there 
are questions still unanswered. Here below I will summarize a few questions which could be 
researched:  
1. Development of a new device with longer implantation period than twelve months. For example 
16, 18 of even 24 months  
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9.2 Conclusions and future perspectives 
In this thesis, we have discussed the different aspect of the DJBL as a treatment for the type 2 
diabetes and obesity. DJBL Treatment is safe and already more than 4000 DJBLs have been implanted 
worldwide with manageable complications and no reported mortality.  The patients who were 
included in this thesis were obese, with a BMI between 30 and 50 kg/m2, and were diagnosed with 
T2DM. From recent studies, we know that bariatric surgery in T2DM patients with BMI less than 35 
km/m2 is also very promising [1,2], especially because the eligibility of the bariatric surgery in this 
group is still matter of debate.  Cohen et al has already published two studies with DJBL including 
patients with low BMI and T2DM with good effect [3,4]. 
Because DJBL is a reversible noninvasive endoscopic procedure, it’s a good alternative for some 
diabetic patients with a low BMI index compared to bariatric surgery. It must however be kept in 
mind that strict follow up and good patient motivation is imminent to achieve a good T2DM 
reduction. We confirmed the weight independent improvement of T2DM, which can be attributed to 
the gut hormones according to the earlier study [5]. In the first comparative study of gastric bypass 
and DJBL, the preliminary data demonstrated that both procedures have a similar impact on diabetes 
remission and significant impact on body weight. With this in mind we do not have to expose patients 
with low BMI to the potential complications of the bariatric surgery.  Some endocrinologists and 
bariatric surgeons might disagree, but in our eyes another important group are young patient’s that 
might be better off with a reversible noninvasive procedure like DJBL in younger life than treating 
them with a definitive procedure like a RYGB or sleeve gastrectomy. Although we do know little about 
the results of the DJBL, we also still know very little about the very long-term complications of 
bariatric surgery.  However, it is questionable if the implantation of the DJBL for only 12 months is 
sufficient to treat a chronic disease such as obesity and T2DM. Furthermore, implantation alone will 
not lead to the results presented in this thesis. There is a need for an intensive lifestyle program and 
dietary support with optimal conservative treatment.  At the start of the current thesis, DJBL 
treatment duration was limited to only six months. Later, the treatment duration was extended to 
one year [6,7]. For this period results are good in terms of weight loss and T2DM, but still too short. 
When explanted and after the end of the intense follow up program many patients go back to their 
old habits. So, patients should still be followed up and in our opinion a second DJBL can be placed 
when either weight or T2DM increases again in patients who have shown to have done well with a 
DJBL the first time. As shown in this thesis, these patients do very well after re-implantation. The 
most common complaint after implantation is abdominal discomfort and nausea. With proper 
medication, these complaints seem to fade in a few weeks, but in some patients the complaints 
persist and in a few patients the DJBL was removed. These explantations seem, even with good 
instructions, not preventable. Although most complications associated with the DJBL are minor, they 
do occur. Especially in the beginning of our learning curve up to one in five DJBL seemed difficult to 
implant. After having completed this curve, nowadays this does not often seem to occur any more. 
Only in patients with a very short bulbus, implantation can be challenging. 
A grave complication is a liver abscess, which was seen in a few patients and was treated successfully 
with antibiotics. These abscesses can develop as a result of translocation of bacteria through the 
duodenal wall due to perforations of the sharp barbs of the anchor of the DJBL. In our series, we have 
seen two patients with a liver abcess so far.  The most critical part of the DJBL is the removal. 
Although it seems simple, it can result in perforation of the esophagus or arterial bleeding of the 
arteria duodenalis. When the latter occurs, it is sometimes necessary to perform emergency surgery. 
Thus, removal should be performed by an experienced professional and team in the proximity of a 
good (intervention) radiological and a surgical facility. To make DJBL placement more effective and 
(financially) available for more patients the DJBL implantation and explantation was performed under 
134   |   Thesis: The Endoscopic Duodenal-Jejunal Bypass Liner in type 2 diabetes and obesity 
conscious sedation our daycare facility.  This brings the possibility of implanting DJBL in de Endoscopy 
room nearby, which will reduce the cost and makes DJBL available for more patients.  
Future of the DJBL 
As it comes to the future perspective of the DJBL, few adjustments could maximize the DJBL effect on 
weight loss and type 2 diabetes. We have learned from our experience with the DJBL that extension 
of the implantation duration of the DJBL maximizes the effect of the device. The implant duration of 
the DJBL can theoretically be extended from twelve months to two years, three years or even five 
years.  Possibly the weight loss will remain stable preventing the progression of type 2 diabetes and 
decreasing cardiovascular risks. However, longer implant duration carries a new set of risk factors:  
The risks of migration will increase and with this the chance of bowel perforation will increase as well. 
Also, it becomes harder to withdraw the device from the bulbus. To prevent migration and 
perforation risk, the anchor design will play a very important role. A possible regimen is to remove 
and directly re-implant a DJBL with intervals of one year. This results, as shown in a stable weight loss, 
but unfortunately adds to the total costs of the treatment. 
There are also some other adjustment which will help the patient to reduce more weight after 
implantation. The introduction of a diaphragm membrane in the entrance of the DJBL, which was 
developed earlier, could theoretically add to the weight loss. This will ensure longer stay of the food 
in the stomach, and as such adds a restrictive component to the bypass mechanism. This was tested 
and resulted in a small patient group to more passage problems and thus was not introduced so far. 
This problem might be overcome by better instruction to the patient. 
Previous studies and one of our own have shown that the DJBL has a positive effect on the production 
gut hormones, for example GLP-1. Today, GLP-1 agonists are being used as a treatment for type 2 
diabetes patients. Combining the DJBL with this hormone will theoretically have a positive effect in 
achieving glycemic control. This requires more research but might add to the results on T2DM 
regression. The complications that occur with DJBL treatment are most often mild, but with the 
possible serious complications one should have proper training before starting implantation. Also, the 
proper facilities should be available and a good treatment and complication protocol must be at 
hand. With the current technique, the technical changes that should be made are mainly concerning 
the anchor. Improvement of the design should focus on explantation after one year (minimal tissue 
ingrowth at that point), minimal chance on translocation of bacteria and thus liver abscesses. We 
think that the proper adjustments have already been made for the removal device, but adding a 
larger silicone protection hood seems good advice. The biggest challenge for the future still is the 
total price of one year of DJBL treatment.  With a price of roughly € 8000,- per year it’s very expensive 
right now, especially when considering that a RYGB has a similar price for the total treatment.  
In conclusion, the DJBL is a promising (non-surgical) endoscopic treatment option for obese patients 
with type 2 diabetes. This device is not perfect yet, but might just fill the gap between medical 
therapy and a surgical bariatric treatment. In the future, the role of gastroenterologists in the 
treatment of obesity will increase due to the various endoscopic techniques that are currently being 
developed. 
Research agenda  
In this thesis, we have only studied a few aspects of the DJBL. From the research point of view there 
are questions still unanswered. Here below I will summarize a few questions which could be 
researched:  
1. Development of a new device with longer implantation period than twelve months. For example 
16, 18 of even 24 months  
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2. A double blind randomized controlled trail with DJBL in combination with GLP-1 agonist and its 
effect on type 2 diabetes.  
3. A randomized controlled trail with DJBL after a sleeve gastrectomy and its effect on type 2 
diabetes  
4. Taking mucosal biopsy from duodenum before the implantation of DJBL, right after explantions 
and six months after explantation. This will give us insight about the mucosal change during the 
treatment.  
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9.3 Samenvatting en conclusies  
Wereldwijd is overgewicht snel een groter probleem aan het worden. Genetisch heeft ons lichaam 
zich in de evolutie zo aangepast dat het zeer zuinig omspringt met calorieën. De dagelijkse voeding 
die we tot ons nemen kan gemakkelijk voor een groot gedeelte worden opgeslagen als reserve voor 
mindere tijden. Ditzelfde mechanisme, wat ooit als redding voor de mens was, begint in onze huidige 
samenleving een steeds groter probleem te worden. Vroeger leefde men in groepen waar dagelijks 
activiteit voor het vinden van de voeding heel erg belangrijk was. Men beschikte niet dagelijks over 
voldoende voeding, voornamelijk in de winter. Daarom werd overgewicht als symbool voor rijkdom 
gezien. Er zijn nog steeds landen waar dik zijn gelijk staat gelijk aan welvaart. Tegenwoordig is vooral 
in de westerse landen (ongezonde) voeding in overvloed aanwezig en is het aantal calorieën dat men 
dagelijks eet snel toegenomen. Daarnaast beweegt men steeds minder. Wat er gegeten wordt is niet 
altijd gezonde voeding. Ongezonde voeding welke voornamelijk suikers en vetten bevatten zijn vaak 
door subsidies goedkoper dan gezonde voeding. Dit zorgt ervoor dat de bevolking in deze landen nog 
steeds in gewicht toe aan het nemen is. Deze toename van overgewicht beperkt zich niet alleen tot 
de Westerse landen, maar ook landen in ontwikkeling zoals India, China, de Arabische emiraten en 
Saudi-Arabië laten een snelle groei van het overgewicht zien. 
Ernstig overgewicht is vaak de aanleiding voor ziekten zoals type 2 suikerziekte hart- en vaatziekten, 
artrose, astma, infertiliteit en een sterk verhoogt risico op sommige soorten kanker. Wereld 
gezondheid organisatie heeft overgewicht als een chronische ziekte erkend. Deze ziekte wordt ook 
wel de ziekte van de 21ste eeuw genoemd. Er overlijden jaarlijks meer en meer mensen aan 
overgewicht en de gevolgen ervan.  De gevolgen van overgewicht brengt de samenleving ook 
economische schade toe. De meest recente cijfers geven aan dat bijna   helft van de Nederlanders lijdt 
aan overgewicht en 1 op de 10 heeft een vorm van het ernstige overgewicht (BMI>30kg/m2).  Drie 
procent van de mensen die kampen met ernstig overgewicht zijn tussen 4 tot 20 jaar oud. Deze groep 
lijkt alleen maar groter te worden. De eerste stap in de behandeling van obesitas is het geven van 
leefstijladviezen die grotendeels neerkomen op meer bewegen en minder eten. Maar wanneer het 
effect hiervan niet toereikend is en er sprake is van extreem overgewicht kan gekozen worden voor 
chirurgische oplossingen. Chirurgie voor morbide obesitas, ook wel bariatrische chirurgie genoemd, 
wordt al enkele decennia toegepast. De meest bekende voorbeelden van bariatrische chirurgie zijn de 
maagband en de gastric bypass, ook wel maagverkleining genoemd. Bariatrische chirurgie kan 
langdurig gewichtsverlies bewerkstelligen. Daarnaast heeft het een positief effect op de aan 
overgewicht gerelateerde co-morbiditeiten zoals diabetes en hart- en vaatziekten. Tot dusver zijn er 
nog weinig data beschikbaar over de zeer lange-termijn effecten van deze operaties en veel patiënten 
met overgewicht durven het niet aan om een operatie te ondergaan. Mede vanwege deze redenen 
wordt er gezocht naar minder invasieve behandelingen. Bij patiënten die een gastric bypassoperatie 
ondergaan is er een zeer snelle verbetering van bijvoorbeeld de diabetes mellitus. Studies hebben 
uitgewezen dat het uitsluiten van een gedeelte van de dunne darm hiervoor deels verantwoordelijk 
is. De Duodenal-Jejunal Bypass Liner (afgekort DJBL) is een volledig endoscopische behandelmethode, 
die probeert deels het effect van de RYGB en het overslaan van het eerste deel van de dunne darm na 
te bootsen zonder operatie. De DJBL bestaat uit een 60 cm lange flexibele teflon sleeve (mouw) die 
endoscopisch, zoals bij een kijkonderzoek van de maag, in de dunne darm geplaatst wordt. 
Momenteel wordt na een jaar deze DJBL door middel van kijkonderzoek weer verwijderd. 
In dit proefschrift wordt er in Hoofdstuk 1 stil gestaan bij de achtergrond van overgewicht vanuit een 
historische perspectief en bij de verschillende. Behandelingen die er bestaan. Hoofdstuk 2 is gewijd 
aan het effect van de DJBL op type 2 diabetes en overgewicht. Deze studie is een 
samenwerkingsverband tussen het Rijnstate ziekenhuis in Arnhem, het Atrium Medisch Centrum in 
Heerlen en de Universiteit van Maastricht. De behandeling met de DJBL gedurende een half jaar 
resulteert in gewichtsreductie en verbetering van de diabetes. Na het verwijderen van de DJBL blijft 
deze verbetering enige tijd aanhouden. Daarnaast zijn de effecten van de DJBL sterker dan de 
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effecten van een intensieve dieetbehandeling. Zo konden meer mensen in de DJBL-groep hun 
diabetes medicijnen afbouwen en waren de bloedsuikers beter in de groep die met de DJBL 
behandeld werd. In Hoofdstuk 3 wordt dieper ingegaan op mogelijk werkingsmechanisme van de 
DJBL. Zoals theoretisch verwacht was blijken de darmhormonen (incretines) een rol te spelen bij de 
verbetering van type 2 diabetes, zoals bij patiënten die maagverkleining of gastric bypass ondergaan. 
De hormonen die hierbij een rol zouden kunnen spelen zijn: GLP-1 (voluit: glucagon-like peptide-1), 
glucagon en GIP (voluit: glucose-dependent insulinotrophic polypeptide). Het hormoon GLP-1 
stimuleert de productie van insuline. Daarnaast zijn er aanwijzingen dat het de gevoeligheid voor 
insuline in de weefsels positief beïnvloedt. Het tweede genoemde hormoon, GIP, kan in patiënten 
met diabetes zorgen voor extra glucagon. Het onderzoek liet zien dat na plaatsing van de DJBL de 
waarden van GLP-1 aanvankelijk afnam en na een week weer toenamen terwijl die van GIP daalden. 
Deze veranderingen zouden kunnen bijdragen aan het positieve effect van de DJBL op type 2 
diabetes. 
Aanvankelijk mocht de DJBL alleen maar gedurende zes maanden in het menselijk lichaam blijven. 
Vanaf december 2011 werd die tijd verlengt naar één jaar. In hoofdstuk vier is er onderzocht wat het 
effect van de DJBL is van twaalf maanden behandeling. In deze studie komt naar voren dat het goede 
effect blijft bestaan gedurende deze periode. Maar na het verwijderen zien we dat dit effect 
langzaam afnemen. Aanvankelijk werd de DJBL onder algehele narcose in de operatiekamer geplaatst 
en verwijderd. Patiënten moesten twee dagen opgenomen worden voor het plaatsen en één dag voor 
het verwijderen. Nadat er voldoende ervaring opgedaan was met het plaatsen werd onderzocht of de 
DJBL (nog wel op de operatiekamer) onder ‘’gedeeltelijk’’ narcose geplaatst kon worden. Dit betekent 
dat de patiënt geen spierverslapper, maar alleen een sterk slaapmiddel toegediend kreeg. In 
Hoofdstuk 5 dat de DJBL zonder complicaties op de operatiekamer onder gedeeltelijke narcose te 
plaatsen was en op de endoscopie kamer te verwijderen was. Hierdoor konden patiënten dezelfde 
dag weer naar huis ontslagen worden. Het Ziekenhuis Rijnstate heeft internationaal de meeste 
patiënten met een DJBL behandeld. Het is een niet invasieve behandeling maar wel met potentiële 
complicaties. Daarom hebben we in hoofdstuk 6 onze ervaringen geëvalueerd en vooral gekeken naar 
de complicaties. Hieruit kwamen een aantal adviezen uit voort die gebruikt kunnen worden door 
ziekenhuizen met minder ervaring of ziekenhuizen die net beginnen. Zoals het eerder al naar voren 
kwam is de implantatieduur beperkt tot 12 maanden. Na het verwijderen neemt het gewicht weer 
toe net als de mate van suikerziekte. In hoofdstuk 7 hebben wij onderzocht of het mogelijk is om de 
DJBL weer opnieuw te plaatsen en of de gunstige effecten weer terug zouden keren. Het blijkt dat bij 
patiënten die initieel goed gereageerd hadden op de DJBL het veilig en effectief was om de DJBL 
nogmaals te plaatsen.  De DJBL lijkt voor bepaalde patiënten een goed alternatief voor de huidige 
behandelingen van diabetes mellitus type 2 en overgewicht. Er is nog veel onbekend over deze 
behandelmethode. Theoretisch kan de DJBL duur verlengd worden van twaalf maanden naar twee 
jaar, drie jaar of zelfs vijf jaar. Hiermee is de hoop dat het gewicht en HbA1c stabiel zullen blijven. De 
uitdagingen die langere implantatie duur met zich mee zou kunnen brengen zijn: de migratie kans 
neemt toe, het risico op verstopping kan hoger zijn en wellicht kan perforatie kans van de darm 
toenemen. Hiervoor is de aanpassingen van het ontwerp zeer belangrijk. Door aanpassingen aan de 
ankers die de DJBL tegen de bulbus houdt, zal eventueel zowel de migratie kans als perforatie risico te 
voorkomen zijn.  Door het inbouwen van een membraan in het begin van de Endobarrier, zal het 
voedsel langer in de maag blijven. Dit kan vervolgens voor een minder inname van de voeding zorgen. 
Het risico dat hiermee gepaard zou kunnen gaan, is de verstopping van de DJBL. Daarom is het zeer 
belangrijk dat de patiënten door een gespecialiseerde diëtiste worden vervolgd.  Uit eerdere 
onderzoeken is gebleken dat de DJBL een positief effect op de darm hormonen heeft. Vooral op het 
darmhormoon GLP-1 is dit goed effect zichtbaar. Ook ons eigen onderzoek heeft dit positieve effect 
aangetoond. Tegenwoordig wordt het GLP-1 analoog ook als behandeling bij de type-2-diabetes 
patiënten gebruikt. Combineren van de DJBL met dit hormoon zal theoretisch een positief effect bij 
diabetes patiënten hebben. Re-implantatie bij de patiënten die bij de eerste DJBL implantatie baat bij 
hadden is een andere optie. Maar dat kan alleen als de momenteel nog hoge kosten voor een DJBL 
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behandeling van rond de €8000, - naar beneden gaan. Implantatie en explantatie in de endoscopie 
kamer onder sedatie en niet onder narcose kan hier mogelijk een bijdrage aan leveren. Er zijn tal van 
onderzoeken gaande die trachten om te beantwoorden welke patiënten de meeste baat bij een DJBL 
kunnen hebben. Vooralsnog lijkt het zeker een plaats in te nemen tussen de (conservatieve) 
medicamenteuze behandeling en bariatrische chirurgie. 
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Beste Willemien, jij was natuurlijk de constante factor voor de Endobarrier studie. Zonder jou was 
haast onmogelijk om Endobarrier studie tot een goed einde te brengen. Mijn oprechte dank voor 
jouw hulp en steun gedurende studie.  
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9.7 Curriculum Vitae
Parweez Koehestanie werd geboren op 27 juli 1982 te Kabul Afghanistan.
Hij is in een zeer dynamische periode van Afghanistan geboren en 
opgegroeid. Hij is geboren in oorlog, opgegroeid in oorlog en gevlucht
voor de oorlog. Met alle verschrikkingen die hij als kind meemaakte en 
afkeer tegen geweld was zijn wens altijd om arts te worden. In 1997 ging
hij op verzoek van zijn familie als zestienjarige in zijn eentje op zoek naar
een veiliger bestaan. Na een lange reis van in totaal twaalf maanden,
waarbij hij dertien landen te voet, met de auto en met de trein had
doorkruist vond hij deze veilige plek in Nederland.
Eenmaal hier aangekomen kwam hij er snel achter dat hij zijn kinderdroom waar wilde maken. Na 
aankomst begon hij direct met een Nederlandse taalcursus en startte in 1999 aan de MAVO op het
college de Mollen Bossen te Venlo. Na drie maanden mocht hij doorstromen naar de HAVO naar
Blariacum College te Venlo welke hij in 2002 wist af te ronden. In 2003, na een jaar toegepaste Natuur
Wetenschappen te hebben gestudeerd in Fontys Hoge school te Eindhoven, begon hij aan zijn studie
Geneeskunde aan de Radboud Universiteit te Nijmegen. In 2010 werd zijn droom gerealiseerd; het
behalen van zijn doctorale examen.
Direct na het behalen van zijn doctoraal begon hij aan zijn promotieonderzoek naar de Endobarrier
onder begeleiding van Dr F.J. Berends, Drs. I.M.C. Janssen en Dr. E.O. Aarts in het Rijnstate ziekenhuis 
te Arnhem.
Sinds 2013 werd hij aangenomen voor de opleiding tot maag-darm en leverarts door prof J.P.H
Drenth van de Radboud Universiteit te Nijmegen. Na het afronden van zijn vooropleiding in het
Jeroen Bosch ziekenhuis te Den Bosch. Momenteel is hij werkzaam in het Radboud Universitair
Medisch Centrum te Nijmegen alwaar hij de laatste twee jaar van zijn opleiding zal volgen.
Dit levensverhaal kent tot dus ver een goed einde aangezien Parweez alweer zes jaar gelukkig
getrouwd is met collega arts Maryam Ghariq en sinds juni 2017 trotse vader van Daniel-Ayub is.
Daarnaast is het zijn broers en ouders gelukt om een veilig onderkomen te vinden in Nederland. Zijn
levensmotto “opgeven is geen optie” kunnen wij allen ter harte nemen.
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Werken bij bariatrie groep in Arnhem hield niet alleen Endobarrier studie in natuurlijk. 
Naast polikliniek en assisteren op de operatiekamer, gaven wij ook voorlichting aan de patiënten. 
Hierbij heb ik me altijd gesteund gevoeld door de Obesitas verpleegkundigen. Beste Nadine, je 
bent een collega op wie je te allen tijde kan rekenen. Ik wil je van harte bedanken voor 
de prettige samenwerking en je steun. Beste Annemieke jou wil ik ook bedanken voor de 
samenwerking. Iedereen die niet genoemd zijn in het bijzonder alle betrokken verpleegkundigen 
en secretaressen van harte bedanken voor hun steun bij dit onderzoek. 
Tevens wil ik collega-onderzoekers uit Wageningen Universiteit bedanken in het bijzonder Nicole voor 
de fijne samenwerking.  
Beste Arjen hartelijk dank voor je hulp! 
Alle collega’s uit Jeroen Boschziekenhuis wil ik bedanken voor de tijd en ruimte die ik kreeg om dit 
proefschrift naar een goed einde te brengen.  
Shafiq: Mijn dank is groot voor de prachtige “minaturi” van de kaft van de proefschrift. 
Mohamed, je was niet mijn paranimf maar je hebt mij niet minder bijgestaan dan een paranimf. 
Ondanks je zeer drukke agenda heb je elk keer weer tijd voor mij vrij gemaakt om de opmaak van het 
proefschrift samen door te nemen. Het boekje is dan ook mede dankzij jouw hulp tot stand gekomen.  
Het onderzoek doen naast je werk vergt natuurlijk veel tijd van je. Deze tijd gaat ten koste van de 
familie en vrienden.  Daarom wil ik al mijn vrienden in het algemeen maar in het bijzonder Mahmood, 
Khaled en Yama bedanken voor hun begrip en steun. Jullie zijn niet alleen mijn studie-maatjes maar 
ook vrienden voor het leven. Hopelijk kan ik het hierna goed maken. 
Sharam, Nazir, Ramin en Atal mijn vrienden bedank voor jullie steun en begrip voor de drukke tijden 
ik ga beloven om het in te halen.  
Dear Raya Shahir, I would like to thank you for all your effort and time. I wish you succes with your 
study and I am happy to have you as my colleague in the future.  
Beste Eidrees, Elyas, Ishaq en Ismael, bedankt voor al jullie hulp en steun van afgelopen jaren. Het is 
altijd leuk om met jullie te sparren over verschillende onderwerpen. Maar gezien 
onze gemeenschappelijke achtergrond worden het toch vaak medische discussies.  
Mijn paranimfen, Yama en Eidrees, bedankt dat jullie deze taak op jullie hebben genomen.  
Mirwais, Ajmal, Farid, Zaki, Sheerzad en mijn zusje Zakya ik heb altijd geweten dat ik op jullie steun 
kon rekenen. Toch wil ik jullie van harte bedanken voor jullie begrip. Ik ga alle 
familiegelegenheden die ik heb gemist weer inhalen! Ik ben trots op jullie. Lieve Zakya, liefste 
zusje van mij, ik ben dankbaar om jou als zusje te mogen hebben. Lieve Zaid, Hamza, Aryan, Bilal, 
Sara en Sumaya, wat ben ik trots om jullie te zien opgroeien.  
Beste schoonouders, jullie zijn zelf een ware inspiratie als het gaat om doorzettingsvermogen en 
motivatie. Bedankt voor jullie onvoorwaardelijke steun van afgelopen en komende jaren. Ik waardeer 
het enorm en ik heb jullie lief. 
Lieve ouders het leven is niet gemakkelijk geweest voor jullie. Jullie hebben een zeer dynamische 
leven gekend. Jullie zijn elk keer weer voor zeer moeilijke keuzes gestaan die nooit van 
zelfsprekend waren. Jullie hebben het huis en aard verlaten om ons een goed toekomst te bieden. 
Jullie waren er altijd voor ons. Mijn danks is groot.  
Lieve zoon mijn lieve Daniel-Ayub ik hou ontzettend veel van jou jij bent oprecht bijzonder althans 
voor mij dan. 
Lieve Maryam: Waar moet ik beginnen om jou te bedanken? Jij bent niet alleen mijn wederhelft 
je bent mijn kameraad, mijn motivator, en soms ook mijn coach. Je hebt me gestimuleerd wanneer 
het minder ging en je hebt samen met mij gevierd wanneer het beter ging. Je bent veel meer dan 
dat ik me ooit kon voorstellen. Ik ben super trots op jou en dankbaar dat jij mijn leven metgezel bent.  
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9.8 Cover information  
The cover of this thesis has been painted by an Afghan/Dutch artist. Shafiq Soroush born (1981 -) in 
Kabul, Afghanistan a Realist painter. His fascination with painting began as a child. He started taking 
lessons in painting at the age of 10. Soroush studied from 2002 at Royal Academy of Art Hague, of 
Netherlands, from where he graduated in Bachelor of fine arts 2006. Since 2006 he has presented 
several exhibitions of his paintings. 
The cover is painted in a Tahzib ‘’Miniature style’’. The style of Kamal -ud -din Behzad Herawi. Kamal 
Ud-Din Behzad Herawi (c.1460- c.1535), also known as Kamal –din Bihzad or Kamaleddin Behzad, was 
a painter of Persian miniatures and head of the roal ateliers in Heart and Tabriz during the late 
Timurid and early Safavid periods. 
Miniature is a style of painting that from its beginning, around the early 15th century, has been 
associated with the demand for illustration and beautification of documents and manuscripts. It is 
most often used to convey a certain message, be it of a poetical, fictional, philosophical, or religious 
nature, thus in these regards miniature is closely related to the art of graphic design. Despite the fact 
that it is not necessarily the case, miniature painting is frequently and erroneously presumed to be of 
small size. 
 
Pictures in between the chapters 
The pictures in between the chapters are mosaic art from the walls and cilling of the 15th century 
Blue Mosque (Rauze Mobaraak). The mosque is located in the center of Mazar-i-Sharif, in the North of 
Afghanistan. A mosaic is a piece of art or image made from the assemblage of small pieces of colored 
glass, stone, or other materials. It is often used in decorative art or as interior decoration. Most 
mosaics are made of small, flat, roughly square, pieces of stone or glass of different colors, known as 
tesserae. Mosaic was widely used on religious buildings and palaces in early Islamic art. 
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